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Introduction: Prescription drug monitoring programs (PDMPs) are one strategy established to 
curb the prescription opioid abuse epidemic. Prescriber use mandates has emerged as a 
promising practice to increase PDMPs impact on prescription opioid abuse; however, evidence 
of its effectiveness has not yet been established. Kentucky was the first state to implement 
comprehensive prescriber use mandates in July 2012. 
Objective: To assess the relationship between prescriber use mandates policy and emergency 
department (ED) visits related to prescription opioid poisoning among adults in Kentucky and 
  
North Carolina. Secondary aim: to evaluate the economic impact of prescriber use mandates in 
Kentucky.    
Methods: A controlled, pre-post study design. Data from the State Emergency Department 
Databases (SEDD) and the State Inpatient databases (SID) were used to identify prescription 
opioid poisoning ED visits among those ≥ 12 years old. Prevalence rate were estimated. 
Prescription opioid poisoning ED visits were characterized based on sociodemographic and 
clinical characteristics. Logistic regression was applied to compare occurrences of prescription 
opioid poisoning ED visits pre and post prescriber use mandates in Kentucky, and between 
Kentucky and North Carolina for the period 2011 to 2014. A cost of illness framework was 
applied to estimate direct medical costs associated with prescription opioid poisoning ED visits. 
The economic impact of prescriber use mandates was quantified based on logistic regression 
coefficient for the interaction term (state*time to implementation).  
Results: There were 7,419 and 12,598 prescription opioid poisoning -related ED visits in 
Kentucky and North Carolina, respectively. Young and Middle age, male gender, white, having 
one or more chronic conditions, and psychiatric conditions (such as depression and drug abuse) 
were significantly associated with prescription opioid poisoning ED visits (p-value<0.05). The 
odds of having a prescription opioid poisoning ED visit in Kentucky were significantly lower 
compared to North Carolina in 2012, 2013, and 2014 compared to 2011 (OR = 0.9, 0.7, and 0.7 
respectively). The total estimated direct medical costs were $13.77 and $24.37 million in 
Kentucky and North Carolina, respectively. In Kentucky, the economic impact of prescriber use 
mandates was estimated at - $2.3 million. 
Conclusion: Prescriber use mandates is effective in reducing prescription opioid poisoning ED 
visits, and its economic impact is considerable. 
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Chapter 1 
 
 
 
Section 1.1: Introduction 
Opioids and their related effects 
Opioids are a class of drugs that include the illicit drug heroin as well as legal prescription pain 
relievers, including hydrocodone, oxycodone, morphine, and codeine.1 Opioids can be naturally 
occurring (morphine), semi-synthetic (heroin), or synthetic (fentanyl). They are further classified 
as agonists, partial agonists, and antagonists based on their effect on opioid receptors.2 Opioid 
agonists relieve pain by interacting with opioid receptors, thus, inhibiting the transmission of 
pain signals (codeine). In contrast, opioid antagonists block opioid receptors and have no 
functional response; naloxone is an example of an opioid antagonist that is used to reverse 
symptoms of opioid overdose. Opioids with partial agonist activity have some functional 
response when binding to opioid receptors (buprenorphine). Three major types of opioid 
receptors have been identified: mu, delta, and kappa, which are located in the central nervous 
system and the periphery.3  
Opioids may also induce a number of behavioral effects, including euphoria, due to activation of 
reward regions in the brain.1, 4 This may promote repeated use of opioids for pleasure, rather than 
pain relief. Continued opioid use may lead to abuse, dependence, addiction, and other related 
behaviors.
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The literature provides no consistent definition of opioid-related health behaviors like abuse, 
dependence, and addiction. According to the American College of Preventive Medicine 
(ACPM), abuse is defined as “self-administration of medications to alter one’s state of 
consciousness.”5 
The World Health Organization (WHO) defines abuse as “persistent or sporadic excessive drug 
use inconsistent with or unrelated to acceptable medical practice.”6 Drug abuse is also defined in 
the literature as “a disease characterized by continued misuse of drugs even when faced with 
drug-related job, legal, health, or family difficulties.”7 Definitions of other related health 
behaviors are presented in Table 1.1.  
Table 1. 1: Terms and definitions of opioid related behaviors 
Term Definition 
Opioid use disorder “A problematic pattern of opioid use that causes 
clinically significant impairment or distress”1 
 
Misuse “The use of prescription drugs without a 
prescription, or in a manner other than as directed 
by a doctor”2 
Addiction “A primary, chronic, neurobiological disease, 
with genetic, psychosocial, and environmental 
factors influencing its development and 
manifestations”3 
Physical dependence “Adaptation to a drug that produces symptoms of 
withdrawal when the drug is stopped”2 
Diversion “Redirection of a prescription drug from its lawful 
purpose to illicit use; can be done with criminal 
intent”4 
Non-medical use “Intentional or unintentional use of legitimately 
prescribed medication in an un-prescribed manner 
for its psychic effect (either experimentation or 
recreationally)”5 
1. Opioid overdose: prevent opioid use disorder. United States: Centers for Disease Control and Prevention; 
October, 2017. Available from: https://www.cdc.gov/drugoverdose/prevention/opioid-use-disorder.html.  
2. Opioid overdose: commonly used terms. Centers for Disease Control and Prevention; August, 2017. Available 
from: https://www.cdc.gov/drugoverdose/opioids/terms.html. 
3. Definitions Related to the Use of Opioids for the Treatment of Pain:  Consensus Statement of the American 
Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. United 
States: American Society of Addiction Medicine; 2001. Available from: https://www.asam.org/docs/default-
source/public-policy-statements/1opioid-definitions-consensus-2-011.pdf.     
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4. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clinic Proc. 2009; 
84(7):593-601. 
5. Use, Abuse, Misuse & Disposal of Prescription Pain Medication Clinical Reference United States: the American 
College of Preventive Medicine; 2011. Available from: www.acpm.org/?UseAbuseRxClinRef.  
  
Based on the risk of abuse, the Food and Drug Administration (FDA) has classified opioids into 
one of the five federal schedules of controlled substances. Heroin is classified in Schedule I, 
which contains illegal drugs with the highest tendency of abuse. Prescription opioids, which have 
a lower risk of abuse than heroin, are classified in Schedules II to V depending on their specific 
risks. Although the use of prescription opioids is associated with abuse risk, opioids are widely 
accepted as pain relievers. 
Prescription opioid abuse epidemic 
The number of prescriptions for opioids in the United States has increased dramatically over the 
last two decades. According to the Quintiles IMS (Formerly IMS Health), the number of opioid 
prescriptions increased from 76 million in 1991 to 207 million in 2013.8 Each day, more than 65 
thousand of opioid prescriptions are dispensed.9 In the United States, the use of prescription 
opioids varies largely among states, healthcare providers, and patients’ characteristics.10 The 
difference in opioid prescribing rates between states with the highest and lowest prescribing rate 
is about three fold. Among medical specialties, primary care physicians are responsible for 
almost half of opioid prescriptions dispensed.11 Adults aged 40 years and older, women, and 
non-Hispanic white are prevalent users of prescription opioids. The commonly prescribed opioid 
analgesics are oxycodone, hydrocodone, morphine, and methadone.  
Prescription opioid abuse has increased concurrently over the past two decades. Opioid abuse has 
reached epidemic levels in the United States, prompting the US Surgeon General to write a 2016 
letter to all American physicians asking for help to solve the epidemic.12 According to the 
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National Survey on Drug Use and Health (NSDUH), about two million Americans abuse 
prescription opioids.13 Almost four thousand people initiate non-medical use of prescription 
opioids on a single day.9 The prevalence of abuse varies by age, sex, and other factors. Among 
people aged 12 years and older, young adults (18-25 years old) are the biggest abusers of 
prescription opioids.14 Compared to women, men are more likely to abuse opioid analgesics.14 
The risk of abuse increases when patients obtain multiple prescriptions from multiple prescribers 
and/or pharmacies, a behavior known as doctor shopping or multiple provider episode (MPE). 15, 
16 Other risk factors include high daily dose of opioid [>100 morphine milligram equivalents 
(MME)], patients with low income, and presence of a mental illness or a history of drug abuse.17 
Prescription opioid abuse and related health and economic outcomes 
The prescription opioid abuse epidemic is associated with significant negative health outcomes. 
Opioid overdose or poisoning is the most serious health outcome. The Centers for Disease 
Control and Prevention (CDC) defines overdose as “injury to the body that happens when a drug 
is taken in excessive amounts.”18 Opioids in high doses can lead to respiratory distress and death 
due to their impact on respiratory control regions in the brain. The World Health Organization 
(WHO) describes opioid overdose as a combination of three symptoms: pinpoint pupils, 
unconsciousness, and respiratory depression.19 Opioid overdose is the leading cause of drug 
overdose deaths in the United States and was responsible for more than 15 thousands deaths in 
2015.20 The rate of opioid analgesic overdose deaths increased by more than fourfold from 2000 
- 2014. Currently, half of opioid overdose deaths involve prescription opioids. The risk of opioid 
overdose increases with a high daily dose of opioid (>100 MME), use of long acting opioids, and 
the concurrent use of benzodiazepines.  
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Additional negative health outcomes are associated with the prescription opioid abuse epidemic. 
According to the National Poison Data System (NPDS), a comprehensive poisoning surveillance 
database in the United States, more than 40 thousand exposure cases involved a single 
prescription opioid. Adults, aged 13 years and older, constituted more than 30% of total exposure 
cases.21 Moreover, more than 360 thousands emergency department (ED) visits were attributed 
to non-medical use of prescription opioids in 2011.22 The negative health impact of prescription 
opioid abuse become more serious when abusers of prescription opioids shift to heroin use due to 
its lower cost, ready availability in the black market, and higher level of induced euphoria. 
According to the Substance Abuse and Mental Health Services Administration (SAMSHA), four 
in five new heroin users have previously used prescription painkillers.23 
The prescription opioid abuse epidemic has created a substantial economic burden. In a study by 
Birnbaum et al. in 2011, the annual cost of prescription opioid abuse in the United States was 
estimated at $55.5 billion. Of this cost, 46% was attributed to lost workplace productivity, 45% 
to health care costs, and 9% to spending on criminal justice.24 In a more recent study by 
Inocencio et al, the total cost of prescription opioid poisoning was estimated at $16 billion. 
Emergency department (ED) visits shared 0.5 billion of the total estimated cost.25 
The causes of the prescription opioid abuse epidemic are multifactorial. The rapid increase in the 
number of prescriptions written for opioids has increased accessibility to these medications. 
According to the CDC, about 259 million opioid prescriptions were written in 2012 alone.26 Pill 
mills, or operations in which doctors prescribe large quantities of pills for little or no medical 
reason, have been one main driver for the massive increase in opioid prescriptions. In addition, 
increased social acceptability of prescription opioid use for pain relief and aggressive 
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pharmaceutical marketing have facilitated the use of prescription opioids for first-line treatment 
of pain. 
Combating the prescription opioid abuse epidemic 
Controlling the prescription opioid abuse epidemic is complex and requires multifaceted efforts. 
The subjectivity of pain presents the first obstacle to limiting opioid prescribing. Patients have 
the right to receive adequate pain relief, but the severity of pain and the appropriateness of 
opioids to address that pain are difficult to determine and often depend on the prescriber’s 
judgment. Doctor shopping behavior, or multiple provider episode (MPE), presents another 
obstacle to controlling this epidemic. MPE, defined as “the use of five or more prescribers and 
five or more pharmacies within three months”27 makes it difficult for doctors, pharmacists, and 
the drug enforcement agencies to identify abusers and target them for interventions. Finally, 
efforts to control the opioid abuse epidemic must address the multiple pathways by which 
abusers can obtain prescription opioids. These pathways include taking or purchasing 
prescription opioids from relatives, friends, or the black market.28 According to the NSDUH, 
more than half of non-medical users of prescription opioids obtain them from a friend or relative 
for free.28 Due to the complexity of the prescription opioid abuse epidemic, policies or 
interventions developed at the federal or state level must ensure a balance between ensuring 
access to prescription opioids for patients who need them while minimizing the risk of abuse. 
Opioid prescribing guidelines 
One method for addressing the prescription opioid abuse epidemic is to decrease access to 
opioids for nontherapeutic use. Prescribers are the gate keepers of prescription opioids and thus, 
must ensure proper prescribing of opioids to patients. Several guidelines have been developed for 
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prescribing opioids which provide recommendations on dosing threshold, cautious titration, and 
risk mitigation strategies. The most recent opioid prescribing guideline was published by the 
CDC in 2016 and provides recommendations for prescribing opioids for adults population (≥18 
years old) with chronic non-cancer pain in primary care settings.29  
Prescription Drug Monitoring Programs (PDMPs) 
In 2011, the Federal Government identified PDMPs as one of four key areas of focus to prevent 
prescription drug abuse.30 PDMPs are state-run electronic databases that collect information on 
the prescribing and dispensing of prescription opioids and other controlled substances. The 
pharmacy-reported prescription fill records contained in the PDMPs ease the tracking and 
analyzing of prescription data. PDMPs thereby help to identify improper prescribing, dispensing 
behavior, and doctor shopping. PDMPs cover controlled substances as defined by federal and 
state laws; most PDMPs monitor drug schedules II-V. PDMPs are primarily used by physician 
prescribers, nurses, and pharmacists. Other authorized entities, including law enforcement 
agencies and regulatory boards, may access prescribing data. States’ PDMPs are operated mainly 
by pharmacy boards, departments of health, or law enforcement agencies. A sustained source of 
funding is essential to maintain PDMP functioning; state general funds are the major source of 
funding. Also, federal grants play an important role in supporting states PDMPs; the most 
common federal grant is Harold Rogers PDMP Grant Program. 
PDMP use process 
The PDMP use process begins when a patient comes to a physician office or other outpatient 
setting seeking a prescription for opioids. Before issuing the prescription, the physician must log 
in to the PDMP database to retrieve the patient’s schedules II-V prescription history. The 
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checkup step should be done for all new and established patients. If abuse behavior is suspected, 
opioids may not be prescribed. Otherwise, the prescription is issued and sent to the pharmacy. 
Before dispensing, the PDMP database should be double checked by the pharmacist to ensure 
safe and appropriate use of prescription opioids. When inappropriate use of opioids is suspected, 
the pharmacist may not dispense the prescription. The pharmacist is responsible for reporting all 
dispensed prescriptions for opioids to the PDMP program manager who stores the information 
on a database accessible to authorized parties. The transmission of prescribing data from 
pharmacy to the state PDMP database is done through an external vendor, where data are 
checked for any errors. The PDMP use process cycle continues whenever the same patient seeks 
another prescription for opioids. The PDMPs use process is summarized in Figure 1.1 
 
Figure 1. 1: PDMP use process 
PDMP adoption  
PDMPs are currently operational in all states. However, state PDMPs differ in practices 
pertaining data collection, analysis, user access, utilization, and user education. A PDMP 
practice is defined as “a database operation, or a particular policy that PDMP staff might adopt 
A prescriber 
checks a state 
PDMPs 
system before 
issuing a 
prescription
Writes a 
prescription 
and send it to 
a pharmacy
A pharmacist 
checks the 
state PDMPs 
system
Dispenses the 
prescription
Reports 
prescription 
data to the 
state PDMPs 
system
Takes other 
actions
No 
prescription
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when carrying out its functions.”31 PDMPs practices can be used to evaluate the effectiveness of 
PDMPs.  
PDMP effectiveness 
The effectiveness of PDMPs has been questioned since their implementation. The impact of 
PDMPs on physician prescribing behavior, doctor shoppers, and health outcomes including 
overdose deaths and ED visits has been evaluated. The literature reveals inconsistent evidence on 
the effectiveness of PDMPs. However, a growing body of evidence suggests that PDMPs are 
effective tools.  
The effectiveness of PDMPs may be influenced by the degree to which they conform with best 
practices related to data collection, analysis, utilization, user access, and education. In 2012, the 
Center of Excellence (COE) at Brandies University published a white paper proposing 35 
potential best practices for PDMPs.32 Most of the promising best practices proposed in the paper 
had no or weak evidence supporting their effectiveness and were suggested based primarily on 
expert opinion. As a result, more research on the effectiveness of PDMPs best practices is 
needed.  
To be effective, PDMPs must be utilized by their intended users, which include prescribing 
physicians, nurses, and pharmacists. Currently, utilization of PDMPs is low and highly variable 
among different states and health care providers.31, 33-35 Current efforts to improve PDMPs 
therefore focus on implementing best practices to maximize their utilization. At the 2016 
National Prescription Drug Abuse and Heroin Summit, eight best practices were proposed to 
increase the use of PDMPs that focused on PDMPs utilization.36 Recently, the National Alliance 
for Model State Drug Laws (NAMSDL) published a report advocating for these PDMP best 
practices.31 Nevertheless, support for these practices only comes from case studies of selected 
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states implementing one or more practices. Although its effectiveness is not yet supported by 
high-quality evidence, prescriber mandated utilization seems to be the most promising best 
practice. 
Prescriber use mandates 
Prescriber use mandates are defined as “state laws and regulations that require prescribers to 
view a patient’s PDMP data under certain circumstances.”31 As of January, 2017, 32 states 
enacted laws requiring prescribers to check PDMPs in specific scenarios.37  
States differ widely in how they require prescribers to check PDMPs.38, 39 Some states have 
comprehensive rules regarding when and how frequently a prescriber should access PDMPs. For 
example, in Kentucky, prescribers are required to check PDMPs before prescribing some opioids 
and benzodiazepines for all patients and every three months thereafter. New York, Ohio and 
Connecticut have similarly comprehensive regulations. In contrast, Tennessee, Oklahoma, and 
other states do not require PDMP use for all patients and allow for longer follow-up intervals. In 
Delaware, North Dakota, and Utah the use of PDMPs is dependent upon a prescriber’s judgment.   
Mandatory use of PDMPs has been opposed by prescribers nationwide for a number of reasons. 
Concerns surrounding technical issues with PDMPs systems have created some opposition to 
mandatory utilization laws.40, 41 Many physicians assert that checking PDMPs unnecessarily adds 
to an already high work load and delays other important duties. Sustained funding for PDMPs is 
also a concern, as mandatory use may require additional staff to maintain the workflow of 
mandatory utilization.  
Most of the currently available evidence of the effectiveness of mandatory PDMPs consists of 
analyses from selected states comparing utilization rates and opioid-related outcomes before and 
after the implementation of prescriber mandatory use regulations.31, 38 A study by the University 
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of Kentucky found that a prescriber use mandate policy sharply increased in prescriber 
utilization of the Kentucky All Schedule Prescription Electronic Reporting (KASPER) PDMP.42 
Improvements in opioid prescribing behavior, doctor shopping, and patients’ health outcomes 
were also reported. Comparable results were documented for New York and Ohio, states that 
implemented similar comprehensive prescriber use mandates.31 Although preliminary studies 
suggest that prescriber use mandates are effective, the strength of this evidence is limited by a 
lack of comparison with non-prescriber use mandates states. Only one study compared opioid 
overdose death rates in mandated states with non-mandated states and found a positive impact.43 
In addition to prescribers, pharmacists are other potential users of PDMPs. As of January 2017, 
21 states require pharmacists to enroll in state PDMPs, and 11 states mandate pharmacist use of 
PDMPs prior to dispensing a controlled substance prescription. Evidence on the effectiveness of 
pharmacist PDMPs use mandate policies is lacking and more research is required to establish its 
value. 
Other PDMP best practices  
In addition to prescriber use mandates, NAMSDL report discusses seven more evidence-based 
practices that may increase prescriber utilization of PDMPs.31 As the case with prescriber use 
mandates, evidence on the effectiveness of these practices is derived from case studies of 
selected states. The definitions of these best practices are presented in Table 1.2.  
Table 1. 2: Evidence based practices to increase prescriber utilization of PDMPs31 
Best practice Definition 
Delegate access Allowing staff, such as a nurse, to access the 
PDMPs database on behalf of a provider 
 
Unsolicited reports Proactively send reports on prescription opioid 
utilization to healthcare providers, law 
enforcement agencies, and regulators to flag 
suspicious drug use or prescribing behavior 
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Data timeliness Uploading information into the database at set 
intervals, whether in real time, daily, 
weekly, or monthly 
 
Streamlined enrollment Simplifying prescriber enrollment to the PDMPs 
database 
 
Educational and promotional initiatives Efforts that promote the use of PDMPs, such as 
educating prescribers on PDMPs access and use 
 
Health information technology (IT) integration Combining PDMP data with other clinical data 
through technologies that are used 
to store, communicate, and analyze health 
information, such as electronic health 
records 
 
Enhanced user interfaces Implementing user-friendly technologies, such as 
dashboards and mobile applications 
that provide PDMPs data in easily understandable 
formats 
 
Other strategies to curb opioid abuse epidemic 
In addition to PDMPs, the report published by the Federal Government discussed three other 
plans to curb the prescription opioid abuse epidemic.30 One is to implement educational 
programs to increase patients’ awareness of the danger of abusing prescription opioids. In 
addition, health care providers should be trained on how to identify and respond to suspicious 
drug use behavior. Unused and expired prescription opioids are another risk for abusing opioids. 
Patients often keep unneeded medications at home making them readily available for family 
members and friends to use. Providing people with proper drug disposal methods is a way to 
reduce the risk of abuse. The last proposed plan develops enforcement actions against doctor 
shoppers and improper prescribing behavior. 
The current research described in this dissertation evaluates the effectiveness of PDMPs by 
assessing the impact of mandated prescriber use of PDMPs on emergency department (ED) visits 
related to prescription opioid poisoning. This was measured by comparing ED visits within states 
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before and after mandate implementation and between states with and without requirements for 
mandatory use. To our knowledge, no previous studies have evaluated the relationship between 
mandated prescriber PDMPs utilization and ED visits.  
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Section 1.2: Conceptual Framework 
This research uses Donabedian’s structure-process-outcome quality framework to evaluate the 
effectiveness of PDMPs (Figure 1.2).44 “Structure” refers to the presence of things associated 
with a quality initiative such as having a PDMP program and the potential best practices 
employed within the program. Simply having a PDMP program is unlikely to result in quality if 
people do not follow the policies and procedures within the program. Therefore, “process” 
describes the actions taken by program participants like checking the PDMP before prescribing 
or dispensing. The assumption is that quality occurs when people follow certain processes, 
although this may not be true when the structure is poorly designed and/or the processes are 
ineffective. Donabedian’s framework argues although structure and process are important for 
measuring quality, “outcomes” or the end result of care are ideal for assessing the quality of 
healthcare. Positive health outcomes are desired and therefore will be used to assess the 
effectiveness of PDMP interventions.   
The existence of PDMPs and policies mandating that prescribers use them (i.e., structure) is 
proposed as an intervention to improve their utilization (i.e., process) among prescribers. It is 
additionally proposed that this will reduce prescription opioid-related ED visits associated with 
opioid poisoning (i.e., outcomes). In addition, the economic impact of prescriber use mandates 
will be assessed.   
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Figure 1. 2: The Donabedian model 
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Section 1.3: Rationale 
Mandated use of PDMPs by prescribers is a relatively new policy. A number of states have 
implemented prescriber use mandates, and these mandates contain differing stipulations on the 
scenarios requiring PDMPs utilization. These mandates have been enacted with the expectation 
that they will increase the low utilization rate of PDMPs and in turn, reduce inappropriate 
prescribing and adverse health outcomes associated with prescription opioid abuse. These 
expectations are supported by limited evidence of the association between prescriber use 
mandates and increased PDMPs utilization as well as reduced opioid prescribing rates, doctor 
shopping, and adverse health outcomes.31, 32, 38   
PDMPs use mandates are opposed by many prescribers around the country and may be 
associated with unintended consequences on their prescribing behaviors.40, 41 Thus, adopting 
prescriber use mandates is not a smooth process for policy makers, and stronger evidence of its 
effectiveness is needed to promote this policy. 
The current literature provides a limited evidence on the impact of prescriber use mandates on 
prescription opioid abuse- related health outcomes. More rigorous study designs are needed to 
demonstrate or refute the effectiveness of prescriber use mandates. To our knowledge, none of 
the evidence has assessed the relationship between PDMPs and prescription opioid poisoning- 
related ED visits while specifically considering prescriber use mandates. 
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Section 1.4: Objectives 
The main objective of this research is to examine the impact of PDMP prescriber use mandates 
policy on ED visits related to prescription opioid poisoning among adults in the United States. 
The underlying concept of this research is study the relationship between prescriber use 
mandates and prescription opioid abuse-related health outcomes. The population of interest is 
ambulatory (out-patient) individuals aged 12 years and older who receive their opioids from 
prescribers in outpatient settings including physician offices and EDs. Four specific aims fall 
under the main objective. 
Specific aim I: 
A. To identify and select states with laws or regulations mandating prescriber use of 
PDMPs.  
B. To identify comparison state(s) without mandatory use policies. 
Specific aim II: 
Among Kentucky and North Carolina residents: 
A. To determine the prevalence of prescription opioid poisoning ED visits.  
B. To characterize prescription opioid poisoning ED visits based on socio-demographic and 
clinical characteristics. 
C. To examine associations between patients’ sociodemographic and clinical characteristics 
and prescription opioid poisoning ED visits. 
Specific aim III: 
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A. To compare occurrences of prescription opioid poisoning ED visits pre and post 
prescriber use mandates in Kentucky. 
B. To compare occurrences of prescription opioid poisoning ED visits in Kentucky and 
North Carolina, after prescriber use mandate implementation. 
Specific aim IV: 
A. To estimate the direct medical costs associated with prescription opioid poisoning ED 
visits in Kentucky and North Carolina. 
B. To estimate the economic impact of prescriber use mandates in Kentucky.
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Chapter 2 
 
 
 
Literature Review on Prescription Drug Monitoring Programs (PDMPs) 
A comprehensive literature review on PDMPs was completed in April 2017. A search of 
PubMed/MEDLINE (limited to English) and Cumulative Index to Nursing and Allied Health 
Literature (CINHAL) was conducted, using different combinations of keywords and Medical 
Subject Headings (MeSH) terms. A predetermined inclusion and exclusion criteria were used to 
screen for eligible studies. The following inclusion and exclusion criteria were considered in the 
literature search: 
Inclusion criteria: 
The literature search considered original studies that: 
a. Assessed the impact of PDMPs implementation on outcomes related to prescriber, 
patient, or health outcomes. 
b. Assessed PDMPs utilization among prescribers.  
c. Evaluated the impact of prescriber use mandates on opioid prescribing, doctor shopping, 
or health outcomes. 
d. Examined the influence of adopting other PDMPs best practices on PDMPs effectiveness.
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Exclusion criteria: 
Studies with one or more of the following criteria were excluded: 
a. Conducted outside the United States. 
b. Considered veterans or cancer patients as the study population. The current research 
considers prescription opioid abuse among the general population. Veterans or cancer 
patients have different characteristics and thus, were excluded. 
c. Assessed prescribers’ knowledge, opinion, or perception toward PDMPs or PDMPs best 
practices.  
d. Examined PDMPs utilization solely among pharmacists. 
e. Descriptive studies: these include studies that utilize PDMPs data to describe patterns of 
opioid abuse, identify risk factors and risky prescriber and patient behaviors.  
Search terms used are summarized in Table 2.1. Titles and abstracts of articles were checked for 
inclusion and exclusion criteria. The original 885 articles were reduced to 37 after applying 
inclusion and exclusion criteria and eliminating duplicates. Similar articles to the included 
studies were also reviewed, yielding 5 studies. A total of 42 studies were included for discussion. 
The literature search is summarized in Figure 2.1. 
Table 2. 1: Search terms history 
Search term Eligible studies 
 
Prescription drug monitoring program 
Prescription drug monitoring program AND 
emergency room visits 
Prescription drug monitoring program AND 
(prescriber mandate OR mandatory use OR 
mandates OR provider mandate) 
PubMed                        CINHAL 
42                                       35 
3                                          5 
 
7                                          3 
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“Analgesics, opioid” [Mesh] AND (prescriber                                                                     
mandate OR mandatory use OR mandates OR 
provider mandate) AND (monitor OR control 
OR manage) 
Total unique eligible studies 
2   0 
                                           
 
 
 
                                                 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1: Flow chart summary of literature search 
 
 
Articles retrieved based on 
search terms 
n= 885  
 
Excluded articles that did not 
meet the inclusion/exclusion 
criteria  
n= 731 
Eligible articles 
n= 154 
 
Eliminated duplicates 
n= 69 
Unique eligible research 
articles 
n= 85 
 
Unique eligible research 
articles 
n= 37 
Excluded reports, reviews, 
letters  
n= 48  
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Overview of the literature 
Prescription opioid abuse has reached epidemic levels in the United States. Concurrently, the 
number of opioid overdose deaths and related emergency room visits has dramatically increased. 
In response to the epidemic, the federal government released in 2011, the Prescription Drug 
Abuse Prevention Plan that includes actions in four major areas to combat the epidemic. 
Increased utilization of prescription drug monitoring programs (PDMPs) was one major area. 
PDMPs are state run electronic databases that track prescribing and dispensing data and thus, 
help identify doctor shoppers and improper prescribing behaviors. The effectiveness of PDMPs 
have been assessed through their impact on doctor shoppers, opioid prescribing behavior, and 
health outcomes like overdose deaths. The existing literature found mixed evidence on the 
effectiveness of PDMPs, however, there is a growing body of literature that supports their 
effectiveness. Studies have shown that PDMPs are effective if utilized. A recent report from the 
National Alliance for Model State Drug Laws (NAMSDL) indicated that utilization of PDMPs is 
low and highly variable among the states and healthcare providers within a state.31 The low and 
inconsistent utilization of PDMPs makes it difficult to evaluate their effectiveness.  
To be effective, PDMPs must be utilized by prescribers, dispensers, and other intended users. 
Correspondingly, many states implemented laws, regulations, or policies that mandate 
prescribers and/or dispensers to check the system before issuing a controlled substance 
prescription. Case studies from Kentucky, New York, and Ohio showed that prescriber use 
mandates increase PDMPs utilization and are effective in reducing doctor shopping and opioid 
prescribing.31 However, higher levels of evidence are needed to approve the effectiveness of this 
policy. 
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The aim of the literature review was to evaluate PDMPs effectiveness with a focus on the impact 
of prescriber use mandates. The search terms identified studies in three related areas:     
a. Studies that assessed prescriber utilization of PDMPs. These studies were considered, 
because PDMPs utilization is part of their effectiveness. 
b. Studies that assessed the impact of PDMPs on patient behavior, prescriber behavior, or 
health outcomes. 
c. Studies that specifically evaluated the impact of prescriber use mandates on patient 
behavior, prescriber behavior, or health outcomes.  
Part 1: Literature review on prescriber utilization of PDMPs 
A total of 17 studies have evaluated prescriber utilization of PDMPs in different medical 
settings. Five studies focused on emergency providers’ usage of PDMPs. One study included 
only primary care physicians, and another study assessed PDMPs utilization among dentists. The 
remaining ten studies evaluated PDMPs utilization among pharmacists, dentists, and/or 
physicians in different specialties. Studies are summarized in Table 2.2. 
Poon et al. conducted a mixed method study to assess usability of PDMPs among emergency 
providers (EPs) in Massachusetts.45 The first part of the study involved quantitative analysis of 
PDMPs usability compared to three other commonly performed tasks in the ED. Accessing 
PDMPs took a longer time and required more mouse clicks compared to other tasks. In addition, 
PDMPs were the most difficult task compared to others (mean = 4.29 on a 1–7 scale). In terms of 
frequency of use, PDMPs were less frequently utilized compared to two other tasks (mean = 2.41 
on a 1–5 scale). The second part of the study involved semi-structured interviews with EPs to 
identify barriers to use PDMPs. Difficulty in accessing the system, retrieving patient’s history, 
and analyzing patient information were common barriers.  
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In a similar study by Young et al., EPs in Florida were surveyed about their utilization of 
PDMPs.46 The findings of the study indicated low and infrequent use of the system. Only 3% of 
providers check PDMPs before issuing a controlled substance prescription; almost half of them 
check the system only when misuse is suspected. As low as 12% of EPs use PDMPs most of the 
time. Among frequent users, the chief complaint when using PDMPs is the frequent time out of 
the system (55%). Common barriers among all other users included frequent need to renew the 
password (68%) and difficulty in accessing the system (52%).   
A third survey was conducted by Fleming et al.47 The study evaluated emergency physicians’ 
utilization of PDMPs in Texas and included those with PDMP accounts and non-registrants. 
Among all physicians, 76% were non-PDMP users; among users, 83% utilized PDMP (≤20%) of 
the time. 
The fourth survey of EPs was by Wang et al. who investigated PDMPs utilization among 
pediatric emergency physicians.48 The study included physicians from 21 states, assessing their 
knowledge about the state PDMP and identifying barriers to use the system. Thirty percent of 
physicians were not aware of their state PDMPs. Among those who registered with the state 
PDMPs, almost 60% rarely use the system and 35% have never used it. However, these findings 
may not be nationally representative to pediatric emergency physicians in the United States due 
to the small sample size (n= 47). In accordance with previous studies, the most common barrier 
to using PDMPs were difficulty to access the system; insufficient time and forgetting to check 
the system were also reported as common barriers.  
The last survey was conducted by Perrone et al. and assessed PDMPs utilization among medical 
toxicologists (MTs).49 The survey utilized a nationally representative sample of MTs (n=205), 
most of whom practiced emergency medicine for a significant portion of their clinical practice. 
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The survey responses indicated variable knowledge and utilization of PDMPs. Most MTs had 
some knowledge about their state PDMPs, but more than 25% did not access it. Among all 
surveyed MTs, 50% have used the state PDMPs with 30% of them utilizing it daily. Most 
respondents complained about the time lag between data entry and retrieving patient information. 
Also, being unaware of the PDMPs existence and lack of registration to the system prevented 
MTs from accessing the state PDMPs.  
PDMPs utilization was also assessed among primary care physicians. A study by Rutkow et al. 
included a national representative sample of primary care physicians in the United States.50 
Authors found that approximately one quarter of surveyed physicians were unaware of their state 
PDMPs. Fifty three percent of all physicians have used PDMPs. Among those with existing 
knowledge of their state PDMPs, 87% have used the system. However, only 23% check the 
system when abuse behavior is not suspected. Information on frequency of using PDMPs was 
not provided in the study. Among barriers to use the system, the lengthy period of the process 
was the most common. 
Dentists are another group of prescribers who significantly contributed to the prescription opioid 
epidemic. Almost 12% of immediate release opioids are prescribed by dentists.51 A study by 
McCauley et al. examined dentists use of PDMPs as an opioid abuse risk mitigation strategy in 
South Carolina.52 About 62% have never used the system. Among users, only 12% of dentists 
check PDMPs before issuing an initial prescription of opioid each time. For refill prescriptions, 
about 15% of dentists use PDMPs each time; however, more than 36% have never used it. Most 
dentists were unaware of the PDMPs existence (72%) and one third did not know how to access 
the system. 
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The remaining studies (n =10) involved prescribers with different specialties to evaluate and 
compare their utilization of PDMPs. Most of the studies (n =7) were conducted in single states, 
one study compared PDMPs utilization between Connecticut (CT) and Rhode Island(RI), and 
two studies included national representative samples.  
Three studies focused on PDMPs utilization among prescribers in Oregon.53-55 The first study 
compared PDMP users (n=619) to non-users (n=439).53 Most PDMP users were primary care 
physicians (56.4%), followed by emergency physicians (17.2%). Among non-users, physicians 
in other specialties constituted the largest group (27.5%), followed by surgical specialties 
(20.7%). Also, the study identified high and low frequency PDMP users (≥ or < four times in 
three month periods, respectively). Among high frequency users, 50% use the system ten or 
more times a month, compared to 10% of low frequency users. Almost all physicians reported 
checking PDMPs when abuse behavior is suspected and/or early refill is requested. Only one 
third of respondents use PDMPs whenever a controlled substance is prescribed.  
A mixed method study in Oregon assessed PDMP registration, use, and barriers to use among 
clinicians with different specialties.54 In 2013, using Oregon’s PDMP registry, authors found that 
25% of all licensed prescribers had PDMP accounts; 45% of accounts were attributed to medical 
doctors. Among controlled substance prescribers, 36% were registered with PDMPs. Of these 
prescribers, 50% of osteopathic physicians and nurse practitioners had active PDMPs accounts, 
compared to 36% of medical doctors. Among medical doctors, the number of PDMPs queries 
have been almost doubled from 2012 to 2013. The average number of queries per user have 
increased from 14 to 16 queries per month. When surveyed about reasons for not registering and 
barriers using PDMPs, prescribers were divided into three groups: frequent users (> one query 
per month, n= 358), infrequent users (≤ one query per month + one query to PDMP, n= 261), and 
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non-registrants (n= 439). Almost half of non-registrants were not aware that they could register. 
Among the three groups, time constraints were reported as the most common barriers to using 
PDMPs, followed by an inability to delegate PDMPs access to other medical staff. A sample of 
prescribers who were PDMP users was further studied by Leichtling et al.55 In this study, 
clinicians were interviewed to identify patterns of PDMP use. Most PDMP users were regular 
users with 78% accessing PDMPs ten or more times a month. Authors compared patterns of 
PDMP use among short and long term prescribers. Long term prescribers used PDMPs routinely 
compared to their counterparts who were less frequent users. However, long term prescribers 
checked PDMPs more frequently for new patients than existing patients. Conversely, short term 
prescribers depend more on their clinical judgment and suspected abuse behavior, when deciding 
to use the system. 
A survey by Rittenhouse et al. measured PDMPs utilization among medical doctors, nurse 
practitioners, and pharmacists in Arkansas.56 The sample had an equal distribution of the three 
groups of providers; similarly, PDMPs utilization was evenly distributed among the three groups 
in terms of frequency of accessing the system. Accessing PDMPs varied from daily use (21.1%) 
to less than three times a month (26.2%). Most medical doctors and nurse practitioners accessed 
PDMPs when abuse behavior was suspected (91% and 87%, respectively); less percentage use 
the system with any involvement of controlled substance prescription (36% and 45%, 
respectively). 
A similar survey in Maryland evaluated PDMPs registration and use among primary care, pain, 
and emergency providers (EPs).57 The sample included three groups of providers: registered 
users (46%), registered non-users (28%), and non-registrants (26%). PDMP users included 
prescribers with at least one PDMPs access in the 18 month period preceding the survey. Among 
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non-registrants, about one third were not aware of the state PDMPs or lacked knowledge of how 
to register. Among registered non-users and non-registrants with PDMPs access, 69% and 49% 
respectively, have ever used the system in their practice. More than 70% of prescribers 
(including registered users, non-users, and non-registrants) found the system easy to access. In a 
multivariable regression model, physicians who wrote opioid prescriptions for more than 50 
patients accessed the PDMPs three times as often as those prescribing opioids for less than ten 
patients monthly (IRR = 3.00, 95% CI = (1.07–8.43)). Common barriers to using PDMPs for 
registered physicians were: multiple IDs for same the patient, system slowness, and missing data. 
No data on frequency of use or drivers to use PDMPs were reported in the study. 
An older study in Ohio (2011) revealed a significant difference in PDMPs awareness and 
utilization among physicians with different specialties.58 The study found that 84% of all survey 
respondents were aware of the Ohio PDMPs; however, only 59% used it. Among all specialties, 
pediatric physicians were least aware of the PDMPs (67%). Emergency medicine had the highest 
proportion of utilization compared to pediatric physicians (p-value ≤0.001). The study did not 
report figures on frequency of utilization. Almost all physicians (91%) reported concerns about 
drug abuse that drive accessing the system; no significant difference, in reasons to use PDMPs, 
between different specialties were noted. 
Another survey in Ohio compared PDMPs utilization among attending and resident physicians 
(n=25 and 70, respectively).59 The study found that almost all attending physicians (96%) and 
most resident physicians (81%) were aware of the system. However, about one third of attending 
physicians and half of the resident physicians do not utilize PDMPs. Most PDMP users utilized 
the system to address concerns about prescription drug abuse. Unlike most previous studies, the 
current study did not assess frequency of PDMP use among different specialties. 
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Green et al. conducted a survey among prescribers in CT and RI.60 The study found significant 
differences in PDMPs utilization among prescribers in the two states (44% and 16.3% have ever 
used the system, respectively, p-value = <0.0001). Prescribers in CT used the PDMPs more 
frequently compared to those in RI (p-value <0.0001). Almost 35% of CT prescribers accessed 
the PDMPs weekly or more often, compared to 3.3% in RI. More than two thirds of prescribers 
in both states did not use PDMPs, because they were not aware of their existence (68% in CT, 
84% in RI). The second reported barrier to using PDMPs in CT and RI was a lack of knowledge 
of how to use the system and lack of internet access, respectively.  
The last two studies assessed PDMP utilization among nationally representative samples of 
prescribers.61, 62 The first study was carried by Fleming et al.61 The study involved PDMP 
administrators from 15 states to evaluate prescribers, pharmacists, and law enforcement 
personnel utilization of PDMPs. Authors found that prescribers had the highest rate of requests 
per population of 100,000, followed by pharmacists and law enforcement personnel. Also, it was 
found that availability of online access and fast turnover of PDMP requests increased utilization. 
The study did not evaluate frequency of PDMP use among prescribers with different specialties 
or assessed barriers to use. 
Hildebran et al. conducted a qualitative study including 35 prescribers from nine states.62 
Prescribers with different specialties were interviewed to identify patterns of PDMP use. Most 
clinicians reported checking PDMPs for clinical purposes, others use it for administrative 
requirements. Examples of clinical use included verifying prescription history and coordinating 
with other prescribers when suspected prescribing behavior is noted. Consistency for using 
PDMPs were varied among specialties. Long term prescribers checked PDMPs more consistently 
for their patients compared to emergency providers. Barriers to using PDMPs were also 
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identified; patient satisfaction rating was one important barrier. Some organizations evaluated 
prescribers based on patient satisfaction; utilizing PDMPs may delay treatment sessions or forbid 
an opioid prescription, adversely affecting patient satisfaction. Also, lack of training on how to 
access PDMPs was another reported barrier.  
Summary of part I literature review:  
Studies of PDMPs utilization revealed low and inconsistent use of the system among prescribers 
in different states. The literature also documented variation in PDMP use among prescribers with 
different specialties. Most of the encountered surveys had a low response rate (≤50%) and small 
sample size. Thus, findings of the studies may not be generalized to the whole population of 
prescribers. PDMP utilization was assessed in terms of frequency of accessing the system and 
reasons that drive access of the system. Studies used different terms to describe PDMP users. 
Some studies considered prescribers who used the system at least one time in the past as PDMP 
users. Other studies classified prescribers as frequent or infrequent users based on their 
frequency of checking the system in a defined period of time. Many studies agreed that most 
prescribers check the system when abuse behavior is suspected; fewer prescribers use PDMP 
with every controlled substance prescription. Studies also shared common barriers for using 
PDMPs including difficulty in accessing the system, lack of knowledge of the system’s 
existence, and time constraints. The low and inconsistent utilization among prescribers may 
adversely affect PDMP effectiveness. PDMPs must be utilized sufficiently to have a powerful 
impact on the prescription opioid abuse epidemic.  
The second part of the literature review evaluates the effectiveness of PDMPs through assessing 
their impact on prescription opioid abuse risk measures, opioid prescribing, and health outcomes 
related to prescription opioid abuse. 
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Table 2. 2: Summary of included studies (prescriber utilization of PDMPs) 
Author Study design 
and sample 
Sample size Outcome 
measure of 
interest 
Period Setting and 
data source 
Related findings 
Poon et al45 
2016 
- Mixed 
method study 
 
- Emergency 
physicians 
(EPs) 
17 - Time and 
number of 
mouse clicks 
required to 
complete the 
PDMP task 
compared to 
three 
commonly 
performed 
tasks in the 
ED 
 
- Ease of use 
 
5 months One large 
urban 
academic 
medical 
center in MA 
- PDMPs require more time and 
greater number of mouse clicks 
 
- PDMPs are more difficult to 
use compared to other tasks 
Young et al46 
2017 
-Web based 
survey 
 
-EPs 
88 - Utilization 
of PDMP 
5 weeks Florida - Most EPs (99%) are aware of 
PDMPs,  21% rarely use it 
 
- Only 3% use it with every CS 
prescription 
 
Fleming et 
al47 
2014 
- Survey 
 
- EPs 
76 - PDMP 
utilization 
_ Emergency 
medicine 
conference in 
Texas 
-76% do not use PDMPs as a 
screening tool 
 
- Most users (83%) utilize 
PDMPs ≤ 20% of the time 
 
Wang et al48 
2016 
- Web based  
Survey 
 
- Pediatric EPs 
 
47 - PDMP 
utilization 
_ 21 states - 60% rarely use the system 
 
- 35% have never used it 
 
Perrone et 
al49 
2012 
-Web based 
survey 
 
- Medical 
toxicologists 
(MTs) 
205 - PDMP 
utilization 
2 months 35 states - More than 25% do not access 
PDMPs 
 
- 50% have ever used PDMPs 
 
- only 30% access it daily 
 
Rutkow et al50 
2015 
- Mail survey 
 
- Primary care 
physicians 
420 - PDMP 
utilization 
18 weeks 51 states - 53% of all physicians have 
used PDMPs 
 
-77% check the system only 
when abuse behavior is  
suspected 
 
McCauley et 
al52 
2015 
-Web based 
survey 
 
- Dentists 
86 -PDMP 
utilization 
_ South- 
Carolina 
- 38% have ever used PDMPs 
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- 27% use PDMPs all the times 
for initial and refill opioid 
prescriptions 
 
Irvine et al53 
2014 
-Mail survey 
 
- Clinicians 
with DEA  
license 
1,058 
(PDMP users 
and non-users) 
-PDMP 
utilization 
_ -Oregon 
 
-PDMP 
registry 
- 95% access PDMPs when 
abuse or diversion is suspected 
 
- Less than 50% check it for 
every new patient or every time 
they prescribe a CS 
 
Deyo et al54 
2014 
- Mixed 
method study 
 
- Clinicians 
with DEA 
 
- 612 PDMP 
frequent  users 
 
- 503 
infrequent 
users 
 
- 1,789 non-
registrants 
 
- PDMPs 
registration 
and use 
_ -Oregon 
 
-PDMP 
registry 
- 25% of all licensed prescribers 
had PDMPs accounts 
 
- 36% of CS prescribers were 
registered with PDMPs 
 
- Among medical doctors, 
number of PDMPs queries have 
almost doubled in 2013 
Leichtling et 
al55 
2017 
- Qualitative 
telephone 
interviews 
 
-Clinicians 
registered with 
Oregon PDMP 
33 - Pattern of 
PDMP use 
_ Oregon - Most of PDMP users were 
regular users 
 
- Long term prescribers used 
PDMPs routinely compared to 
short term prescribers 
 
- Short term prescribers depend 
more on their clinical judgment 
and suspected abuse behavior, as 
a driver to use PDMPs 
 
Rittenhouse 
et al56 
2015 
-Web based 
survey 
 
- Medical 
doctors, nurse 
practitioners, 
and 
pharmacists 
1541 -PDMPs 
utilization 
30 days Healthcare 
practices in 
all 75 
Arkansas 
counties 
- PDMPs access varied from 
daily access (21.1%) to < 3 times 
a month (26.2%) 
 
- Most medical doctors and nurse 
practitioners accessed PDMPs 
when abuse behavior is 
suspected 
 
Lin et al57 
2016 
-Mail survey 
 
- Primary care, 
pain, and EPs 
 
405 
(105 non-
registrants, 
114 registered 
non-users, 186 
registered 
users) 
-PDMP 
registration 
and use 
4 months - Maryland 
 
- Maryland 
(DHMH) 
 
- 85% of all prescribers with 
PDMPs access have ever used 
the system in their practice 
 
- Physicians who wrote opioid 
prescriptions for more than 50 
patients accessed the PDMPs 
three times as often as those 
prescribing opioids for less than 
10 patients monthly (IRR = 3.00, 
95 % CI = 1.07–8.43) 
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Feldman et 
al58 
2011 
- Survey 
 
- Physicians 
with different 
specialties 
95 -Awareness 
and 
utilization of 
state PDMPs 
3 months One 
academic 
medical 
center in 
Ohio 
-84% of all survey respondents 
were aware of Ohio PDMPs, 
59% used PDMPs 
 
- Emergency medicine had the 
highest proportion of utilization 
compared to pediatric physicians 
(p-value ≤0.001) 
 
Feldman et 
al59 
2012 
- Survey 
 
-Attending and 
resident 
physicians 
- 70 resident 
physicians and 
25 attending 
physicians 
-Utilization 
of state 
PDMPs and 
reasons for 
accessing the 
system 
3 months One 
academic 
medical 
center in 
Ohio 
- One third of attending 
physicians and half of resident 
physicians do not utilize PDMPs 
 
- Most of PDMP users utilized 
the system to address concerns 
about prescription drug abuse 
 
Green et al60 
2012 
-Web based 
and mail 
survey 
 
- All providers 
licensed to 
prescribe 
scheduled 
medications 
with an email 
address 
 
1,385 
prescribers 
(998 in CT and 
375 in RI) 
-PDMPs 
utilization 
6 months CT and RI - Prescribers in CT used PDMPs 
more frequently compared to 
those in RI (p-value <0.0001) 
 
-More than 60% of prescribers in 
both states did not use PDMPs 
because they were not aware of 
its existence 
Fleming et 
al61 
2013 
-Web based 
survey 
 
- Operational 
PDMPs 
Administrators 
15 -PDMP 
utilization 
3 months 15 states -Prescribers had the highest rate 
of requests per 100,000 
population 
 
-Availability of online access 
and fast turnover of PDMPs 
requests increase utilization 
 
Hildebran et 
al62 
2014 
-Qualitative 
study (online 
focus groups 
and telephone 
interviews) 
 
- Prescribers 
35 -Pattern of 
PDMP use 
_ 9 states - Most clinicians reported 
checking PDMPs for clinical 
purposes, followed by 
administrative requirements 
 
- Long term prescribers checked 
PDMPs more consistently for 
their patients compared to 
emergency providers 
 
CS: controlled substance. 
DEA: drug enforcement agency.  
DHMH: Department of Health and Mental Hygiene. 
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Part II: Literature review on PDMP effectiveness 
This part of the literature review is divided into three parts. The first part discusses studies that 
evaluate PDMPs impact on prescription opioid abuse risk measures. The second part reviews 
studies on the impact of PDMPS on opioid prescribing. The last part discusses studies assessing 
the impact of PDMPS on health outcomes related to prescription opioid abuse.  
PDMP impact on prescription opioid abuse risk measures: 
A total of seven studies assessed the impact of PDMPs on a variety of prescription opioid abuse 
risk measures.62-69 The studies compared changes in abuse risk measures by analyzing 
longitudinal data or evaluating changes in measures before and after implementing PDMPs. One 
of the encountered studies was a randomized clinical trial in a managed care organization. The 
remaining studies had a quasi-experimental study design with a control group. Four studies 
assessed differences in abuse risk measures between PDMPs and non-PDMPs states. Three 
studies examined changes in single states. Following is a review for studies that evaluated 
PDMPs effectiveness, arranged in a sequential manner based on date of data collection. Studies 
are summarized in Table 2.3. 
Reisman et al.63 conducted an ecological study examining the impact of PDMPs on opioid 
shipment and inpatient admission rate over the period of 1997 – 2003. The study compared 
changes in the two outcome measures between PDMPs (13 states) and non-PDMPs states (36 
states). Both groups demonstrated increase in opioid shipment (except for codeine). However, a 
significant reduction in the rise of oxycodone shipment was noted in PDMPs states compared to 
non-PDMPs states (p-value= 0.019). Also, increase in rate of opioid inpatient admissions was 
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lower in PDMPs states compared to non-PDMPs states, however, no information on the 
significance of this result was reported.  
A study by Brady et al.64 assessed the impact of state PDMPs on per capita dispensing of 
opioids. To account for variation in opioid potency, the amount of each drug dispensed was 
converted into Morphine Milligram Equivalents (MME). Authors examined the overall effect of 
PDMPs on per capita dispensing of opioid as well as state specific impact of PDMPs, using state 
quarter as the unit of analysis. The amount of MME dispensed increased significantly over the 
study period. However, no significant difference in MME dispensed per capita was found 
between state quarters with and without PDMPs (p-value = 0.68). State specific impact of 
PDMPs showed a great variation. Nine states had significant reduction in MME dispensed per 
capita between state quarters with and without PDMPs. No significant difference was found in 
14 states. Eight states had significant increase in MME dispensed. Also, results were not 
significant when PDMPs characteristics were considered. Type of PDMPs operating agency, 
having statutory requirements for committee oversight of the PDMPs, and having laws that 
explicitly do not require prescribers to check the system were not significantly associated with 
changes in MME dispensed per capita. Differences in other PDMPs characteristics adopted by 
different states may explain variation in states’ specific impact of PDMPs. 
Reifler et al.65 (2003 – 2009) 
Reifler et al. evaluated PDMPs effectiveness by examining their impact on opioid intentional 
exposures and opioid treatment admission rate in PDMPs and non-PDMPs states. The study 
utilized data from poison centers and opioid treatment databases which report both measures on a 
quarterly basis. Over the period of 2003 – 2009, opioid intentional exposures and opioid 
treatment admissions showed an increasing trend over time for PDMPs and non-PDMPs states. 
 35 
 
However, quarterly increase in intentional exposures in PDMPs states was significantly less than 
non- PDMPs states (0.2% vs 1.9%, respectively, p-value = 0.036). Opioid treatment admissions 
increased per quarter by 2.6% in PDMPs states compared to 4.9% in non-PDMPs states (p-value 
0.058). Also, PDMPs characteristics were considered in additional analyses. PDMPs that have 
been active for long time, provide data directly to health care providers, and cover controlled 
substance at least through schedule IV were considered as superior PDMPs. Increase in opioid 
treatment admissions were significantly less in superior PDMPs states compared to others (p-
value= 0.027); however, no significant difference was found for opioid intentional exposure rate 
(p-value = 0.086).  
Gonzalez et al.66 (2009 – 2010) 
A randomized clinical trial by Gonzalez et al. examined the impact of a managed care PDMPs on 
prescription opioid abuse measures. Patients with at least three prescribers and three dispensed 
prescriptions in a three month period were identified. Prescribers in both groups received letters 
indicating an increasing trend of prescription opioid use. Prescribers in the intervention group 
received an additional medical report (intervention) providing data for each controlled substance 
dispensed during the three month period. Three outcome measures were assessed: change in 
number of opioid prescribers, number of pharmacies, and number of opioid prescriptions filled. 
The outcome measures were compared between the first month and 12 month following the 
intervention. A greater reduction in number of prescribers, number of pharmacies, and number of 
prescriptions filled was noted in the intervention group compared to the control group. The study 
did not report information on the significance of the observed difference.  
Young et al.67 (2010 – 2011) 
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Young et al. conducted a study to assess the impact of PDMPs proactive reports on a number of 
patient opioid abuse risk measures. In January 2010, Massachusetts PDMPs started to send 
proactive reports to prescribers whose patients met the multiple prescriber episode criteria 
(utilizing four or more prescribers and four or more pharmacies in a six month period). However, 
not all prescribers were notified due to system limitations. The current study utilized a controlled 
pre – post study design. The intervention group included patients whose prescribers were sent 
proactive reports. The control group was represented by patients who met the multiple prescriber 
episode criteria, without informing their prescribers. Participants in the control group were 
matched on demographics and baseline prescription history using propensity score matching. 
The two groups were assessed for differences in abuse risk measures in the baseline period 
(before January 2010); no significant differences were found. However, following proactive 
reports, significant reductions in abuse risk measures were reported for the intervention group 
relative to the control group. The intervention group had significant reduction in number of 
schedule II opioid prescriptions (P < 0.01), number of prescribers visited (P < 0.01), number of 
pharmacies used (P < 0.01), dosage units (P < 0.01), total days’ supply (P < 0.01), total MME 
(P < 0.01), and average daily MME (P < 0.05) compared to the control group. 
Surratt et al.68 (2009 – 2012) 
A study in Florida examined changes in prescription opioid diversion rate following a 
comprehensive legislation to regulate pain clinic and PDMPs implementation in Florida. Change 
in diversion rate per 100,000 population was assessed on a quarterly basis over a three year 
period (2009 – 2012). A significant reduction in rate of diverted cases was noted for oxycodone, 
methadone, and morphine (p-value: 0.03, 0.001 and 0.05, respectively) following the 
implementation of the policies. Diversion rate for other opioids either remained stable over the 
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study period or did not significantly change. The study did not isolate the impact of pain clinic 
laws (effective in late 2010) from Florida PDMPs (effective in late 2011). Thus, the observed 
change in diversion rates cannot be attributed to Florida PDMPs only.  
Ali et al.69 (2004 – 2014) 
A study by Ali et al. assessed PDMPs impact on non-medical use of prescription opioids 
(NMPO), utilizing the National Survey of Drug Use and Health data (2004 – 2014). The study 
evaluated the impact of PDMPs existence alone or with prescribers’ mandatory 
enrollment/access policy on four outcomes related to NMPO. States with operational PDMPs 
and states with an additional requirement of prescribers’ enrollment/access did not significantly 
differ from other states in: past year NMPO use, past year prescription opioid dependence, and 
past year initiation of NMPO. However, states with PDMPs only or with additional prescriber 
enrollment/access requirements had significantly fewer days of NMPO compared to other states 
(p-value <0.05 and <0.01, respectively). Also, states with operational PDMPs were associated 
with 56% reduction in doctor shopping (≥ two prescribers) compared to non-PDMPs states (p-
value ≤0.05). Further reduction in doctor shopping (80%) was noted in states with additional 
requirement of prescriber use mandates (p-value ≤0.05).   
Summary of PDMP impact on prescription opioid abuse risk measures: 
The literature on PDMPs effectiveness on a variety of prescription opioid abuse risk measures is 
inconsistent. Four studies found that having operational PDMPs significantly reduced oxycodone 
shipment, prescription opioid intentional exposures, days of prescription opioid supply, and 
doctor shopping.63-65, 69 However, PDMPs did not positively impact other abuse risk measures 
including per capita dispensing of opioid, treatment admission rate, and last year non-medical 
 38 
 
use of prescription opioids. Three studies were conducted in single states and reported positive 
impact of PDMPs on prescription opioid abuse risk measures.66-68  
The inconsistency in the reported findings can be related to differences in PDMPs characteristics 
adopted by different states. Also, the presence of other policies implemented at similar times to 
PDMPs can impact the assessment of PDMPs effectiveness. State level unmeasured confounders 
is another contributing factor that should be considered when evaluating differences in outcome 
measures among the states. 
Table 2. 3: Summary of included studies (PDMP impact on prescription opioid abuse risk 
measures) 
Author Study 
design and 
sample 
Sample size 
 
Unit of 
analysis 
Outcome 
measure of 
interest 
Period Setting 
and data 
source 
 
Related findings 
Reisman 
et al63 
2009 
- Ecologic 
cohort study 
 
- PDMPs 
and non-
PDMPs 
states 
- 14 PDMP 
states 
 
- 36 non-
PDMPs 
states 
 
-State - Rate of 
prescription 
opioid 
shipments 
 
- Rate of 
inpatient 
admissions 
for 
prescription 
opioid abuse 
1997–
2003 
-ARCOS 
 
- TEDS 
- PDMPs and non-PDMPs 
states demonstrated increase in 
opioid shipment (except for 
codeine) 
 
- A significant reduction in the 
rise of oxycodone shipment 
was noted in PDMPs states 
compared to non-PDMPs states 
(p-value= 0.019) 
 
- Increase in rate of opioid 
inpatient admissions was lower 
in PDMPs states compared to 
non-PDMPs states (no p-value) 
 
Brady et 
al64 
2014 
-Ecologic 
cohort study 
 
- PDMPs 
and non-
PDMPs 
states 
- 2,040 state 
quarters 
(619 state 
quarters 
with active 
PDMPs) 
 
-State 
quarter 
- Per capita 
dispensing 
of opioid 
(MME) 
1999 -
2008 
-ARCOS - No significant difference in 
MME dispensed per capita was 
found between state quarters 
with and without PDMPs (p-
value = 0.68) 
 
- State specific impact of 
PDMPs showed a great 
variation 
 
Reifler et 
al65 
2012 
-Ecologic 
cohort study 
 
_ -State 
quarter 
- Opioid 
intentional 
exposures 
and opioid 
2003-
2009 
RADARS - Opioid intentional exposures 
and opioid treatment 
admissions showed an 
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-PDMPs and 
non-PDMPs 
states 
treatment 
admission 
rate 
increasing trend over time for 
PDMPs and non-PDMPs states 
 
- Quarterly increase in 
intentional exposures in 
PDMPs states was significantly 
less than non- PDMPs states 
(0.2% vs 1.9%, respectively, p-
value = 0.036) 
 
- Opioid treatment admissions 
increased per quarter by 2.6% 
in PDMPs states compared to 
4.9% in non-PDMPs states (p-
value 0.058) 
 
Gonzalez 
et al66 
2012 
Randomized 
clinical trial 
 
- Patients 
who 
received 
opioid 
prescriptions 
from three 
or more 
prescribers 
at three or 
more 
pharmacies 
in a three 
month 
identifica-
tion period 
 
Intervention 
group (242 
patient) 
 
-Control 
group (220 
patient) 
 
Patient Change in: 
 
- Number of 
opioid 
prescribers 
 
- Number of 
pharmacies 
 
- Number of 
opioid 
prescriptions 
filled 
2009 - 
2010 
-A 
managed 
care 
organiza-
tion in 
New York 
- A greater reduction in number 
of prescribers, number of 
pharmacies, and number of 
prescriptions filled was noted 
in the intervention group 
compared to the control group 
(no p-value) 
Young et 
al67 
2017 
-Controlled 
pre-post 
 
- Patients 
who 
received 
schedule II 
prescriptions 
(with at least 
one opioid) 
from four or 
more 
prescribers 
at four or 
more 
pharmacies 
in a six-
month 
identifica-
tion period 
Intervention 
group (84 
patient) 
 
- Control 
group (504) 
Patient - Seven 
opioid abuse 
risk 
measures 
2010 - 
2011 
MA - Compared to the control 
group, the intervention group 
had significant reduction in: 
 
- Number of schedule II opioid 
prescriptions (P < 0.01) 
 
- Number of prescribers visited 
(P < 0.01) 
 
-Number of pharmacies used 
(P < 0.01) 
 
- Dosage units (P < 0.01) 
 
-Total days’ supply (P < 0.01) 
 
-Total MME (P < 0.01) 
 
-Average daily MME 
(P < 0.05) 
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Surratt et 
al68 
2014 
Longitudinal 
ecologic 
study 
- 219 - Year 
quarter 
- Quarterly 
change in 
prescription 
opioid 
diversion 
rate per 
100,000 
population 
2009 - 
2012 
- Florida 
 
-RADARS 
- Significant reduction in rate 
of diverted cases was noted for 
oxycodone, methadone and 
morphine (p-value: 0.03, 0.001 
and 0.05, respectively 
 
- Diversion rate for other 
opioids either remained stable 
over the study period or did not 
significantly change 
 
Ali et al69 
2017 
Longitudinal 
ecologic 
study 
 
- Civilian 
population 
(12≥ years 
old) 
- 507,000 -State - Four 
outcome 
measures 
related to 
NMPO 
2004 - 
2014 
NSDUH - Significant association 
between PDMPs 
implementation and reduction 
in ‘doctor shopping’ behavior 
 
- No significant associations 
between PDMPs 
implementation on nonmedical 
use/initiation/dependence of 
opioids 
 
ARCOS: Automation of Reports and Consolidated Orders System. 
TEDS: Treatment Episode Data Set. 
RADARS: Researched Abuse, Diversion and Addiction-Related Surveillance. 
MME: Morphine Milligram Equivalents.  
NSDUH: National Survey on Drug Use and Health. 
NMPO: Non-Medical use of Prescription Opioid. 
 
PDMPS impact on opioid prescribing: 
PDMPS impact on opioid prescribing was assessed in eight studies.70 - 77 Five were conducted in 
single states; the remaining studies compared opioid prescribing in PDMP and non-PDMP states. 
Three studies examined changes in opioid prescribing among emergency providers (EPs), while 
others were more general and included prescribers from other ambulatory care settings. Studies 
are summarized in Table 2.4. 
Three studies evaluated changes in opioid prescribing in Florida. The first study by Rutkow et al. 
assessed the impact of pain clinic laws and PDMPS on opioid prescribing and use.70 The study 
followed a comparative interrupted times series design over the period 2010 to 2012; Georgia 
was selected as the comparator state. Four outcome measures were evaluated: total opioid 
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volume, average MME per transaction, number of days supplied, and total number of opioid 
prescriptions. Authors found modest, but a statistically significant reduction in monthly opioid 
volume and mean MME per transaction in Florida compared to Georgia (p-value <0.05 for both 
measures). No significant difference was found in monthly number of days supplied and total 
number of opioid prescriptions dispensed. The impact of policies was further examined among 
groups of prescribers and patient stratified based on volume of opioid prescribing and use. 
Significant reduction in total opioid volume and average MME per prescription was limited for 
prescribers and patients with the highest baseline opioid prescribing and use. The study 
examined the impact of pain clinic laws and PDMPS jointly and findings supported the 
effectiveness of the policies. Nevertheless, the magnitude of the impact was modest and the 
statistical significance could be related to the large sample size. Further evidence is needed to 
support the effectiveness of PDMPs. Findings of the current study were further analyzed in 
another study by Chang et al.71  
The new study examined impact of PDMPs implementation and pain clinic laws on high risk 
prescribers.71 The latter was defined as prescribers in the top fifth percentile of opioid volume 
during four consecutive calendar quarters in the pre-intervention period. The current study 
compared seven prescriber related outcomes in Florida and Georgia using a comparative 
interrupted times series analysis. The impact of policies was assessed by comparing differences 
in level and monthly trend of the outcomes. Among high risk prescribers, the policies had no 
significant impact on the level of any of the outcomes. A slight, but statistically significant 
increase in monthly trend of average days’ supply was reported (p-value<0.05). In contrast, 
significant reduction in the monthly trend of the number of patients receiving opioids, MME per 
transaction, total opioid volume, and number of filled opioid prescriptions was found (p-value 
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<0.05 and <0.01). Despite this significant impact, opioid prescribing remained highly 
concentrated among high risk prescribers after implementation of the policies. In other words, 
high risk prescribers continued to account for the high proportion of opioid volume and opioid 
prescriptions in the post as the pre-implementation period. The impact of policies on the seven 
outcomes were also examined among low risk prescribers and no significant change in level or 
trend of the outcomes was documented. 
The third study in Florida was conducted among emergency providers (EPs).72 The study utilized 
a pre – post study design with a historical control group. Prescribers in the intervention group 
were notified of their patients’ prescription history using reports from Florida PDMPs. The 
average number of controlled substance prescribed per patient was compared between patients in 
the intervention group (in February 2014) and the historical control group (in December 2013). 
Results from the Poisson regression model indicated non-significant difference in average 
number of controlled substance prescribed per patient between the two groups. Thus, authors 
concluded that Florida PDMPs did not influence EPs prescribing of controlled substances. 
However, there are clear limitations that could affect findings of the study. Authors did not use 
propensity score matching or other statistical methods when selecting the historical control group 
and thus, comparison between the two groups might not be acceptable.  Also, in the Poisson 
regression model, only age, sex and chief complaint were included as confounders, while other 
possible confounders were left uncontrolled. The study also investigated PDMPs utilization 
among twenty five prescribers in the ED; one third were registered to use PDMPs and more than 
two thirds rarely or never accessed the system. 
Further assessment of the impact of PDMPs on opioid prescribing in emergency care settings 
was conducted in Ohio.73 EPs were surveyed about their likelihood to prescribe opioid analgesics 
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for patients presented with non-acute injury. PDMPs data were presented to EPs and prescribers’ 
likelihood to prescribe opioid was re-assessed after reviewing patients’ prescription fill history. 
Among all providers, opioid prescribing decisions were altered for 41% of patients; 61% resulted 
in fewer or no opioids prescribed. The study indicated positive impact of PDMPs on opioid 
prescribing in the ED; however, two thirds of patients were treated by only four providers. Thus, 
findings may not be representative to the general population of EPs.  
In North Carolina, Ringwalt et al. examined the relationship between prescribers’ utilization of 
PDMPs and opioid prescribing, utilizing PDMPs data for the period between 2009 – 2011.74 
Over the study period, an increasing trend in the number of providers with PDMPs queries and 
days of access was found. However, the trend of opioid prescriptions and patients filling opioid 
prescriptions remained stable. Linear regression models found that increasing prescriber 
utilization of PDMPs was not associated with significant reduction in the proportion of patients 
or opioid prescriptions filled.  
The remaining three studies included prescribers from multiple states and compared differences 
in opioid prescribers after PDMP implementation or use.75 - 77  
A survey by Pomerleau et al. assessed the impact of PDMPs utilization on opioid prescribing 
among EPs.75 The survey included 443 EPs from seven emergency centers across the United 
States. About 60% of EPs were registered in the state PDMPs and 50% use it less than once per 
shift. The relationship between PDMPs and opioid prescribing was tested in four case scenarios. 
Decisions to prescribe opioid in each scenario were compared between PDMP users and non-
users using Chi-square test. No significant association was found between the two groups. 
Authors concluded that PDMPs have no impact on opioid prescribing among EPs, which is 
contrary to previous studies. To assess the impact of PDMPs on an outcome, regression analysis 
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should be used controlling for possible confounders. Using only Chi-square test does not reflect 
the actual impact of PDMPs on opioid prescribing and this may explain the non-significant 
findings of the current study.  
Another study by Bao et al. evaluated PDMPs impact on opioid prescribing in ambulatory care 
settings during the period between 2001 – 2010.76 Visits after PDMP implementation were 
compared to visits in states without PDMPs. The overall effect of PDMPs on the rate of opioid 
prescribing was examined, as well as, the effect of time since implementation. A 30% reduction 
in schedule II opioid prescribing was found after PDMPs implementation (p-value<0.001). 
However, the reduction in the prescribing of any opioid was not significant. The impact of 
PDMPs on schedule II opioid prescribing showed significant results considering time since 
PDMP implementation. Furthermore, the reduction in rate of schedule II opioid prescribing 
remained significant up to two years after implementation. However, decline in rate of other 
opioid prescribing was not significant after six months of implementation.  
The last study examined changes in opioid prescribing among Medicare population with part D 
coverage.77 The study utilized difference in difference modeling to compare opioid prescribing 
pre and post PDMP implementation in states with and without PDMPs. Two independent 
variables were included in the models: presence of PDMPs with online access and presence of a 
statute that explicitly does not require PDMPs access. The main outcome measure was percent 
change in days of opioid supply. Presence of PDMPs with online access was associated with a 
significant, but limited decrease in days’ supply for all opioids, oxycodone only, and 
hydrocodone only (p-value <0.01). A significant increase in days’ supply for schedule IV was 
also found (p-value <0.05). States where a statute did not explicitly require PDMP access were 
associated with significant increase in days’ supply for all opioids, hydrocodone only, oxycodone 
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only, and schedule IV opioids. Findings of the current study were significant, but limited in 
magnitude. The reported significance may also be related to the large sample size and not due to 
the actual impact of PDMP. 
Summary of PDMP impact on prescribing: 
Studies show inconsistent evidence on the impact of PDMPs on opioid prescribing. Studies in 
Florida did not isolate the impact of PDMPs from pain clinic laws, so any observed effect cannot 
be attributed to PDMPs implementation only. In addition, the positive impact of PDMPs reported 
in few studies are either not generalizable, could not be validated, or statistically but not 
clinically significant. More evidence is needed to support PDMPs effectiveness. In general, there 
is an increasing trend of opioid prescribing in PDMP and non-PDMP states. This suggests that 
PDMPs should not be the only policy to combat the prescription opioid abuse epidemic.  
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Table 2. 4: Summary of included studies (PDMPs impact on prescribing) 
Author Study design 
and sample 
Sample 
size 
Unit of 
analysis 
Outcome 
measure of 
interest 
 
Period Setting and 
data source 
Related findings 
Rutkow et 
al70 
2015 
- Comparative 
interrupted 
times series 
 
- Patients 
2.6 million -Patient - Four 
outcomes 
measures 
related to 
opioid 
prescribing 
2010 - 
2012 
- Florida 
(intervention 
state), 
Georgia 
(control 
state) 
 
- IMS 
Health's 
LRx 
Lifelink 
database 
- Modest, but, 
statistically significant 
reduction in monthly 
opioid volume and 
mean MME per 
transaction in Florida 
compared to Georgia 
(p-value <0.05 for both 
measures) 
 
- No significant 
difference in monthly 
number of days 
supplied and total 
number of opioid 
prescriptions dispensed 
 
Chang et 
al71 
2016 
- Comparative 
interrupted 
times series 
 
- Prescribers 
For Florida: 
 
- High risk 
prescribers 
(1526) 
 
- Low risk 
prescribers 
(36,939) 
Prescriber - Seven 
prescriber 
related 
outcomes 
2010 - 
2012 
- Florida 
(intervention 
state), 
Georgia 
(control 
state) 
 
- IMS 
Health's 
LRx 
Lifelink 
database 
 
- Significant reduction 
in the monthly trend of: 
(- Number of patients 
receiving opioids 
- MME per transaction 
-Total opioid volume, 
and 
- Number of filled 
opioid prescriptions)  
in Florida compared to 
Georgia 
 
- A slight, but 
significant increase in 
monthly trend of 
average days’ supply 
(p-value <0.05) 
 
- No significant 
differences among low 
risk prescribers 
 
McAllister 
et al72 
2015 
- Pre – post 
design 
 
- Patients (≥18 
years old) 
treated at ED 
Interventio
n group 
(356 
patient) 
 
- Historical 
control 
group (354 
patient) 
 
Patient - Change in 
average 
number of CS 
prescribed per 
ED visit 
 
2013 and  
2014 
- ED of a 
tertiary care, 
urban 
university 
teaching 
hospital in 
Florida 
- No significant 
difference in average 
number of controlled 
substance prescribed 
per patients between the 
two groups 
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Baehren et 
al73  
2010 
- Pre – post 
design (using 
survey as data 
collection 
method) 
 
-Patients 
presented at 
the ED with 
painful 
conditions 
 
- 179 
patient 
 
- 18 
provider 
Prescriber - Change in 
opioid 
analgesics 
prescribing for 
patients 
presented with 
non-acute 
injury 
June - 
July 
2008 
Ohio - Opioid prescribing 
decisions were altered 
in 41% of patients 
 
- 61% resulted in fewer 
or no opioids prescribed 
 
Ringwalt 
et al74 
2015 
Longitudinal 
ecologic study 
_ Per six 
months/per 
1000 
persons 
-PDMPs 
utilization and 
its impact on: 
 
- Rate of 
patients filling 
opioid 
prescription 
 
- Rate of 
opioid 
prescriptions 
filled 
 
2009 - 
2011 
NC - Increasing trend in 
number of providers 
with PDMPs queries 
and days of access 
 
- However, no 
significant reduction in 
proportion of patients 
filling opioid 
prescriptions or opioid 
prescriptions filled 
 
Pomerleau 
et al75 
2017 
-Web based 
survey 
 
- EPs 
443 _ - PDMPs 
registration 
and use 
 
- Opioid 
prescribing 
August – 
October 
2014 
- Seven 
emergency 
centers 
across the 
United 
States 
- 60% of EPs were 
registered in state 
PDMPs 
 
- 50% use it less than 
once a shift 
 
- PDMPs utilization did 
not significantly impact 
opioid prescribing 
 
Bao et al76 
2016 
- Pre – post 
design 
 
- Patients (≥ 
18 years old) 
presented to 
an office 
based visit  
with pain 
26,275 
ambulatory 
care office 
visits 
 
Visit - Having at 
least one 
Schedule II 
opioid 
analgesic 
(dichotomous) 
 
- Having at 
least one 
opioid of any 
kind 
prescribed or 
continued at a 
pain-related 
ambulatory 
care visit 
(dichotomous) 
2001 – 
2010 
- 24 states 
with online 
access 
PDMPs 
 
- NAMCS 
a. Impact of PDMP 
existence: 
 
- 30% reduction in 
schedule II opioid 
prescribing following 
PDMPs implementation 
(p-value<0.001) 
 
- Non significant 
reduction in the 
prescribing of any 
opioid 
 
b. Impact of PDMP 
considering time since 
implementation: 
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- Significant reduction 
in schedule II 
prescribing up to two 
years following 
implementation 
 
- Significant reduction 
in the prescribing of 
any opioid for the first 
six months following 
implementation 
 
 
 
Yarbough 
CR77 
2017 
-Controlled 
before and 
after 
 
- Medicare 
population 
with part D 
coverage 
451,583 
physician 
year 
observatio- 
ns 
-Physician -Percent 
change in days 
of opioid 
supply 
2010 – 
2013 
-ProPublica 
 
- CMS 
 
- States with online 
access PDMPs had 
significant reduction in 
days’ supply for all 
opioids (p-value <0.01) 
 
- However, a significant 
increase in days’ supply 
for schedule IV was 
found (p-value <0.05) 
 
IMS Health's LRx Lifelink database: an individual level claims database that represents 65% of retail prescription 
transactions in the United States. 
MME: Morphine Milligram Equivalents. 
CS: controlled substance. 
EPs: emergency providers. 
NAMCS: National Ambulatory Medical Care Survey. 
ProPublica: a non-profit news organization. 
CMS: Centers for Medicare and Medicaid Services. 
 
PDMPs impact on prescription opioid related-health outcomes: 
The existing literature examined PDMPs impact on prescription opioid related overdose deaths 
and emergency room visits. Five studies assessed the impact of PDMPs on overdose deaths,78 - 82 
and one evaluated the impact on ED visits.83 The reviewed studies assessed PDMPs effectiveness 
by comparing the rate of overdose deaths or ED visits in PDMPs and non-PDMPs states over a 
period of time. One study was conducted in Florida and evaluated changes in overdose deaths 
following PDMPs implementation. Studies are summarized in Table 2.5. 
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An early study by Paulozzi et al. examined PDMPs impact on overdose deaths over the period 
1999 – 2005.78 The study compared opioid overdose mortality rate and MME consumption rate 
(per 100,000 population) in PDMPs and non-PDMPs states. PDMPs implementation was not 
associated with significant reductions in opioid overdose mortality or MME consumption rate 
per state-year (p-value = 0.34, 0.55, respectively). 
Over a similar period of time, Li et al. conducted a study comparing the number of drug 
overdose deaths per state per quarter year (i.e. state-quarter) in 31 PDMPs states and 20 non-
PDMPs states during the period 1999 – 2008.79 A state-quarter was coded having PDMP if the 
state implemented the PDMP any time during the quarter year. State-quarters with PDMP were 
associated with a 11% increase in drug overdose deaths compared to state-quarters without 
PDMPs (adjusted risk ratio = 1.11; 95% CI: 1.02–1.21). Also, the impact of PDMPs varied 
among the states. PDMP implementation was associated with a significant reduction in drug 
overdose mortality in three states, a significant increase in 17 states, and no impact in 11 states. 
The impact of PDMPs characteristics was also examined. The increase in overdose mortality was 
more pronounced in state-quarters with PDMPs monitored by a pharmacy board or those without 
an expectation on practitioners to access the system. 
A later study by Patrick et al. evaluated the impact of PDMPs implementation on opioid 
overdose deaths in 34 states.80 The study compared the annual rate of deaths per 100,000 
population pre and post PDMPs implementation over the period 1999 – 2013. Unlike previous 
studies, results from linear regression analysis found a significant decline in the annual rate of 
opioid overdose deaths following PDMPs implementation (p-value<0.001). The impact of 
PDMPs characteristics was also examined. States with PDMPs that monitor four or more drug 
schedules and update data on a weekly basis had a significantly lower rate of opioid overdose 
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deaths compared with other state PDMPs (p-value <0.05 and <0.001, respectively). However, no 
significant impact of PDMPs registration or use mandates was found.  
The significant impact of PDMPs on overdose mortality was also documented in a recent study 
by Pardo.81 The study compared the opioid overdose death rate in PDMPs and non-PDMPs 
states. Unlike previous studies, the current study considered PDMP strength when assessing its 
impact on overdose deaths. PDMP strength was measured based on the adoption of 11 
characteristics or policies related to PDMPs operation. A score (a continuous number) was given 
for each state-year to represent PDMPs strength for the state-year; stronger PDMPs (i.e. more 
policies adopted) received higher scores. States without operational PDMPs received a score of 
zero. The regression model also controlled for the type of administrating agency and the 
presence of other regulatory policies including naloxone access and pain clinic laws. Results of 
the regression model were significant; with every one point increase in the PDMPs score, 
overdose deaths decreased by 1.5% (p-value ≤ 0.05). However, when scoring on quartiles, only 
PDMPs scores in the third quartiles were associated with a significant reduction in overdose 
deaths compared to non-PDMPs states. PDMPs scores in the fourth quartile were not significant. 
Findings of the current study suggest that PDMPs strength matters when assessing PDMPs 
effectiveness. The non-significant impact of PDMPs with scores in the fourth quartile may 
indicate that increasing the number of PDMPs policies may negatively influence the 
effectiveness of PDMPs. 
Also, a recent study in Florida supports PDMPs effectiveness in reducing overdose mortality.82 
The study examined changes in oxycodone-caused deaths following PDMPs implementation. 
The study utilized an interrupted time series design and examined changes from 2003 to 2012. 
Authors compared the monthly number of oxycodone-caused deaths before and after PDMPs 
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implementation in 2010. The model controlled for multiple confounders including pain clinic 
laws and other regulatory policies implemented at a similar time to PDMPs. The impact of 
PDMPs and the rate of PDMPs query by health care providers on oxycodone-related mortality 
were examined. PDMPs were associated with a 25% decline in the number of deaths (p-value = 
0.008). Significant results were also reported for the impact of the rate of PDMPs query. With 
every increase of one query per health care provider, the number of oxycodone deaths decreased 
by 0.23 persons per month (p-value = 0.002).  However, the impact of PDMPs on opioid 
(excluding oxycodone) caused deaths was not significant (p-value 0.7). 
The last study assessed the impact of PDMPs on the prescription opioid related ED visits and the 
findings were not significant.83 The study compared the rate of ED visits per quarter year 
between PDMPs and non-PDMPs states during the period 2004 – 2011. The main outcome 
measure included ED visits related to misuse and non-misuse of prescription opioids. For all 
opioid related visits, the rate of ED visits did not significantly differ between states with and 
without PDMP (p-value = 0.74). Results for ED visits related to prescription opioid misuse or 
abuse were also not significant (p –value = 0.57). Findings of the current study suggest PDMPs 
ineffectiveness. However, authors did not consider differences in PDMPs characteristics or 
policies among states, which may have a huge impact on the reported findings.                      
Summary of PDMP impact on health outcomes: 
As discussed earlier, old studies that examined the PDMPs impact on prescription opioid 
overdose deaths showed mixed evidence of PDMPs effectiveness. Later studies provided more 
evidence supporting the positive impact of PDMPs on reducing overdose mortality. Overdose 
deaths may not be a good measure for opioid safety; many factors may contribute to death. 
Furthermore, documentation for the reason of death may not be accurate and thus, may not truly 
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represent deaths due to prescription opioid overdose. Most studies did not consider differences in 
PDMP characteristics among states, which may have a profound effect on PDMPs effectiveness. 
Only one study considered PDMP strength and the results were significant.  
Prescription opioid related ED visits is a better indicator for opioid safety. Only one study 
examined PDMP impact on ED visits and the results were not significant. More studies are 
needed to examine the impact of PDMPs on ED visits. 
Table 2. 5: Summary of included studies (PDMPs impact on prescription opioid related-health 
outcomes) 
Author Study 
design and 
sample 
Sample 
size 
Unit of 
analysis 
Outcome 
measure of 
interest 
Period Setting and 
data source 
Related findings 
Paulozzi et 
al78 
2011 
- Ecologic 
study 
357 state 
year (247 
without 
active 
PDMPs 
and 110 
with 
PDMPs) 
State-year - Rate of 
prescription 
opioid 
overdose 
death 
 
- Rate of 
MME 
consumption 
1999 - 
2005 
- PDMPs 
and non-
PDMPs 
states 
 
-CDC 
(multiple 
cause of 
death 
mortality 
files) 
 
- ARCOS 
 
PDMPs implementation 
was not associated with 
significant reduction in 
overdose death or MME 
consumption rate 
Li et al79 
2014 
- Ecologic 
study 
 
2040 state 
quarter 
(619 with 
active 
PDMPs) 
State- 
quarter 
- Rate of 
drug 
overdose 
deaths 
1999 - 
2008 
PDMPs (31) 
and non-
PDMPs (20) 
states 
 
-CDC 
(multiple 
cause of 
death 
mortality 
files) 
 
- Overall, 
implementation of 
PDMPs was associated 
with an 11% increase in 
drug overdose mortality 
(ARR = 1.11; 95% 
CI = 1.02–1.21) 
 
- PDMPs impact  on 
drug overdose mortality 
varied greatly across 
states 
Patrick et 
al80 
2016 
 
- Ecologic 
study 
(interrupted 
time-series) 
_ State-year - Annual 
rate of 
opioid-
related 
overdose 
deaths (per 
100,000 
population) 
1999 – 
2013 
- 34 states 
with active 
PDMPs 
 
- CDC 
(multiple 
cause of 
death 
- Significant decline in 
annual rate of opioid 
overdose deaths 
following PDMPs 
implementation (p-value 
<0.001) 
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mortality 
files) 
 
Pardo B81 
2017 
- Ecologic 
study 
816 state 
year 
State-year - Rate of 
opioid 
overdose 
death 
1999 - 
2014 
- PDMPs 
and non-
PDMP 
states 
 
- CDC 
(multiple 
cause of 
death 
mortality 
files) 
 
- PDAPS 
 
- Significant impact of 
PDMPs considering its 
strength: 
 
- With every one point 
increase in PDMPs 
score, overdose deaths 
decreased by 1.5% (p-
value ≤ 0.05) 
Delcher et 
al82 
2015 
- Interrupted 
time-series 
 
120 
monthly 
counts of 
oxycodone-
caused 
mortality 
Month - Monthly 
counts of 
oxycodone-
caused 
mortality 
2003 - 
2012 
- Florida 
 
- Florida 
MEC 
 
- PDMPS was 
associated with 25% 
decline in number of 
deaths (p-value = 0.008) 
 
- With every increase of 
one PDMPS query per 
health care provider, 
number of oxycodone 
deaths decrease by 0.23 
persons per month (p-
value = 0.002) 
 
- PDMPS did not 
significantly impact 
other opioid related 
deaths (p-value= 0.7) 
 
Maughan et 
al83 
2015 
- Ecologic 
study 
_ Quarter 
year 
-Rate of ED 
visits (per 
100,000 
population) 
2004 - 
2011 
- DAWN - Rate of prescription 
opioid related ED visits 
did not significantly 
differ between states 
with and without 
PDMPs (p -value = 
0.57) 
 
MME: Morphine Milligram Equivalents.  
ARR: adjusted Risk Ratio. 
CDC: Centers for Disease Control and Prevention. 
ARCOS: Automation of Reports and Consolidated Orders System. 
State-quarter: Per state per quarter year. 
PDAPS: Prescription Drug Abuse Policy System.  
MEC: Medical Examiners Commission. 
DAWN: Drug Abuse Warning Network. 
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Part III: literature review on prescriber mandates 
As seen in the previous studies (part I and II literature review), the literature provided 
inconsistent evidence of the effectiveness of PDMPs. Studies on PDMPs utilization showed low 
and irregular use of the system; this negatively impacted the expected benefit of PDMPs. 
Prescriber use mandates are a relatively new policy directed to increase PDMPs utilization 
among prescribers. The impact of the policy on increasing PDMPs effectiveness (by increasing 
its utilization) has not been fully studied. This part of the literature review discusses studies on 
prescriber use mandates and its impact on the prescription opioid abuse epidemic. 
A total of four studies have investigated the impact of prescriber use mandates on opioid 
prescribing and opioid related overdose deaths.84-87 Two studies were conducted in New York 
and two studies included multiple states. Studies are summarized in Table 2.6. 
Brown et al. conducted a study to examine the impact of the Internet System for Tracking Over-
Prescribing (I-STOP) on opioid prescribing and related morbidity.84 I-STOP is an extension of 
New York PDMPs with the additional requirement of prescriber use mandates. The study 
examined changes in the trend of opioid prescriptions filled per year, quarterly MME supply, and 
opioid related overdoses before and after I-STOP implementation. Following the introduction of 
I-STOP, quarterly MME supply significantly increased (p-value= 0.006), although the number of 
opioid prescriptions filled appeared to have a negative trend. More data points are required to 
confirm the impact of I-STOP on reducing the number of opioid prescriptions filled. Prescription 
opioid related overdose (as measured by number of ED visits and inpatient admissions) showed 
an increasing trend before I-STOP implementation and leveled off following I-STOP. However, 
differences in slope between pre and post I-STOP periods were not significant (p-value =0.37). 
The study findings indicated that I-STOP did not significantly change the opioid prescription 
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trend in NY. A leveling off in prescription opioid morbidity following I-STOP is promising 
given the national increasing trend of opioid morbidity and mortality. 
In addition to the previous study, Rasubala et al. assessed the impact of I-STOP on dentists 
prescribing of opioids.85 The study examined changes in the odds of opioid prescribing in the 
period following I-STOP implementation compared to the pre-I-STOP period. Results were 
significant; the odds of receiving an opioid analgesic decreased by almost 60% following I-
STOP compared to the pre-I-STOP period (OR = 0.42, 95% CI: 0.35, 0.51, p-value <0.05). Also, 
there was a significant reduction in the total number of opioid prescriptions following I-STOP 
implementation (p-value <0.05). A number of study limitations have been noted. The regression 
model was not clear and results were not shown. Authors did not control for confounders like 
demographics or, if they did so, the included covariates were not reported in the study.  
In a more generalizable study, Dowell et al. evaluated the impact of PDMPs prescriber 
mandatory access and pain clinic laws in 38 states and the District of Colombia.86 The study 
compared rate of opioid prescribing (in MME per state resident) and overdose deaths in states 
with prescriber use mandates and pain clinic laws and those without the policies over the period 
2006 - 2013. A significant reduction in the rate of opioid prescribing and overdose deaths was 
observed in states with both policies compared to controls (p-value <0.05). States who 
implemented pain clinic laws also adopted prescriber use mandates at similar times and thus, the 
impact of prescriber mandates only could not be isolated.  
A more recent study by Wen et al. examined the impact of prescriber mandates on the rate of 
opioid prescribing among Medicaid enrollees for the period 2011- 2014.87 The study 
differentiated mandates into registration mandates only, use mandates only, and registration and 
use mandates. The main outcome measure was the total number of opioid prescriptions filled per 
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100 enrollees per quarter year. Results from linear regression models indicated that states with 
PDMPs registration mandates had a significant reduction in the rate of schedule II opioid 
prescribing compared to states without any mandates (p-value <0.05). Significant reductions in 
the rate of schedule II opioid prescribing were also reported for states with PDMPs registration 
and use mandates (p-value <0.05). However, PDMP use mandates only had a limited impact on 
the rate of schedule II opioid prescribing (results were not significant at a 0.05 level of 
significance). Further analysis differentiated weak and strong (i.e. comprehensive mandates 
without prescriber judgment) mandates, however, no significant impact of any type of mandates 
was found. 
As seen in the previous studies, prescriber use mandates have a limited impact on opioid 
prescribing and prescription opioid related overdose deaths. More studies are needed to prove the 
effectiveness of the new policy. 
Table 2. 6: Summary of included studies (PDMPs prescriber use mandates) 
Author Study 
design and 
sample 
 
Sample 
size 
Unit of 
analysis 
Outcome 
measure 
of interest 
Period Setting 
and data 
source 
Related findings 
Brown et 
al84 
2017 
 
Interrupted 
time series 
_ - Year 
quarter 
 
-Year 
 
 
 
- Changes 
in trend 
of: 
 
- Quarterly 
MME 
supply 
 
- Quarterly 
Opioid 
related 
morbidity 
 
- Yearly 
opioid 
prescriptio
ns filled 
per year 
 
2010 - 
2015 
- NY 
 
- ARCOS 
 
- BN- 
NYSDOH 
 
- SPARCS 
-Following ISTOP 
implementation: 
 
- Significant increase in 
quarterly MME (P-value= 
0.006) 
 
- Prescription opioid related 
morbidity leveled off (no 
significant difference from 
pre-ISTOP period) 
 
- Number of opioid 
prescription filled showed a 
negative trend 
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Rasubala 
et al85 
2015 
- Pre – post 
design 
 
- Dentists 
6204 
visits 
Dentist 
visit 
-Odds of 
receiving 
opioid 
 
- Number 
of opioid 
prescriptio
n 
(12/ 2012– 
02/2013) 
and 
(12/ 2013 – 
02/  2014) 
- A dental 
urgent care 
in NY 
 
- Patient 
records 
- Following ISTOP 
implementation: 
 
- Odds of receiving an opioid 
analgesic decreased by 
almost 60% (OR = 0.42, 
95% CI: 0.35, 0.51) 
 
- Significant reduction in 
total number of opioid 
prescriptions (Chi-square 
test, p-value <0.05) 
 
Dowell et 
al86 
2016 
- Ecologic 
study 
(difference 
in 
difference 
model) 
312 
state 
year 
State 
year 
-Rate of 
opioid 
prescribin
g-g (in 
MME per 
state 
resident) 
 
- Rate of 
prescripti-
on opioid 
overdose 
deaths (per 
100,000 
state 
resident) 
2006 – 
2013 
-Prescriber 
mandates 
and non-
prescriber 
mandates 
states (total 
39 states) 
 
- CDC 
(multiple 
cause of 
death 
mortality 
files) 
 
- IMS 
Health’s 
National 
Prescriptio-
n Audit 
 
- Significant reduction in 
rate of opioid prescribing 
and overdose deaths was 
observed in states with 
prescriber mandates 
compared to controls (p-
value <0.05) 
Wen et 
al87 
2017 
- Ecologic 
study 
 
-Medicaid 
enrolls 
736 
state 
quarter 
Year 
quarter 
-Rate of 
opioid 
prescribe-
ng (per 
100 
enrollee 
per quarter 
year) 
2011- 2014 - CMS 
(Medicaid 
State Drug 
Utilization 
Files) 
- Significant reductions in 
rate of schedule II opioid 
prescribing for state PDMPs 
with both registration and 
use mandates (p-value 
<0.05). 
 
– No significant reduction in 
rate of schedule II opioid 
prescribing for state with use 
mandates only 
ARCOS: Automation of Reports and Consolidated Orders System. 
BNE-NYSDOH: Bureau of Narcotics Enforcement- New York State Department of Health.  
SPARCS: Statewide Planning and Research Cooperative System. 
MME: Morphine Milligram Equivalents.   
CDC: Centers for Disease Control and Prevention. 
CMS: The Centers for Medicare and Medicaid Services. 
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Overview of the literature 
Prescription Drug Monitoring Programs (PDMPs) have been adopted by all states (except 
Missouri). However, the effectiveness of these systems has not been fully demonstrated. Earlier 
studies provided inconsistent evidence on PDMPs effectiveness. However, there is a growing 
body of literature to support their positive impact on the prescription opioid abuse epidemic. 
Studies have shown that PDMP utilization is low and variable among healthcare providers; this 
may explain the inconsistent findings reported in the literature. In addition, studies examining the 
impact of PDMPs on prescription opioid related health outcomes have selected overdose death as 
the outcome measure even though it may not be a good indicator for PDMP effectiveness. Only 
one study has selected ED visits as a measure for prescription opioid safety, and results were not 
significant.  
In the proposed research, PDMPs effectiveness will be examined in terms of their impact on 
prescription opioid poisoning related ED visits. Also, the impact of prescriber use mandates on 
increasing PDMPs utilization will be considered. The connection between prescriber use 
mandates and their impact on ED visits can be explained by the Donabedian model discussed in 
Chapter 1. 
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Chapter 3 
 
 
 
Methods and results for specific aim 1: 
A. To identify and select states with laws or regulations mandating prescriber use of 
PDMPs. 
B. To identify and select comparison state(s) without mandatory use policies. 
 
Section 3.1-Methods 
Data source 
Three data sources were used to identify states with or without PDMPs prescriber use mandate 
policies, the Center of Excellence (COE) at Brandeis University, the National Alliance for Model 
State Drug Laws (NAMSDL), and the Prevention Status Report (PSR) from the CDC. The COE 
at Brandeis University is the first comprehensive source of information on PDMPs.88 Established 
in 2010, the COE is a joint project between the Bureau of Justice Assistance (BJA) and Brandeis 
University, and it was created to evaluate PDMPs effectiveness. One major use of the CEO data 
is to disseminate information on PDMPs best practices or policies in order to enhance their 
effectiveness in combating the prescription opioid abuse epidemic.  
The NAMSDL is another valuable source of information on PDMPs.89 NAMSDL is a non-profit 
organization that drafts model drug and alcohol laws, policies, and regulations. NAMSDL also 
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compares state policies and regulations related to alcohol and substance abuse prevention and 
treatment. For example, in December 2016, NAMSDL published a report on eight evidence 
based practices to optimize prescriber utilization of PDMPs.31 The report discussed states’ 
adoption of the policies and preliminary findings on their impact on prescription opioid abuse as 
well as prescriber use mandates policy. Compared to the COE, the NAMSDL provided more 
information on the type of prescriber use mandates adopted by the states. States were classified 
based on the level of prescriber requirements to check the PDMPs. 
Lastly, the PSR was utilized. First published by the CDC in February 2012, PSR provides 
information on states adoption of PDMPs prescriber use mandates.90 The PSR focuses on two 
PDMP policies: state requirement for prescriber comprehensive PDMP use and timely data 
submission to PDMP. The CDC used a three-level rating scale (green, yellow, red) to describe 
the extent of state adoption of these policies. The rating scale is based on data from the COE at 
Brandeis University and NAMSDL supported by emerging evidence and/or expert opinion. The 
green rating is the highest level rating and is given to states with comprehensive prescriber use 
mandates, defined as “requiring prescribers to consult the PDMP before initially prescribing 
opioids and benzodiazepines, and at least every three months thereafter.”90 The latest PSR 
assessment of state adoption of prescriber use mandates was conducted on October 31, 2015; 
however, it does not provide information on timing of policy implementation. Table 3.1 
describes the three-level rating scale. 
 
 
 
   
 61 
 
Table 3. 1: Requirements for comprehensive use of state PDMPs90 
Rating  State PDMP use requirement  
Green Prescribers are required to consult the PDMP before initial 
 opioid and benzodiazepine prescriptions and at least every three months thereafter 
Yellow Prescribers are required to consult the PDMP before initial opioid prescriptions and again 
within one year 
Red  Prescribers are not required to consult the PDMP before initial opioid prescriptions,  
OR such a requirement does exist but there is no required subsequent check and/or the policy 
includes subjective standards or broad exceptions 
 
 
 
Selection of eligible states 
Using the COE, NAMSDL and PSR, an overall assessment of states adoption of PDMPs 
prescriber use mandates was conducted. As of 2017, the COE classified 39 states as “mandate 
states”. As of 2015, the NAMSDL identified 13 states with requirements for comprehensive 
prescriber use and 15 states with requirements for prescribers to check the system in narrower 
circumstances; the remaining 22 states were classified as non-mandates states.31 Comprehensive 
prescriber use mandates require all prescribers to check the state PDMPs with just a few 
exceptions.  Based on the PSR, only four states were classified as comprehensive prescriber use 
mandates, four states had non-comprehensive mandates, and all other states were non-mandated. 
For the current study, the selection of mandates and non-mandates states was based on the three-
level rating scale. States with green rating (comprehensive prescriber use mandates) were 
considered as gold standards and represented the intervention state(s) in order to examine the full 
impact of the prescriber use mandates policy. Comparator states were selected from states who 
received a red rating. The HCUP State Emergency Department Databases (SEDD) and the State 
Inpatient Databases (SID) provide information on treat and release ED visits and ED visits that 
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resulted in hospital admission. The SEDD and the SID are the only available databases that 
provide ED visits on the state level and were selected as the source of data for the current 
study.91   
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Section 3.2-Results 
States with prescriber use mandates policy 
States require prescribers to check PDMPs based on specific scenarios — which varies 
significantly based on the situation. In July 2012, Kentucky was the first state that implemented a 
comprehensive prescriber use mandate policy followed by New York, Ohio, and Connecticut. 
New Jersey, Oklahoma, Rhode Island, and Tennessee received a yellow rating from the CDC 
while all other states were rated red. States with comprehensive mandate policies were 
considered as intervention states. To select an intervention state, the state should have available 
data on prescription opioid poisoning ED visits at least one year before and one year after the 
policy implementation. Out of the four states that received green rating from the CDC, only 
Kentucky and New York have ED visits data available in the HCUP. However, the latest 
available data for New York were in 2014 and the mandates policy was implemented in August 
2013. The after mandates period was not sufficient to examine the impact of the policy. Thus, 
Kentucky was selected as the intervention state. The comparator state was selected from states 
that received red rating in the PSR. The selection was based on geographic proximity to 
Kentucky and availability of data in the HCUP. ED visits data were not available for the seven 
neighboring states. The closest state with available data was North Carolina, which was selected 
as the comparator state. Table 3.2 summarizes information on states adoption of prescriber use 
mandates policy and availability of ED visits data in the HCUP. 
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Table 3.2: States adoption of prescriber use mandates policy and availability of ED visits data in 
the SEDD and the SID92 
 
State Intervention 
vs. 
comparator 
statea 
Effective 
date of 
policyb 
Data in the 
SEDD 
Data in the 
SID 
Eligibility 
for the 
current 
study 
Rationale 
Kentucky Intervention 7/20/2012 2008 - 
2015 
2000 - 
2015 
Eligible Implemented 
comprehensive mandates 
and has available ED 
visits data before and 
after 2012 
New York Intervention 8/27/13 2006 - 
2014 
1999 - 
2014 
Not 
eligible 
ED visits data are not 
available one year after 
August 2013 
Ohioc,d Intervention/ 
comparator 
4/1/15 Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
Connecticutd Intervention 10/1/2015 Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
West 
Virginiad 
Comparator - Not 
available 
2000 - 
2014 
Not 
eligible 
ED visits data are not 
available in the SEDD 
Virginiad Comparator - Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
Tennesseed Comparator - Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
Indianad Comparator - Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
Missourid Comparator - Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
Illinoisd Comparator - Not 
available 
Not 
available 
Not 
eligible 
ED visits data are not 
available 
North 
Carolina 
Comparator - 2000 - 
2015 
2007 - 
2015 
Eligible - A non-mandates state. 
-Geographically close to 
Kentucky 
- Has available ED visits 
data one year before and 
one year after 2012 
a. States with green rating were considered as intervention states, states with red rating were considered as 
reference. 
b. NAMSDL report. 
c. Ohio is a neighboring state to Kentucky and it implemented mandates policy in 2015, thus, it could be 
considered as intervention state (if ED data were available) or a comparator state. 
d. A neighboring state to Kentucky.
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Chapter 4 
 
 
 
Methods and results for specific aim 2: 
Among Kentucky and North Carolina residents: 
A. To determine the prevalence of prescription opioid poisoning ED visits. 
B. To characterize prescription opioid poisoning ED visits based on socio-demographic 
and clinical characteristics. 
C. To examine associations between patients’ sociodemographic and clinical 
characteristics and prescription opioid poisoning ED visits. 
 
Section 4.1-Methods 
Study Setting  
All prescription opioid poisoning ED visits in Kentucky and North Carolina for the years 2011 to 
2014. 
Data source 
Data from the State Emergency Department Databases (SEDD) and the State Inpatient Databases 
(SID) were used for the current study.91 Both SEDD and SID are part of the family of databases 
and software tools developed for the Healthcare Cost and Utilization Project (HCUP). The 
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SEDD is a longitudinal dataset that contains information on emergency visits at hospital-
affiliated EDs that do not result in hospitalization, and clinical, socio-demographic, and resource 
utilization information. Currently, 22 states release their ED data through the SEDD; however, 
not all variables are available for each year data was collected. 
To analyze all ED visits, data from the SEDD need to be combined with the SID. The SID 
records ED visits that result in hospital admissions and contains information about patients 
initially seen in the ED and then admitted to the hospital. The SID includes inpatient discharges 
from community hospitals per state per year. Currently, 31 states have their inpatient data 
available through the SID. Similar to the SEDD, the SID includes clinical, socio-demographic, 
and resource utilization variables for each inpatient discharge. Both the SEDD and the SID for 
Kentucky and North Carolina were used in the current study.  
Sample 
The inclusion and exclusion criteria considered to determine the final study samples are listed 
below. Figure 4.1 illustrates the sample selection process. 
Inclusion criteria: 
a. Patients had to be at least 12 years of age. 
b. ED visits with all listed diagnosis of prescription opioid poisoning were considered. 
There are up to 25 diagnosis variable in the SEDD and the SID (DX1 to DX25), an 
indicator variable of prescription opioid poisoning event was created using all 25 
variables.  
c. Intentional, unintentional, and prescription opioid poisoning events with undetermined 
intent were considered. Patients may have the intention to abuse prescription opioid, 
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however, they may develop a poisoning event unintentionally. Since there is no clear 
guidance on how to classify intention of opioid poisoning, all intentions were considered 
for this study. The variables (ECODE1 to ECODE7) were utilized to identify poisoning 
intention.  
Exclusion criteria: 
a. Prescription opioid poisoning ED visits for patients with cancer were excluded. Cancer 
patients are considered a special population due to severity of pain and complexity of 
their medical condition. PDMPs are intended to capture doctor shoppers; therefore, 
including cancer patients does not reflect the population of interest. Single level Clinical 
Classifications Software (CCS) was used to identify patients with cancer diagnosis. A list 
of CCS for cancer is available in Appendix A. 
b. Opioid poisoning ED visits for patients who were not residents in Kentucky or North 
Carolina. Prescriber use mandates policy is state specific and thus, including non-
residents may bias the evaluation of the policy.  
c. Fatal prescription opioid poisoning events. Death might not be a good indicator for 
prescription opioid poisoning because many factors can contribute to a patient’s death.  
d. Heroin related poisoning events because illicit drugs are not covered under PDMPs. 
Identification of prescription opioid poisoning events 
Opioid poisoning events were identified using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes. External Cause of Injury codes (E-codes) 
are an extension of ICD-9-CM codes used to specify intent of opioid poisoning. Description of 
ICD-9-CM codes and E-codes related to opioid poisoning is available in Table 4.1. 
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Table 4. 1: ICD-9-CM codes and E-codes for opioid poisoning  
ICD-9-CM code Description  
965.00  
965.02  
965.09  
 
Poisoning by opium (alkaloids), unspecified  
Poisoning by methadone  
Poisoning by other opiates  
E-code Description 
 
 E850.1  
 E850.2 
 E950.0  
 E980.0  
Accidental poisoning by methadone  
Accidental poisoning by other opiates and related narcotics  
Suicide and self-inflicted poisoning by analgesics, antipyretics, & antirheumatics  
Poisoning by analgesics, antipyretics & antirheumatics, undetermined whether 
accidentally or purposely inflicted  
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Number of ED visits (SID) in KY 
from 2011 to 2014  
(N= 1,167,966) 
  
Number of ED visits (SID) in NC 
from 2011 to 2014  
(N=2,152,796) 
  
Number of all ED visits (combined 
SEDD and SID) in KY from 2011 to 
2014  
(N=9,364,242) 
  
Number of all ED visits (combined 
SEDD and SID) in NC from 2011 to 
2014 
 (N=18,102,397) 
  
Exclude ED 
visits for 
patients <12 
years old 
(N= 8,190,898) 
Exclude ED 
visits for 
cancer 
patients 
Exclude ED 
visits for 
non-
residents 
 
(N= 7,842,812) 
 
(N= 7,442,262) 
Exclude ED 
visits 
resulted in 
patient 
death 
 
c 
(N= 7,408,933) 
Exclude ED 
visits for 
patients <12 
years old 
Exclude ED 
visits for 
cancer 
patients 
(N=15,674,886) 
(N=15,030,316) 
Exclude ED 
visits for 
non-
residents 
 (N=14,410,161) 
Exclude ED 
visits 
resulted in 
patient 
death 
 
c 
 
(N= 14,346,788) 
Figure 4.1:  Sample flow chart for specific aim 2 
a. Final sample size for NC from 2011 to 2014, b. Final sample size for KY from 2011 to 2014, c. based on 
ICD-9-CM codes in Table 4.1  
 
 
 
 
(N= 7,419)b 
c 
Total ED 
visits with 
prescription 
opioid 
poisoning c 
 
c 
Total ED 
visits with 
prescription 
opioid c 
poisoning 
(N= 12,598)a 
Figure 4. 1: Sa ple flo  chart for specific ai  2 
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Variables 
Clinical Variables 
In the SEDD and the SID, the variable (DXn) represents patient’s diagnosis based on ICD-9-CM 
codes. There are up to 25 listed diagnosis for each patient discharge abstract (DX1 to DX25). An 
indicator variable was created to identify prescription opioid poisoning event using all listed 
diagnoses. For the SID, the first listed diagnosis is the principle diagnosis responsible for 
hospital admission; however, in the SEDD, the first listed diagnosis is the main condition, 
symptom, or problem responsible for the ED visit. The first listed diagnosis in the SEDD and the 
SID cannot be substituted, if missing, with the second, third, or any following diagnosis. 
However, starting from the first secondary diagnosis, the diagnoses are shifted to eliminate blank 
secondary diagnoses. 
Number of chronic conditions was recoded into six categories based on the Agency for the 
Healthcare Research and Quality (AHRQ) classification.93 Number of chronic conditions was 
selected because it is a risk factor for opioid poisoning. The more chronic conditions the patient 
has, the higher is the risk of having a prescription opioid poisoning event. 
Other risk factors for opioid poisoning include pre-existing conditions of psychoses, depression, 
alcohol, and drug abuse. Indicator variables for each condition was created based on ICD-9-CM 
codes. An indicator variable for each condition was created using all listed diagnoses (DX1 to 
DX25). A description of ICD-9-CM codes for depression, psychoses, alcohol abuse, and drug 
abuse is available in Table 4.2. 
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Table 4. 2: ICD-9-CM codes for depression, psychoses, alcohol abuse, and drug abuse94  
Comorbidity ICD-9-CM code 
Depression 296.2, 296.3, 296.5, 300.4, 309.x, 311  
 
Psychoses  293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x 
Alcohol abuse  265.2, 291.1, 291.2, 291.3, 291.5, 291.6, 291.7, 291.8, 291.9, 303.0, 303.9, 305.0, 357.5, 
425.5, 535.3, 571.0, 571.0, 571.1, 571.2, 571.3, 980.x, V11.3 
Drug abuse 292.x, 304.x, 305.2, 305.3, 305.4, 305.5, 305.6, 305.7, 305.8, 305.9, V65.42 
 
Sociodemographic variables 
Age was categorized into five groups based on the literature related to opioid poisoning.95, 96 
Other sociodemographic variables available in the SEDD and the SID include gender, race, 
ethnicity, insurance, median household income, and patient’s location (urban/rural). A 
description of all original variables and recoded variables used in this study is available in Table 
4.3. 
Table 4. 3: Description of variables included for specific aim 2  
Variable name in the 
SEDD and the SID 
Description  Name of the recoded 
variable in this study 
Description  
DX1 – DX25 ICD-9-CM codesa Poisoning_indicator 1 = yes 
0 = no 
NCHRONIC Number of chronic 
conditions 
New-nchronic 0 = no chronic conditions 
1= 1 chronic condition 
2= 2 chronic conditions 
3= 3 chronic conditions 
4= 4 chronic condition 
5 ≥ 5 chronic conditions 
DX1 – DX25 ICD-9-CM codesb Depression 1 = yes 
0 = no 
DX1 – DX25 ICD-9-CM codesb Psychoses 1 = yes 
0 = no 
DX1 – DX25 ICD-9-CM codesb Alcohol 1 = yes 
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0 = no 
DX1 – DX25 ICD-9-CM codesb Drug_abuse 1 = yes 
0 = no 
AGE  Age in years New_age 1 = (12 -17) 
2= (18-15) 
3= (26-34) 
4= (35-50) 
5 >50 
FEMALE Indicator of sex New_female 1 = female 
2= male 
RACE Race and ethnicity New_race 1 = white 
2= black 
3= Hispanic 
4= other 
PAY1 Expected primary payer New_pay1 1 = Medicare 
2 = Medicaid 
3= private insurance 
4= self-pay 
5= others 
MEDINCSTQ  Median household 
income state quartile 
for patient ZIP Code 
New_medincstq 1= first quartile(poor) 
2= second quartile 
(lower-average) 
3= thirds quartile (higher-
average) 
4= fourth quartile (rich) 
PL_UR_CAT4   Patient location: urban-
rural 4 categories 
New_pl_ur_cat4 1= urban 
2= rural 
a. Description of ICD-9CM codes for opioid poisoning considered in the study is available in Table 4.1. 
b. Description of ICD-9CM codes for depression, psychoses, alcohol abuse and, drug abuse is available in 
Table 4.2. 
 
Statistical analyses 
Prevalence 
Annual prevalence of prescription opioid ED visits in Kentucky and North Carolina were 
estimated using the following equation: 
Prevalence = number of prescription opioid poisoning ED visits per state per year 
Estimate of the resident population in that state/year 
 
Number of prescription opioid poisoning ED visits were obtained from the SEDD and the SID. 
Estimates of the resident population in Kentucky and North Carolina are available from the 
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United States Census Bureau.97 Estimates for residents of 12 years of age and older were 
calculated and used for this study. Also, total four years (2011 -2014) prevalence in Kentucky 
and North Carolina was reported using the following equation: 98 
Total prevalence = total number of prescription opioid poisoning ED visits in each state over the 
period 2011-2014 
                             Estimate of the average resident population in that state over the same period 
Annual prevalence rates by age group were also calculated and compared to examine changes in 
prescription opioid poisoning ED visits among different age groups: 
Prevalence by age group = number of prescription opioid poisoning ED visits in each age group 
per state 
                           Estimate of the resident population in that age group/state 
Prevalence estimates of prescription opioid poisoning ED visits among all ED visits in Kentucky 
and North Carolina were calculated as follows: 
Prevalence among all ED visits = number of prescription opioid poisoning ED visits per state per 
year 
                                   Total number of all ED visits in that state/year 
Descriptive statistics 
Descriptive statistics were used to describe basic sociodemographic and clinical characteristics 
of prescription opioid poisoning ED visits in each state over the 2011 – 2014 period. Age as a 
continuous variable was described by mean and standard deviation; frequencies and percentages 
were used to describe all categorical variables reported in Table 4.3. Prescription opioid 
poisoning ED visits were described by age group and intent of poisoning. Bivariate analyses 
using Chi-square test and/or Fisher’s exact test were applied to examine associations between 
patients’ sociodemographic and clinical characteristics and prescription opioid poisoning ED 
visits in each state. This study was qualified for exemption by Virginia Commonwealth 
University Institutional Review Board (IRB) (ID: HM20009965). 
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Section 4.2-Results 
Aim 2A: To determine the prevalence of prescription opioid poisoning ED visits in Kentucky 
and North Carolina. 
Kentucky  
Over the four-year period, a total of 7,419 prescription opioid poisoning ED visits were reported 
among people aged 12 years and older. The total (four year) prevalence rate of prescription 
opioid poisoning ED visits was 199.6 per 100,000 population. The prevalence of prescription 
opioid poisoning ED visits by year is reported in Table 4.4. There was 26.1% decrease in the 
prevalence of prescription opioid poisoning ED visits from 2011 to 2014.  
The total and annual prevalence rate of prescription opioid poisoning ED visits among different 
age groups was examined (Table 4.5). The total prevalence rate was higher in adults 26-34 years 
old and 35-50 years old, 68.4 and 65.5 per 100,000 population, respectively, compared to other 
age groups. There was an overall reduction in the annual rate of prescription opioid poisoning 
ED visits in people ≤ 50 years of age. The decrease in the annual prevalence rate was greater 
among 18 to 25 years old and 26 to 34 years old compared to other age groups. On the other 
hand, there was 0.7% increase in the prevalence of prescription opioid poisoning ED visits 
among people greater than 50 years old from 2011 to 2014.  
The annual prevalence rate of prescription opioid ED visits among all ED visits is reported in 
Table 4.6. There was 26.1% reduction in annual rate of non-fatal prescription opioid ED visits 
from 2011 – 2014. 
North Carolina 
Over the four-year period, a total of 12,598 prescription opioid poisoning ED visits were 
reported among people aged 12 years and older. Total (four years) prevalence rate of prescription 
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opioid poisoning ED visits was 151.94 per 100,000 population. The prevalence of prescription 
opioid poisoning ED visits by year is reported in Table 4.4. There was 3.2% increase in the 
prevalence of prescription opioid poisoning ED visits from 2011 to 2014.  
The total and annual prevalence rate of prescription opioid poisoning ED visits among different 
age groups was assessed (Table 4.7). The total prevalence rate was higher in adults 26-34 years 
old and 35-50 years old, 43.18 and 42.12 per 100,000 population, respectively, compared to 
other age groups. The annual prevalence rate of prescription opioid poisoning ED visits 
increased in children 12 to 17 years old, adults 26 to 34 years, and >50 years. On the other hand, 
there was reduction in annual prevalence rate of prescription opioid poisoning ED visits in adults 
18 to 25 years old and 35 to 50 years.  
The annual prevalence rate of prescription opioid ED visits among all ED visits is reported in 
Table 4.6. The annual prevalence rate of prescription opioid ED visits (per 100,000 ED visits) 
was stable over the years 2011 – 2014. 
Table 4. 4: Annual prevalence rate of prescription opioid-poisoning ED visits (per 100,000 
population) by state 
 
State KY NC 
2011 59.31 36.29 
2012 54.94 37.68 
2013 41.67 39.49 
2014 43.82 37.45 
Percent change 2011 - 2014 -26.12 3.20 
Note: KY= Kentucky; NC = North Carolina 
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Table 4. 5: Annual and total prevalence rate of prescription opioid poisoning ED visits (per 
100,000 population) by age group in Kentucky 
 
Age   
(in years) 
2011 2012 2013 2014 Percent 
change 
2011 - 
2014 
Total 
prevalence 
rate 
12 - 17 19.00 14.00 
 
12.56 11.71 -38.40 14.25 
18 - 25 62.15 58.3 32.2 34 -45.3 46.50 
26 - 34 94 77 48.3 54.2 -42.3 68.43 
35 - 50 78 69 58 56.3 -27.8 65.46 
>50 43 46.5 39 43.3 0.7 43.00 
 
Table 4. 6: Annual prevalence rate of prescription opioid poisoning ED visits (per 100,000 ED 
visits) by state 
 
State KY NC 
2011 117 86.8 
2012 109.4 87.1 
2013 87.2 90.5 
2014 86.5 86.8 
Percent change 2011 - 2014 -26.1 0 
Note: KY= Kentucky; NC = North Carolina 
Table 4. 7: Annual and total prevalence rate of prescription opioid poisoning ED visits (per 
100,000 population) by age group in North Carolina  
 
Age   
(in years) 
2011 2012 2013 2014 Percent 
change 
2011 - 
2014 
Total 
prevalence 
rate 
12 - 17 12.7 14.0 11.1 14.7 15.7 13.12 
18 - 25 41.9 38.6 37.2 38.3 -8.6 39.00 
26 - 34 43.0 39.7 45.5 44.5 3.5 43.18 
35 - 50 41.1 42.4 44.6 40.3 -1.9 42.12 
>50 34.3 39.2 41.6 41.2 20.1 39.14 
 
 
Aim 2B: To characterize prescription opioid poisoning ED visits based on socio-demographic 
and clinical characteristics. 
 
Kentucky 
Sociodemographic characteristics 
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The mean age was 43 years (SD=15.9). More than two thirds of prescription opioid ED visits 
were related to adults 35 to 50 years old and >50 years. Children 12 to 18 years old were the 
least group among all age groups. More females were involved compared to males (54.1% and 
45.9%, respectively). The majority of prescription opioid poisoning ED visits involved whites 
(93.9%). About one third of prescription opioid poisoning ED visits were related to people with 
low income. Most of ED visits were paid by Medicare or Medicaid (29.1% and 27.0%, 
respectively). Descriptions of all sociodemographic are reported in Table 4.8. 
Clinical characteristics 
Prescription opioid poisoning ED visits were more common in people with at least one chronic 
condition. One third of prescription opioid poisoning ED visits involved people with five or 
more chronic conditions. About one quarter of ED visits were related to patients diagnosed with 
depression. Other psychiatric conditions like psychoses, drug abuse, and alcohol abuse were 
rarely reported (Table 4.8).  
Table 4. 8: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits in Kentucky from 2011 – 2014 
 
Sociodemographic variable N (%) 
Age (in years) 
0-17 
18-25 
26-34 
35-50 
>50 
 
195 (2.63) 
902 (12.16) 
1393 (18.78) 
2445 (32.96) 
2484 (33.48) 
Gender 
Male 
Female 
 
3406 (45.91) 
4013 (54.09) 
Race 
White 
Black 
Hispanic 
Other 
 
6967 (93.91) 
262 (3.53) 
113 (1.52) 
77 (1.04) 
Primary expected payer 
Medicare 
Medicaid 
 
2150 (29.09) 
1994 (26.98) 
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Private insurance 
Self-pay 
Other 
1294 (17.51) 
1411 (19.09) 
543 (7.35) 
Median household income 
Poor 
Lower average 
Higher average 
Rich 
 
2487 (34.42) 
1789 (24.76) 
1647 (22.79) 
1303 (18.03) 
Patient location 
Urban 
Rural 
 
3838 (51.90) 
3557 (48.10) 
Clinical variable N (%) 
No. of chronic conditions 
0 
1 
2 
3 
4 
≥5 
 
834 (11.24) 
1092 (14.72) 
1095 (14.76) 
953 (12.85) 
829 (11.17) 
2616 (35.26) 
Psychoses 
Yes 
No 
 
3 (0.04) 
7416 (99.96) 
Alcohol abuse 
Yes 
No 
 
61 (0.82) 
7358 (99.18) 
Drug abuse 
Yes 
No 
 
6 (0.08) 
7413 (99.92) 
Depression 
Yes 
No 
 
1815 (24.46) 
5604 (75.54) 
 
Sociodemographic and clinical characteristics were further examined by age group. Results are 
summarized in Tables 4.9. Prescription opioid poisoning ED visits were more common in males 
35 to 50 years old and in females >50 years. Although females were the predominant group 
across all ages, males had a higher percentage among young adults (18-25 and 26-34 years old). 
Among white, black, Hispanic, and others prescription opioid poisoning ED visits were more 
common in adults 35 to 50 years old and >50 years compared to other age groups. Low income 
patients had the highest proportion of prescription opioid poisoning ED visits among all age 
groups; however, they were most common in middle age adults (35 to 50 years old). With the 
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exception of patients 35 to 50 years old, urban areas had higher prevalence of prescription opioid 
poisoning ED visits as compared to rural. Medicaid was the most common primary payer for 
patients 12 to 17 years old and 35 to 50 years (60% and 31.6%, respectively). Among young 
adults (18- 25 and 26-34 years old), private insurance was the most prevalent payer (31.8% and 
34.1%, respectively). Medicare was the primary source of payment for two thirds of prescription 
opioid ED visits for patients >50 years old. 
Among patients with zero to three chronic conditions, one third of prescription opioid poisoning 
ED visits were related to people 35 to 50 years old. Two thirds of patients 35 to 50 years old had 
five or more chronic conditions. Prescription opioid poisoning ED visits for patients with 
depression and alcohol abuse were more common in those 35 to 50 years old and > 50 years. 
Table 4. 9: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits by age group in Kentucky from 2011 – 2014 
 
Characteristics  Age (in years) 
n (%) 
 0 – 17 18 – 25 26 – 34 35 – 50 >50 
Gender 
Male 
Female 
 
95 (1.28) 
100 (1.35) 
 
 
523 (7.05) 
379 (5.11) 
 
742 (10.00) 
651 (8.77) 
 
1102 (14.85) 
1343 (18.10) 
 
944 (12.72) 
1540 (20.76) 
Race 
White 
Black 
Hispanic 
Other 
 
164 (2.21) 
22 (0.30) 
6 (0.08) 
3 (0.04) 
 
817 (11.01) 
55 (0.74) 
16 (0.22) 
14 (0.19) 
 
1309 (17.64) 
39 (0.53) 
27 (0.36) 
18 (0.24) 
 
2326 (31.35) 
64 (0.86) 
33 (0.44) 
22 (0.30) 
 
2351 (31.69) 
82 (1.11) 
31 (0.42) 
20 (0.27) 
Primary expected 
payer 
Medicare 
Medicaid 
Private insurance 
Self-pay 
Other 
 
 
0 (0.00) 
115 (1.56) 
58 (0.78) 
17 (0.23) 
5 (0.07) 
 
 
22 (0.30) 
219 (2.96) 
255 (3.45) 
284 (3.84) 
114 (1.54) 
 
 
104 (1.41) 
432 (5.84) 
194 (2.62) 
472 (6.39) 
183 (2.48) 
 
 
576 (7.79) 
769 (10.40) 
415 (5.61) 
508 (6.87) 
169 (2.29) 
 
 
1448 (19.59) 
459 (6.21) 
372 (5.03) 
130 (1.76) 
72 (0.97) 
Median household 
income 
Poor 
Lower average 
Higher average 
Rich 
 
 
63 (0.870 
41 (0.57) 
37 (0.51) 
52 (0.72) 
 
 
264 (3.65) 
210 (2.91) 
192 (2.66) 
213 (2.95) 
 
 
492 (6.81) 
318 (4.40) 
307 (4.25) 
242 (3.35) 
 
 
 866 (11.98) 
585 (8.10) 
525 (7.27) 
393 (5.44) 
 
 
802 (11.10) 
635 (8.79) 
586 (8.11) 
403 (5.58) 
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Patient location 
Urban 
Rural 
 
105 (1.42) 
90 (1.22) 
 
535 (7.23) 
361 (4.88) 
 
 
735 (9.94) 
649 (8.78) 
 
1187 (16.05) 
1249 (16.89) 
 
1276 (17.25) 
1208 (16.34) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
≥ 5 
 
 
66 (0.89) 
55 (0.74) 
36 (0.49) 
18 (0.24) 
9 (0.12) 
11 (0.15) 
 
 
159 (2.14) 
221 (2.98) 
227 (3.06) 
137 (1.85) 
91 (1.23) 
67 (0.90) 
 
 
209 (2.82) 
301 (4.06) 
292 (3.94) 
208 (2.80) 
164 (2.21) 
219 (2.95) 
 
 
235 (3.17) 
343 (4.62) 
348 (4.69) 
363 (4.89) 
281 (3.79) 
875 (11.79) 
 
 
165 (2.22) 
172 (2.32) 
192 (2.59) 
227 (3.06) 
284 (3.83) 
1444 (19.46) 
Alcohol abuse 
No 
yes 
 
195 (2.63) 
0 (0.00) 
 
901 (12.14) 
1 (0.01) 
 
1385 (18.67) 
8 (0.11) 
 
2421 (32.63) 
24 (0.32) 
 
2456 (33.10) 
28 (0.38) 
Drug abuse 
No 
yes 
 
195 (2.63) 
0 (0.00) 
 
901 (12.14) 
1 (0.01) 
 
1392 (18.76) 
1 (0.01) 
 
2442 (32.92) 
3 (0.04) 
 
2483 (33.47) 
1 (0.01) 
Depression 
No 
yes 
 
151 (2.04) 
44 (0.59) 
 
718 (9.68) 
184 (2.48) 
 
1123 (15.14) 
270 (3.64) 
 
1842 (24.83) 
603 (8.13) 
 
1770 (23.86) 
714 (9.62) 
Psychoses 
No 
yes 
 
195 (2.63) 
0 (0.00) 
 
902 (12.16) 
0 (0.00) 
 
1392 (18.76) 
1 (0.01) 
 
2445 (32.96) 
0 (0.00) 
 
2482 (33.45) 
2 (0.03) 
 
Also, sociodemographic and clinical characteristics were described by intent of poisoning. 
Results are summarized in Tables 4.10. Accidental prescription opioid poisoning constituted 
51% of all visits. On the other hand, intentional represented more than half visits in children 12 
to 17 years old (53.5%). Among all other age groups, accidental prescription opioid poisoning 
was more common. Females had a higher proportion of accidental and intentional opioid 
poisoning as compared to males (58.1%, 54.5%) and (41.9%, 45.6%), respectively. 
Table 4. 10: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits by intent of poisoning in Kentucky from 2011-2014 
 
Characteristics N (%) Intent of poisoning 
 Unintentional 
(N= 3370) 
Intentional 
(N= 1678) 
Undetermined 
(N=1571) 
Age (in years) 
0 – 17 
18 – 25 
26 – 34 
 
47 (0.71) 
348 (5.26) 
535 (8.08) 
 
92 (1.39) 
251 (3.79) 
324 (4.89) 
 
33 (0.50) 
203 (3.07) 
349 (5.27) 
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35 – 50 
>50 
1006 (15.20) 
1434 (21.66) 
626 (9.46) 
385 (5.82) 
550 (8.31) 
436 (6.59) 
Gender 
Male 
Female 
 
1535 (23.19) 
1835 (27.72) 
 
703 (10.62) 
975 (14.73) 
 
782 (11.81) 
789 (11.92) 
Race 
White 
Black 
Hispanic 
Other 
 
3174 (47.95) 
113 (1.71) 
50 (0.76) 
33 (0.50) 
 
1544 (23.33) 
82 (1.24) 
35 (0.53) 
17 (0.26) 
 
1497 (22.62) 
41 (0.62) 
16 (0.24) 
17 (0.26) 
Primary expected payer 
Medicare 
Medicaid 
Private insurance 
Self-pay 
Other 
 
1225 (18.58) 
835 (12.66) 
526 (7.98) 
565 (8.57) 
210 (3.18) 
 
328 (4.97) 
465 (7.05) 
414 (6.28) 
329 (4.99) 
130 (1.97) 
 
390 (5.91) 
509 (7.72) 
215 (3.26) 
349 (5.29) 
104 (1.58) 
Median household income 
Poor 
Lower average 
Higher average 
Rich 
 
1052 (16.33) 
853 (13.24) 
772 (11.99) 
614 (9.53) 
 
498 (7.73) 
424 (6.58) 
389 (6.04) 
328 (5.09) 
 
661 (10.26) 
328 (5.09) 
311 (4.83) 
211 (3.28) 
Patient location 
Urban 
Rural 
 
1828 (27.71) 
1534 (23.25) 
 
876 (13.28) 
797 (12.08) 
 
665 (10.08) 
897 (13.60) 
No. of chronic conditions 
0 
1 
2 
3 
4 
≥ 5 
 
381 (5.76) 
466 (7.04) 
457 (6.90) 
382 (5.77) 
351 (5.30) 
1333 (20.14) 
 
130 (1.96) 
254 (3.84) 
281 (4.25) 
258 (3.90) 
223 (3.37) 
532 (8.04) 
 
192 (2.90) 
256 (3.87) 
245 (3.70) 
198 (2.99) 
173 (2.61) 
507 (7.66) 
Alcohol abuse 
No 
Yes 
 
3346 (50.55) 
24 (0.36) 
 
1667 (25.19) 
11 (0.17) 
 
1549 (23.40) 
22 (0.33) 
Drug abuse 
No 
Yes 
 
3367 (50.87) 
3 (0.05) 
 
1677 (25.34) 
1 (0.02) 
 
1569 (23.70) 
2 (0.03) 
Depression 
No 
Yes 
 
2625 (39.66) 
745 (11.26) 
 
1062 (16.04) 
616 (9.31) 
 
1275 (19.26) 
296 (4.47) 
Psychoses 
No 
Yes 
 
3370 (50.91) 
0 (0.00) 
 
1677 (25.34) 
1 (0.02) 
 
1570 (23.72) 
1 (0.02) 
 
North Carolina 
Sociodemographic characteristics 
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The mean age was 44.5 years (SD =17.2). Prescription opioid poisoning ED visits were more 
common in adults >50 years old (39%). Children 12 to 18 years old had the least proportion of 
prescription opioid ED visits among all other age groups. More females were involved compared 
to males (56.6% and 43.4%, respectively). The majority of prescription opioid poisoning ED 
visits involved whites (81.4%). About one third of prescription opioid poisoning ED visits were 
related to people with low income. Medicare was the most common primary payer (29.2%) 
followed by private insurance (23.8%), self-pay (22.5%), and Medicaid (21.4%). More than two 
thirds of prescription opioid poisoning ED visits belonged to patients living in urban areas. 
Description of all sociodemographic is reported in Table 4.11. 
Clinical characteristics 
Prescription opioid poisoning ED visits were more common in people with at least one chronic 
condition. More than one third of prescription opioid poisoning ED visits involved people with 
five or more chronic conditions. About one quarter of ED visits were related to patients 
diagnosed with depression. Other psychiatric conditions including psychoses, drug abuse and 
alcohol abuse constituted ≤1% of total prescription opioid poisoning ED visits (Table 4.11).  
Table 4. 11: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits in North Carolina from 2011-2014 
 
Sociodemographic variable n (%) 
Age (in years) 
0-17 
18-25 
26-34 
35-50 
>50 
 
403 (3.20) 
1723 (13.68) 
1973 (15.66) 
3587 (28.48) 
4911 (38.99) 
Gender 
Male 
Female 
 
5465 (43.39) 
7131 (56.61) 
Race 
White 
Black 
Hispanic 
 
10212 (81.44) 
1600 (12.76) 
226 (1.80) 
 83 
 
Other 502 (4.00) 
Primary expected payer 
Medicare 
Medicaid 
Private insurance 
Self-pay 
Other 
 
3663 (29.18) 
2680 (21.35) 
2984 (23.77) 
2823 (22.49) 
403 (3.21) 
Median household income 
Poor 
Lower average 
Higher average 
Rich 
 
3806 (31.23) 
3433 (28.17) 
3088 (25.34) 
1861 (15.27) 
Patient location 
Urban 
Rural 
 
8213 (65.78) 
4272 (34.22) 
Clinical variable  
No. of chronic conditions 
0 
1 
2 
3 
4 
≥5 
 
1137 (9.03) 
1738 (13.80) 
1815 (14.41) 
1708 (13.56) 
1524 (12.10) 
4676 (37.12) 
Psychoses 
Yes 
No 
 
11 (0.09) 
12587 (99.91) 
Alcohol abuse 
Yes 
No 
 
128 (1.02) 
12470 (98.98) 
Drug abuse 
Yes 
No 
 
44 (0.35) 
12554 (99.65) 
Depression 
Yes 
No 
 
3044 (24.16) 
9554 (75.84) 
 
Description of sociodemographic and clinical characteristics by age group is available in Table 
4.12. Prescription opioid poisoning ED visits were more common in males and females >50 
years old (33.8% and 42.9%, respectively). Although females were the predominant group across 
all ages, males had a higher proportion among young adults (18-25 and 26-34 years old). Among 
white, black, and others prescription opioid poisoning ED visits were more common in adults 35 
to 50 years old and >50 years compared to other age groups. Hispanics had similar proportions 
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among all adult age groups (i.e. ≥18 years old). Among patients with high income, one quarter of 
prescription opioid poisoning involved children 12 to 18 years old. Medicaid was the most 
common primary payer for patients 12 to 17 years old and 35 to 50 years (51.7% and 26.5%, 
respectively). Among young adults (18- 25 and 26-34 years old), private insurance was the most 
prevalent primary payer (38.3% and 48.3%, respectively). Medicare was the primary source of 
payment for about half of prescription opioid ED visits for patients >50 years old. 
Prescription opioid ED visits with one chronic condition were more common in children 12 to 17 
years old, adults 18 to 25 years, and 26 to 34 years. About two thirds of patients 35 to 50 years 
old had five or more chronic conditions. Prescription opioid poisoning ED visits with existing 
diagnosis of depression, alcohol abuse, and drug abuse were more common in patients > 50 years 
old (Table 4.12). 
Table 4. 12: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits by age group in North Carolina from 2011 to 2014 
 
Characteristics  Age (in years) 
n (%) 
 0 – 17 18 – 25 26 – 34 35 – 50 >50 
Gender 
Male 
Female 
 
 
188 (1.49) 
215 (1.71) 
 
 
940 (7.46) 
782 (6.21) 
 
1035 (8.22) 
938 (7.45) 
 
1453 (11.54) 
2134 (16.94) 
 
1848 (14.67) 
3062 (24.31) 
Race 
White 
Black 
Hispanic 
Other 
 
267 (2.13) 
85 (0.68) 
24 (0.19) 
26 (0.21) 
 
1329 (10.60) 
259 (2.07) 
48 (0.38) 
73 (0.58) 
 
1641 (13.09) 
225 (1.79) 
50 (0.40) 
52 (0.41) 
 
2907 (23.18) 
452 (3.60) 
51 (0.41) 
161 (1.28) 
 
4067 (32.43) 
579 (4.62) 
53 (0.42) 
190 (1.52) 
Primary expected 
payer 
Medicare 
Medicaid 
Private insurance 
Self-pay 
Other 
 
 
0 (0.00) 
208 (1.66) 
154 (1.23) 
23 (0.18) 
17 (0.14) 
 
 
34 (0.27) 
419 (3.34) 
526 (4.19) 
657 (5.23) 
78 (0.62) 
 
 
131 (1.04) 
486 (3.87) 
331 (2.64) 
945 (7.53) 
64 (0.51) 
 
 
801 (6.38) 
946 (7.54) 
845 (6.73) 
872 (6.95) 
111 (0.88) 
 
 
2697 (21.49) 
621 (4.95) 
1128 (8.99) 
325 (2.59) 
133 (1.06) 
Median household 
income 
Poor 
 
 
114 (0.94) 
 
 
453 (3.72) 
 
 
562 (4.61) 
 
 
1065 (8.74) 
 
 
1611 (13.22) 
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Lower average 
Higher average 
Rich 
94 (0.77) 
89 (0.73) 
101 (0.83) 
469 (3.85) 
449 (3.68) 
300 (2.46) 
557 (4.57) 
487 (4.00) 
298 (2.45) 
996 (8.17) 
887 (7.28) 
521 (4.28) 
1317 (10.81) 
1176 (9.65) 
641 (5.26) 
Patient location 
Urban 
Rural 
 
289 (2.31) 
112 (0.90) 
 
1197 (9.59) 
512 (4.10) 
 
1322 (10.59) 
628 (5.03) 
 
2349 (18.82) 
1205 (9.65) 
 
3055 (24.47) 
1815 (14.54) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
≥ 5 
 
 
117 (0.93) 
143 (1.14) 
64 (0.51) 
44 (0.35) 
20 (0.16) 
15 (0.12) 
 
 
245 (1.94) 
450 (3.57) 
397 (3.15) 
283 (2.25) 
171 (1.36) 
177 (1.41) 
 
 
242 (1.92) 
403 (3.20) 
391 (3.10) 
338 (2.68) 
235 (1.87) 
364 (2.89) 
 
 
278 (2.21) 
432 (3.43) 
528 (4.19) 
530 (4.21) 
523 (4.15) 
1296 (10.29) 
 
 
255 (2.02) 
310 (2.46) 
435 (3.45) 
513 (4.07) 
574 (4.56) 
2824 (22.42) 
Alcohol abuse 
No 
Yes 
 
403 (3.20) 
0 (0.00) 
 
1721 (13.66) 
2 (0.02) 
 
1970 (15.64) 
3 (0.02) 
 
3546 (28.15) 
41 (0.33) 
 
4829 (38.33) 
82 (0.65) 
Drug abuse 
No 
Yes 
 
401 (3.18) 
2 (0.02) 
 
1716 (13.62) 
7 (0.06) 
 
1966 (15.61) 
7 (0.06) 
 
3579 (28.41) 
8 (0.06) 
 
4891 (38.83) 
20 (0.16) 
Depression 
No 
Yes 
 
312 (2.48) 
91 (0.72) 
 
1351 (10.72) 
372 (2.95) 
 
1567 (12.44) 
406 (3.22) 
 
2692 (21.37) 
895 (7.10) 
 
3632 (28.83) 
1279 (10.15) 
Psychoses 
No 
Yes 
 
403 (3.20) 
0 (0.00) 
 
1723 (13.68) 
0 (0.00) 
 
1971 (15.65) 
2 (0.02) 
 
3580 (28.42) 
7 (0.06) 
 
4909 (38.97) 
2 (0.02) 
 
Sociodemographic and clinical characteristics were further analyzed based by intent of opioid 
poisoning. Results are reported in Table 4.13. More than half of non-fatal prescription opioid 
poisoning were accidental. Intentional prescription opioid poisoning ED visits were more 
common among children 12 to 17 years old.  In contrast, accidental poisoning was more 
common for all adult age groups. Female had a higher proportion of ED visits across all intent as 
compared to men. 
Table 4. 13: Sociodemographic and clinical characteristics of prescription opioid poisoning ED 
visits by intent of poisoning in North Carolina from 2011 – 2014 
 
Characteristics  Intent of poisoning 
n (%) 
 Unintentional 
(N=6130) 
Intentional 
(N=3065) 
Undetermined 
(N=1822) 
Age (in years)    
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0 – 17 
18 – 25 
26 – 34 
35 – 50 
>50 
130 (1.18) 
693 (6.29) 
871 (7.91) 
1580 (14.34) 
2855 (25.92) 
180 (1.63) 
564 (5.12) 
557 (5.06) 
1044 (9.48) 
720 (6.54) 
61 (0.55) 
292 (2.65) 
346 (3.14) 
527 (4.78) 
596 (5.41) 
Gender 
Male 
Female 
 
2756 (25.02) 
3372 (30.61) 
 
1219 (11.07) 
1846 (16.76) 
 
845 (7.67) 
977 (8.87) 
Race 
White 
Black 
Hispanic 
Other 
 
5023 (45.79) 
725 (6.61) 
84 (0.77) 
271 (2.47) 
 
2393 (21.81) 
491 (4.48) 
64 (0.58) 
107 (0.98) 
 
1509 (13.76) 
205 (1.87) 
38 (0.35) 
60 (0.55) 
Primary expected payer 
Medicare 
Medicaid 
Private insurance 
Self-pay 
Other 
 
2137 (19.48) 
1222 (11.14) 
1359 (12.38) 
1214 (11.06) 
173 (1.58) 
 
520 (4.74) 
715 (6.52) 
924 (8.42) 
772 (7.04) 
119 (1.08) 
 
474 (4.32) 
430 (3.92) 
331 (3.02) 
537 (4.89) 
46 (0.42) 
Median household income 
Poor 
Lower average 
Higher average 
Rich 
 
1906 (17.84) 
1680 (15.73) 
1452 (13.59) 
907 (8.49) 
 
875 (8.19) 
819 (7.67) 
754 (7.06) 
526 (4.92) 
 
572 (5.35) 
485 (4.54) 
480 (4.49) 
227 (2.12) 
Patient location 
Urban 
Rural 
 
3861 (35.32) 
2230 (20.40) 
 
2116 (19.36) 
913 (8.35) 
 
1167 (10.68) 
643 (5.88) 
No. of chronic conditions 
0 
1 
2 
3 
4 
≥ 5 
 
616 (5.59) 
812 (7.37) 
763 (6.93) 
764 (6.93) 
741 (6.73) 
2434 (22.09) 
 
184 (1.67) 
459 (4.17) 
540 (4.90) 
496 (4.50) 
443 (4.02) 
943 (8.56) 
 
194 (1.76) 
297 (2.70) 
303 (2.75) 
235 (2.13) 
189 (1.72) 
604 (5.48) 
Alcohol abuse 
No 
Yes 
 
6076 (55.15) 
54 (0.49) 
 
3043 (27.62) 
22 (0.20) 
 
1800 (16.34) 
22 (0.20) 
Drug abuse 
No 
Yes 
 
6108 (55.44) 
22 (0.20) 
 
3055 (27.73) 
10 (0.09) 
 
1814 (16.47) 
8 (0.07) 
Depression 
No 
Yes 
 
4906 (44.53) 
1224 (11.11) 
 
1988 (18.04) 
1077 (9.78) 
 
1467 (13.32) 
355 (3.22) 
Psychoses 
No 
Yes 
 
6129 (55.63) 
1 (0.01) 
 
3056 (27.74) 
9 (0.08) 
 
1822 (16.54) 
0 (0.00) 
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Aim 2C: To examine associations between patients’ sociodemographic and clinical 
characteristics and prescription opioid poisoning ED visits in Kentucky and North Carolina. 
Bivariate analyses were performed using Chi-square test to examine the relationship between 
various sociodemographic/clinical characteristics and prescription opioid poisoning ED visits. In 
Kentucky, with the exception of patient location and psychoses, all variables were statistically 
significant (p-value<0.0001). The largest coefficients were associated with number of chronic 
conditions, depression, and age (Chi-square = 5514.9, 5233.3, and 444.7, respectively). In North 
Carolina the results were similar, where with the exception of only psychoses, all variables were 
significantly associated with prescription opioid poisoning ED visits. The largest coefficients 
were associated with number of chronic conditions, race, and depression (Chi-square = 10840.8, 
8994.5, and 2980.6, respectively).
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Chapter 5 
 
 
 
Methods and results for specific aim 3: 
A. To compare occurrences of prescription opioid poisoning ED visits pre and post 
prescriber use mandates in Kentucky. 
B. To compare occurrences of prescription opioid poisoning ED visits in Kentucky and 
North Carolina, after prescriber use mandate implementation. 
Section 5.1-Methods 
Study design 
Controlled pre-post study design. Kentucky and North Carolina represented the intervention state 
and the control (comparator) state, respectively. Figure 5.1 describes the study design. 
   
 
Kentucky
Before
Intervention
(Comprehensive 
prescriber use mandates) 
effective in July 2012
Kentucky
After
North Carolina
Before
North Carolina
after
Compare 
Figure 5.1 Controlled pre-post study design Figure 5. 1: Controlled pre-po t study design 
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Study settings 
Prescription opioid poisoning ED visits in Kentucky and North Carolina for the period 2011 to 
2014. 
Data source 
The SEDD (treat and release ED visits) and the SID (ED visits that resulted in hospital admission) 
for Kentucky and North Carolina. See section 4.1 
Sample 
 Prescription opioid poisoning ED visits in Kentucky were compared between the years (2011, 
2012), (2011, 2013), and (2011, 2014). In addition, comparisons were made between Kentucky 
and North Carolina utilizing the same sets of years. Sample selection process for specific aim 3A 
and 3B, including exclusion criteria is illustrated in Figure 5.2 and 5.3, respectively.  
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Number of ED visits (SEDD) in KY  
2011(N=2,133,987), 2012 (N=2,136,069), 
2013 (N=2,036,780), 2014 (N=2,154,440) 
  
Number of hospital admissions with evidence of ED 
visits (SID) in KY  
2011 (N=299,484), 2012 (N=294,358), 
2013 (N=285,070), 2014 (N=289,054) 
  
Number of all ED visits (combined SEDD and SID) in KY  
2011 (N=2,433,471), 2012 (N=2,430,427), 
2013 (N=2,321,850), 2014 (N=2,443,494) 
  
Exclude ED visits for patients <12 years of age 
2011 and 2012 (N=4,121,655), 2011 and 2013 (N=4,036,712), 2011 and 2014 (N=4,158,623) 
 
 
Exclude ED visits for cancer patients 
2011 and 2012 (N=3,956,679), 2011 and 2013 (N=3,867,454), 2011 and 2014 (N=3,985,977) 
  
 
Combine the years: (2011 and 2012), (2011 and 2013), (2011 and 2014) 
 
Exclude ED visits for non-residents 
2011 and 2012 (N=3,750,307), 2011 and 2013 (N=3,667,967), 2011 and 2014 (N=3,782,854) 
  
 
Exclude ED visits resulted in patient death 
2011 and 2012 (N=3,733,535)a, 2011 and 2013 (N=3,651,453)b, 2011 and 2014 (N=3,765,843)c 
  
 Figure 5.2:  Sample flow chart for specific aim 3A (Kentucky only) 
a. Final sample size for the years 2011 and 2012, b.  Final sample size for the years 2011 and 2013 
c. Final sample size for the years 2011 and 2014  
 
 
 
 
 
(N=4,755,321) (N=4,863,898) (N=4,876,965) 
i r  . 2: l  fl  rt f r s ifi  i   ( t  l ) 
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Number of all ED visits (combined SEDD and SID) in KY 
2011 (N=2,433,471), 2012 (N=2,430,427), 2013 (N=2,321,850), 2014 (N=2,443,494) 
  
Number of all ED visits (combined SEDD and SID) in NC 
2011(N=4,278,071), 2012(N=4,500,472), 2013 (N=4,591,023), 2014 (N=4,732,831) 
 
Number of all ED visits in KY and NC  
2011(N=6,711,542), 2012(N=6930,899), 2013 (N=6,912,873), 2014 (N=7,176,325) 
  
Combine the years: (2011 and 2012), (2011 and 2013), (2011 and 2014) 
 
(N=) (N=) (N=) 
Exclude ED visits for patients <12 years of age 
2011 and 2012 (N=11,698,646), 2011 and 2013 (N=11,713,122), 2011 and 2014 (N=11,968,130) 
 
 
Exclude ED visits for cancer patients 
2011 and 2012 (N=11,248,304), 2011 and 2013 (N=11,237,165), 2011 and 2014 (N=11,476,345) 
  
 
Exclude ED visits for non-residents 
2011 and 2012 (N=10,741,599), 2011 and 2013 (N=10,737,167), 2011 and 2014 (N=10,964,285) 
  
 
Exclude ED visits resulted in patient death 
2011 and 2012 (N=10,691,826)a, 2011 and 2013 (N=10,688,407)b, 2011 and 2014 (N=10,915,644)c 
  
 Figure 5.3:  Sample flow chart for specific aim 3B (Kentucky and North Carolina) 
a. Final sample size for the years 2011 and 2012, b.  Final sample size for the years 2011 and 2013 
c. Final sample size for the years 2011 and 2014 
 
d.  
 
 
 
(N=13,642,441) (N=13,624,415) (N=13,887,867) 
Figure 5. 3: Sample flow chart for specific aim 3B (Kentucky and North Carolina) 
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Variables 
Main predictor and outcome variables for specific aims 3A and 3B are listed in Table 5.1. Other 
sociodemographic and clinical variables considered for specific aim 3 are similar to specific aim 
2 (Table 4.3). The unit of analysis is the ED visit. 
Table 5. 1: Main predictor and outcome variables for specific aims 3A and 3B 
Aim Main predictor 
variable 
Type of variable Outcome variable Type of variable 
3A Post Dichotomous variable: 
1 = post mandates 
(i.e. second half of 2012, 
2013, and 2014), 
0 = pre-mandates 
(i.e. 2011 and first half of 
2012) 
Poisoning_indicator Dichotomous 
variable: 
1 = yes, 0= no 
3B Mandates*post Interaction term of two 
dichotomous variables. 
Mandates: 
1= Kentucky, 0= North 
Carolina. 
Post: 1= post mandates 
(i.e. second half of 2012, 2013 
and, 2014), 
0 = pre-mandates 
(i.e. 2011 and first half of 
2012) 
Poisoning_indicator Dichotomous 
variable 
1 = yes, 0= no 
 
Statistical analyses 
Specific aim 3A: 
Multivariable logistic regression analysis was used to examine the impact of prescriber use 
mandates on prescription opioid poisoning ED visits in Kentucky. A stepwise selection with 0.05 
level of significance was used to identify confounders to include in the final model. Three 
models were created to compare ED visits before and after prescriber use mandates 
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implementation in Kentucky. The mandates policy became effective in July 2012, the first set of 
comparison was made for the years 2011 and 2012. The subsequent set of comparisons included 
the years (2011, 2013) and (2011, 2014).  
Specific aim 3B: 
Multivariable logistic regression was used to assess changes in prescription opioid poisoning ED 
visits relative to prescriber use mandates, in Kentucky and North Carolina. A difference in 
difference (DID) framework was applied to analyze the casual effect of prescriber use mandates 
policy on prescription opioid poisoning ED visits. The DID framework is a common analytical 
technique used to evaluate the impact of policy change.99, 100 It estimates the difference in 
changes of an outcome variable over time between the intervention and control group. Three sets 
of comparison models were conducted including the years (2011, 2012), (2011, 2013), and 
(2011, 2014). Each model compared the occurrences of prescription opioid poisoning ED visits 
in Kentucky and North Carolina. The main outcome measure was the occurrence of prescription 
opioid poisoning ED visit (a binary variable). The main predictor variable was an interaction 
term of state with time relative to policy implementation. The logistic regression analysis with 
DID framework can be explained by the following equation: 
Logit (poisoning_indicator=1) = β0 + β1 mandates + β2 post+ β3 (mandates*post) + β(4 – n) X(4 –n) 
 - Mandates is a dummy variable for prescriber mandates (1= Kentucky, 0= North Carolina). 
 - Post is a dummy variable for post mandates period (1= post mandates (i.e. second half of 2012, 
2013 and, 2014), 0= pre-mandates (i.e. 2011 and first half of 2012)). 
 - β3 is the DID estimator which represents the true effect of mandates: 
 β3= (KY post - KY pre) - (NC post - NC pre). 
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- X (4 – n) are the potential confounders considered in the final model, n = number of confounders. 
Scenario analyses 
Scenario analyses were performed for specific aim 3B to test the impact of two inclusion criteria 
on the final estimates:  
a. Including only ED visits with prescription opioid poisoning listed as the first diagnosis 
(variable: DX1). This ensured that prescription opioid poisoning was the main diagnosis 
or chief compliant responsible for the ED visit or the hospital stay and thus, eliminate 
overestimation of the study sample. 
b. Including only ED visits with unintentional prescription opioid poisoning. The population 
of interest was patients who abuse prescription opioid and developed a poisoning event as 
a result of the abuse behavior. Thus, suicide attempts and poisoning events with 
undetermined intent may not reflect the intended population.  
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Section 5.2-Results 
 
Aim 3A: To compare occurrences of prescription opioid poisoning ED visits pre and post 
prescriber use mandates in Kentucky. 
Three logistic regression models were conducted to examine the impact of prescriber use 
mandates on occurrences of prescription opioid poisoning ED visits. Table 5.2 summarizes 
results of the logistic regression analysis for the years 2011 and 2012. The final model included 
the variables listed in Table 5.2 and the interaction term of age with number of chronic 
conditions. All covariates had a significant relationship with opioid poisoning ED visits (i.e. p-
value<0.05). Holding all other variables constant, the odds of having an opioid poisoning ED 
visit in 2012 was 11% (95% CI= 6.0% - 17.0%) less compared to 2011. 
Table 5. 2: Adjusted logistic regression for prescription opioid poisoning ED visits in (KY 2011-
2012) 
 
 
OR 95% CI 
Lower limit  Upper limit 
Wald 
Chi-Square (p-
value) 
Year 
 2011* 
2012 
 
- 
0.89 
 
- 
0.83 
 
- 
0.94 
 
- 
10.9668 (0.0009) 
Age (in years) 
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
2.57 
2.87 
3.27 
2.34 
- 
 
1.06 
2.06 
2.68 
2.06 
- 
 
6.22 
4.01 
3.98 
2.65 
- 
 
4.3458 (0.0371) 
38.6180 (<.0001) 
139.0875 (<.0001) 
177.6008 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.23 
 
- 
1.16 
 
- 
1.31 
 
- 
42.4909 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.30 
0.57 
0.95 
 
- 
0.25 
0.38 
0.71 
 
- 
0.35 
0.87 
1.26 
 
- 
190.9968 (<.0001) 
6.7231 (0.0095) 
0.1326 (0.7157) 
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Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
 
1.29 
0.97 
1.35 
1.46 
 
 
1.17 
0.88 
1.22 
1.28 
 
 
1.42 
1.07 
1.50 
1.66 
 
- 
24.4983 (<.0001) 
0.3761 (0.5397) 
31.9044 (<.0001) 
32.8242 (<.0001) 
Median household 
income 
Poor* 
Lower average 
Higher average 
Rich 
 
 
- 
0.87  
0.77  
0.85  
 
 
- 
0.80 
0.71  
0.78  
 
 
- 
0.94  
0.84 
0.94 
 
 
- 
11.1926 (0.0008) 
38.2778 (<.0001) 
11.4361 (0.0007) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
5* 
 
 
0.19 
0.26 
0.38 
0.49 
0.78 
- 
 
 
0.15 
0.21 
0.31 
0.40 
0.66 
- 
 
 
0.23 
0.33 
0.46 
0.60 
0.94 
- 
 
 
210.6224 (<.0001) 
142.2541 (<.0001) 
87.3323 (<.0001) 
50.1801 (<.0001) 
7.3415 (0.0067) 
- 
Drug abuse 
No 
Yes* 
 
0.05 
- 
 
0.01 
- 
 
0.20 
- 
 
16.8625 (<.0001) 
- 
Depression 
No 
Yes* 
 
0.40 
- 
 
0.37 
- 
 
0.44 
- 
 
518.7315 (<.0001) 
- 
Note: OR= odds ratio; CI= confidence interval 
* Reference category 
The following models for years 2011, 2013 and 2011, 2014 included the same covariates as the 
final model above. The second logistic regression model compared occurrences of prescription 
opioid poisoning ED visits between the years 2011 and 2013. Results of the adjusted analysis are 
summarized in Table 5.3. All covariates were statistically significant (i.e. p-value <0.05). 
Holding all other variables constant, the odds of having an opioid poisoning ED visit in 2013 
was 33% (95% CI= 28.0% - 37.0%) less compared to 2011.  
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Table 5. 3: Adjusted logistic regression for prescription opioid poisoning ED visits (KY 2011-
2013) 
 
 
OR 95% CI 
Lower limit  Upper limit 
Wald 
Chi-Square (p-
value) 
Year 
 2011* 
2013 
 
- 
0.67 
 
- 
0.63 
 
- 
0.72 
 
- 
140.1676 (<.0001) 
Age (in years) 
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
3.90 
2.16 
3.02 
2.41 
- 
 
1.84 
1.45 
2.30 
2.12 
- 
 
8.27 
3.21 
3.53 
2.74 
- 
 
12.5565 (0.0004) 
14.3199 (0.0002) 
91.1886 (<.0001) 
180.7251 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.20 
 
- 
1.12 
 
- 
1.28 
 
- 
28.0746 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.33 
1.20 
0.70 
 
- 
0.27 
0.95 
0.45 
 
- 
0.39 
1.53 
1.10 
 
- 
155.9573 (<.0001) 
2.3506 (0.1252) 
2.4134 (0.1203) 
Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
- 
1.20 
0.90 
1.35 
1.28 
 
- 
1.08 
0.80 
1.21 
1.11 
 
- 
1.34 
1.00 
1.50 
1.48 
 
- 
11.3530 (0.0008) 
4.0724 (0.0436) 
28.8509 (<.0001) 
11.8466 (0.0006) 
Median household 
income 
Poor* 
Lower average 
Higher average 
Rich 
 
 
- 
0.90 
0.84  
0.94  
 
 
- 
0.82  
0.77  
0.86  
 
 
- 
0.98 
0.92 
1.04 
 
 
- 
6.0363 (0.0140) 
14.0983 (0.0002) 
1.4479 (0.2289) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
5* 
 
 
0.20 
0.26 
0.36 
0.51 
0.82 
- 
 
 
0.16 
0.20 
0.28 
0.42 
0.69 
- 
 
 
0.25 
0.33 
0.44 
0.63 
0.99 
- 
 
 
180.8271 (<.0001) 
127.9302 (<.0001) 
83.0225 (<.0001) 
41.2326 (<.0001) 
4.2864 (0.0384) 
- 
Drug abuse 
No 
Yes* 
 
0.05 
- 
 
 
0.01 
- 
 
 
0.20 
- 
 
17.1835 (<.0001) 
- 
 
Depression     
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No 
Yes* 
0.40 
- 
0.37 
- 
0.43 
- 
470.7818 (<.0001) 
- 
Note: OR = odds ratio; CI = confidence interval 
*Reference category 
 
The third regression model compared occurrences of prescription opioid poisoning ED visits 
between the years 2011 and 2014. Results of the adjusted analysis are summarized in Table 5.4. 
All covariates were statistically significant (i.e. p-value <0.05) except for drug abuse. Holding all 
other variables constant, the odds of having an opioid poisoning ED visit in 2014 was 35.0% 
(95% CI= 30.0%- 39.0%) less compared to 2011. 
Table 5. 4: Adjusted logistic regression for prescription opioid poisoning ED visits (KY 2011-
2014) 
 
 
OR 95% CI 
Lower limit     Upper limit 
Wald 
Chi-Square (p-
value) 
Year 
 2011* 
2014 
 
- 
0.65 
 
- 
0.61 
 
- 
0.70 
 
- 
86.9103 (<.0001) 
Age category (years) 
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
2.61 
2.17 
2.53 
2.06 
- 
 
1.16 
1.51 
2.05 
1.81 
- 
 
5.85 
3.13 
3.12 
2.34 
- 
 
5.3772 (0.0204) 
17.2781 (<.0001) 
74.8696 (<.0001) 
124.9205 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.21 
 
- 
1.13 
 
- 
1.29 
 
- 
31.5105 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.33 
0.94 
0.73 
 
- 
0.28 
0.70 
0.51 
 
- 
0.39 
1.27 
1.05 
 
- 
160.7185 (<.0001) 
0.1589 (0.6901) 
2.8720 (0.0901) 
Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
- 
1.33 
0.96 
1.42 
1.38 
 
- 
1.20 
0.86 
1.26 
1.19 
 
- 
1.47 
1.06 
1.60 
1.61 
 
- 
31.4368 (<.0001) 
0.6929 (0.4052) 
33.5470 (<.0001) 
17.5406 (<.0001) 
Median household 
income 
Poor* 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
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Lower average 
Higher average 
Rich 
0.86  
0.78  
   0.92  
0.79  
       0.71  
       0.83  
0.94 
0.85 
    1.01 
11.7200 (0.0006) 
32.3057 (<.0001) 
3.3122 (0.0688) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
5* 
 
 
0.19 
0.24 
0.33 
0.46 
0.70 
- 
 
 
0.15 
0.19 
0.27 
0.37 
0.59 
- 
 
 
0.24 
0.30 
0.42 
0.56 
0.85 
- 
 
 
200.2151 (<.0001) 
148.4039 (<.0001) 
98.5405 (<.0001) 
57.2555 (<.0001) 
13.8377 (0.0002) 
- 
Drug abuse 
No 
Yes* 
 
0.51 
- 
 
0.19 
- 
 
1.36 
- 
 
1.8345 (0.1756) 
- 
Depression 
No 
Yes* 
 
0.40 
- 
 
 
0.37 
- 
 
 
0.44 
- 
 
 
470.2845 (<.0001) 
- 
 
Note: OR= odds ratio; CI= confidence interval 
*Reference category 
 
Aim 3B: To compare occurrences of prescription opioid poisoning ED visits in Kentucky and 
North Carolina, after prescriber use mandate implementation  
Logistic regression model (KY and NC 2011-2012) 
All variables listed in Table 4.3 were considered for inclusion in the model. The selection of 
these variables was based on the existing literature, which supports their association with opioid 
abuse. The logistic regression model was used to assess changes in prescription opioid poisoning 
ED visits relative to prescriber use mandates, in Kentucky and North Carolina for the years 2011 
and 2012. A stepwise selection with 0.05 level of significance was applied. The stepwise 
selection works by removing or adding variables during the various steps of model building. The 
stepwise selection resulted in a model not including the interaction term (state*post), the state 
variable, and the variables: psychoses, alcohol abuse, and patient location. This means that these 
variables were not significantly associated with prescription opioid poisoning ED visits. 
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The interaction term (state*post) and the state variable were forced as regressors in the final 
model. Variables sometimes need to be forced into regression equations because they are 
necessary to conduct the analysis. The resultant model experienced poor fit (Pearson Goodness-
of-Fit Statistic: Value/DF=1.76, p-value <0.0001). 
To enhance model fit, a PROC GENMOD procedure was used with logit link function; the 
resultant models did not show any improvement. The PROC GENMOD procedure conducts a 
generalized linear model, which is a large class of models containing logistic regression model 
and others. The advantage of PROC GENMOD is the possibility of using other links to improve 
the fit of the model. Also, adding interaction terms of age with all other covariates did not 
improve model fit. However, single inclusion of the interaction term of age with number of 
chronic conditions showed a better model fit (based on -2 Log L).  
The final model included the variables listed in Table 5.5 and an interaction term of age with 
number of chronic conditions. All covariates, including the main predictor variable, were 
significantly associated with prescription opioid poisoning ED visit (i.e. p-value <0.05). Holding 
all other variables constant, the odds of having an opioid poisoning ED visit in Kentucky 
compared to North Carolina is 9% (95% CI= 1% - 16%) less in 2012 compared to 2011. Hence, 
there is a 9% reduction in likelihood of prescription opioid poisoning ED visit going from 2011 
to 2012 in Kentucky, controlling for North Carolina in the model. To recall, prescriber use 
mandates policy was implemented in Kentucky in July 2012; thus, the reduction in the odds of 
having an opioid poisoning ED visit may be related to the policy. 
The odds of having an opioid poisoning ED visit varied according to other model variables. The 
odds were significantly higher among 18 to 25 years old, 26 to 34 years, and 35 to 50 years 
compared to those >50 years old; however, no significant difference in these odds for children 12 
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to 17 years old compared to adults >50 years. Males were 1.2 (95% CI= 1.1 - 1.2) more likely to 
experience an opioid poisoning ED visit compared to females. Black and Hispanic were 69.5% 
(95% CI= 67.2% – 71.6%) and 54.1% (95% CI= 44.3% - 62.3%) less likely to have an opioid 
poisoning ED visit compared to white. The odds of an opioid poisoning ED visit were 
significantly lower among patients with median household income in the second and third 
quartile compared to those in the first quartile. Medicaid and self-pay patients had 1.1(95% CI= 
1.1 - 1.2) and 1.1 (95% CI=1.05 - 1.20) higher odds of an opioid poisoning ED visit compared to 
Medicare patients. On the other hand, the odds of an opioid poisoning ED visit were 9% (95% 
CI= 3.1% - 14.4%) less when the primary payer is a private insurance compared to Medicare. 
Patients not diagnosed with depression or did not have a previous history of drug abuse were 
58% (95% CI= 56.0% - 60.0%) and 84% (95% CI= 73.0% - 90.0%) less likely to develop an 
opioid poisoning ED visit compared to their counterparts. Patients with no chronic conditions 
were 80% (95% CI= 77% - 83%) less likely to have an opioid poisoning ED visit compared to 
those with five or more chronic conditions. Similarly, these odds were significantly lower for 
patients with one to four chronic conditions as compared to those having five or more chronic 
conditions. The association of the number of chronic conditions with opioid poisoning ED visits 
varied by age. The odds of an opioid poisoning ED visit for patients with no chronic conditions 
were not significantly different in patients 35 to 50 years old compared to > 50 years. On the 
other hand, these odds were significantly lower in other age groups compared to those >50 years 
old. Among patients with five or more chronic conditions, the odds of an opioid poisoning ED 
visit were significantly different in adults 18 to 25 years old, 26 to 34 years, and 35 to 50 years 
compared to > 50 years; however, these odds were not significantly different in children 12 to 17 
years compared to adults >50 years. The odds of an opioid poisoning ED visit for patients with 
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one to four chronic conditions were significantly different comparing all age groups to > 50 
years old.  
Table 5. 5: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC 
2011-2012) 
 
 
OR 95% CI 
Lower limit  Upper limit 
Wald 
Chi-Square (p-
value) 
Year 
2011* 
2012 
 
- 
0.97 
 
- 
0.92 
 
- 
1.02 
 
- 
1.5355 (0.2153) 
State 
KY 
 NC* 
 
1.14 
- 
 
1.08 
- 
 
1.21 
- 
 
19.6692 (<.0001) 
Mandates*post: 
KY*2012 
 
0.91 
 
0.84 
 
0.99 
 
4.7572 (0.0292) 
Age (in years) 
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
1.41 
3.47 
2.86 
2.15 
- 
 
0.67 
2.86 
2.50 
1.98 
- 
 
2.97 
4.21 
3.27 
2.33 
- 
 
0.8156 (0.3665) 
158.6206 (<.0001) 
230.9870 (<.0001) 
330.761 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.16 
 
- 
1.11 
 
- 
1.21 
 
- 
50.7203 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.31 
0.46 
1.04 
 
- 
0.28 
0.38 
0.93 
 
- 
0.33 
0.56 
1.17 
 
- 
1031.9464 (<.0001) 
61.1671 (<.0001) 
0.4599 (0.4977) 
Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
- 
1.14 
0.91 
1.13 
1.31 
 
- 
1.07 
0.86 
1.05 
1.19 
 
- 
1.22 
0.97 
1.20 
1.44 
 
- 
15.9351 (<.0001) 
8.8403 (0.0029) 
12.1622 (0.0005) 
30.7756 (<.0001) 
Median household 
income 
Poor* 
Lower average 
Higher average 
Rich 
 
 
 
0.90  
0.94 
0.96  
 
 
 
0.85  
0.89 
0.91  
 
 
 
0.95 
     0.99 
     1.02    
 
 
 
16.9101 (<.0001) 
5.4201 (0.0199) 
1.5666 (0.2107) 
No. of chronic 
conditions 
0 
1 
 
 
0.20 
0.30 
 
 
0.17 
0.27 
 
 
0.23 
0.35 
 
 
469.431 (<.0001) 
314.1063 (<.0001) 
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2 
3 
4 
5* 
0.42 
0.61 
0.76 
- 
0.38 
0.55 
0.68 
- 
0.48 
0.68 
0.85 
- 
200.2062 (<.0001) 
82.0078 (<.0001) 
25.6835 (<.0001) 
- 
Drug abuse 
No 
 Yes* 
 
0.16 
- 
 
0.10 
- 
 
0.27 
- 
 
48.8300 (<.0001) 
- 
Depression 
No 
 Yes* 
 
0.42 
- 
 
0.40 
- 
 
0.44 
- 
 
1140.7458 (<.0001) 
- 
Note: OR = odds ratio; CI= confidence interval 
* Reference category 
 
Results of the adjusted analysis for the years 2011 and 2013 are summarized in Table 5.6. All 
covariates were statistically significant (i.e. p-value <0.05). Holding all other variables constant, 
the odds of having an opioid poisoning ED visit in Kentucky compared to North Carolina is 30% 
(95% CI= 24% - 35%) lower in 2013 compared to 2011. So, these odds were reduced by three-
fold compared to the reduction in 2012. The odds of having an opioid poisoning ED visit were 
significantly higher among all other age groups compared to those >50 years old. Males were 
1.14 (95% CI= 1.1 - 1.2) more likely to experience an opioid poisoning ED visit compared to 
females. Black and Hispanic were 67.5% (95% CI= 65.2% - 69.7%) and 37.4% (95% CI=26.6% 
- 46.6%) less likely to have an opioid poisoning ED visit compared to white. The odds of an 
opioid poisoning ED visit were 8.0% (95% CI= 3.0% - 12.0%) lower for patients with median 
household income in the second quartile compared to those in the first quartile. Medicaid and 
self-pay patients had 1.2 (95% CI= 1.1 - 1.3) and 1.14 (95% CI= 1.1 - 1.2) higher odds of an 
opioid poisoning ED visit compared to Medicare patients. On the other hand, the odds of an 
opioid poisoning ED visit were 8.3% (95% CI=2.4 % - 13.8%) less when the primary payer is a 
private insurance compared to Medicare. Patients not diagnosed with depression or did not have 
a previous history of drug abuse were 55.0% (95% CI= 53.0% - 58.0%) and 83.0% (95% CI= 
75.0% - 88.0%) less likely to develop an opioid poisoning ED visit compared to their 
counterparts. Patients with no chronic conditions were 83% (95% CI= 80% - 85%) less likely to 
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have an opioid poisoning ED visit compared to those with five or more chronic conditions. 
Similarly, these odds were significantly lower for patients with one to four chronic conditions as 
compared to those having more than five chronic conditions.  
The association of the number of chronic conditions with opioid poisoning ED visits varied by 
age. The odds of an opioid poisoning ED visit for patients with no chronic conditions were not 
significantly different in patients 26 to 34 years old and 35 to 50 years compared to > 50 years. 
In contrast, these odds were significantly lower among other age groups compared to the 
reference age group. Among patients with four chronic conditions, the odds of an opioid 
poisoning ED visit were not significantly different in children 12 to 17 years old compared to 
adults >50 years; however, these odds were significantly higher in all age groups compared to 
those >50 years old. Among patients with five or more chronic conditions, the odds of an opioid 
poisoning ED visit were not significantly different in adults 18 to 25 years old compared to > 50 
years; however, these odds were significantly higher in children 12 to 17 years old, adults 26 to 
34 years, and 35 to 50 years compared to adults >50 years. The odds of an opioid poisoning ED 
visit for patients with one to three chronic conditions were significantly higher comparing all age 
groups to > 50 years old.  
Table 5. 6: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC 
2011-2013) 
 
 
OR 95% CI 
Lower limit   Upper limit 
Wald 
Chi-Square (p-
value) 
Year 
 2011* 
2013 
 
- 
0.97 
 
- 
0.92 
 
- 
1.02 
 
- 
1.6341 (0.2011) 
State 
KY 
 NC* 
 
1.15 
- 
 
1.08 
- 
 
1.21 
- 
 
21.8591 (<.0001) 
- 
Mandates*post:     
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KY*2013 0.70 0.65 0.76 69.5745 (<.0001) 
Age (in years) 
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
2.39 
2.66 
2.73 
2.09 
- 
 
1.38 
2.16 
2.39 
1.93 
- 
 
4.13 
3.28 
3.12 
2.26 
- 
 
9.6482 (0.0019) 
83.6690 (<.0001) 
222.8204 (<.0001) 
322.1580 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.14 
 
- 
1.09 
 
- 
1.19 
 
- 
38.4994 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.33 
0.63 
1.00 
 
- 
0.30 
0.53 
0.88 
 
- 
0.35 
0.73 
1.13 
 
- 
987.9433 (<.0001) 
33.3024 (<.0001) 
0.0000 (0.9971) 
Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
- 
1.18 
0.92 
1.14 
1.26 
 
- 
1.10 
0.86 
1.06 
1.14 
 
- 
1.26 
0.98 
1.22 
1.39 
 
- 
24.2162 (<.0001) 
7.3700 (0.0066) 
14.1759 (0.0002) 
19.6974 (<.0001) 
Median household 
income 
Poor* 
Lower average 
Higher average 
Rich 
 
 
- 
0.92 
0.98  
1.00  
 
 
- 
0.88 
0.93 
0.94  
 
 
- 
0.97 
1.04 
1.07     
 
 
- 
8.7359 (0.0031) 
0.3267 (0.5676) 
0.0013 (0.9716) 
No. of chronic 
conditions 
0 
1 
2 
3 
4 
5* 
 
 
0.17 
0.27 
0.38 
0.54 
0.71 
- 
 
 
0.15 
0.24 
0.33 
0.48 
0.64 
- 
 
 
0.20 
0.31 
0.43 
0.66 
0.79 
- 
 
 
508.7096 (<.0001) 
356.7509 (<.0001) 
242.8057 (<.0001) 
119.5279 (<.0001) 
39.6031 (<.0001) 
- 
Drug abuse 
No 
  Yes* 
 
0.17 
- 
 
0.12 
- 
 
0.25 
- 
 
86.4097 (<.0001) 
- 
Depression 
No 
  Yes* 
 
0.445 
- 
 
0.423 
- 
 
0.469 
- 
 
970.2113 (<.0001) 
- 
Note: OR = odds ratio; CI= confidence interval 
* Reference category 
 
The last model compared occurrences of prescription opioid poisoning ED visits in Kentucky 
and North Carolina for the years 2011 and 2014. Results of the adjusted analysis are summarized 
in Table 5.7. All covariates were statistically significant (i.e. p-value <0.05). Holding all other 
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variables constant, the odds of having an opioid poisoning ED visit in Kentucky compared to 
North Carolina is 29.8% (95% CI= 24.0% - 35.0%) lower in 2014 compared to 2011. Thus, no 
further reduction in these odds was noticed in 2014 as compared to 2013.The odds of having an 
opioid poisoning ED visit were significantly higher among all other age groups compared to 
those >50 years old. Males were 1.15 (95% CI= 1.1 - 1.2) more likely to experience an opioid 
poisoning ED visit compared to females. Black and Hispanic were 69.5% (95% CI= 67.2% - 
71.6%) and 37.5% (95% CI=26.9% - 46.6%) less likely to have an opioid poisoning ED visit 
compared to white. The odds of an opioid poisoning ED visit were not significantly different 
among patients with median household income in the third and fourth quartile compared to those 
in the first quartile. Medicaid and self-pay patients had 1.2 (95% CI= 1.1 - 1.3) and 1.2 (95% CI= 
1.1 - 1.3) higher odds of an opioid poisoning ED visit compared to Medicare patients. On the 
other hand, the odds of an opioid poisoning ED visit were 6.2% (95% CI=0.0% - 11.8%) less 
when the primary payer is a private insurance compared to Medicare. Patients not diagnosed 
with depression or did not have a previous history of drug abuse were 56.0% (95% CI= 53.0% - 
58.0%) and 73.0% (95% CI= 59.0% - 82.0%) less likely to have an opioid poisoning ED visit 
compared to none. Patients with no chronic conditions were 81% (95% CI= 78% - 83%) less 
likely to have an opioid poisoning ED visit compared to those with five or more chronic 
conditions. Similarly, these odds were significantly lower for patients with one to four chronic 
conditions as compared to those having five or more chronic conditions. The association of the 
number of chronic conditions with opioid poisoning ED visits varied by age. The odds of an 
opioid poisoning ED visit for patients with no chronic conditions were significantly lower in 
patients 12 to 17 years old, 18 to 25 years, 26 to 34 years, and 35 to 50 years compared to > 50 
years. Among patients with one to four chronic conditions, the odds of an opioid poisoning ED 
 107 
 
visit were significantly higher in all age groups compared to adults >50 years. However, for 
patients with five or more chronic conditions, these odds were not significantly different in all 
age groups compared to those >50 years old.  
Table 5. 7: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC 
2011-2014) 
 
 
OR 95% CI 
Lower limit   Upper limit 
 
Wald 
Chi-Square (p-
value) 
Year 
 2011* 
2014 
 
- 
0.92 
 
- 
0.87 
 
- 
0.97 
 
- 
10.5260 (0.0012) 
State 
KY 
 NC* 
 
1.14 
- 
 
1.08 
- 
 
1.21 
- 
 
19.6814 (<.0001) 
- 
Mandates*post: 
KY*2014 
 
0.70 
 
0.65 
 
0.76 
 
69.4210 (<.0001) 
Age (in years)  
12 -17 
18 -25 
26 -34 
35 -50 
>50* 
 
1.99 
2.72 
2.48 
1.93 
- 
 
1.17 
2.23 
2.18 
1.78 
- 
 
3.38 
3.31 
2.83 
2.09 
- 
 
6.5185 (0.0107) 
98.6129 (<.0001) 
182.7046 (<.0001) 
259.3394 (<.0001) 
- 
Sex 
Female* 
Male 
 
- 
1.15 
 
- 
1.10 
 
- 
1.20 
 
- 
44.4086 (<.0001) 
Race 
White* 
Black 
Hispanic 
Other 
 
- 
0.31 
0.63 
0.99 
 
- 
0.28 
0.53 
0.88 
 
- 
0.33 
0.73 
1.12 
 
- 
1074.5333 (<.0001) 
34.3520 (<.0001) 
0.0223 (0.8813) 
Primary expected payer 
Medicare* 
Medicaid 
Private insurance 
Self-pay 
Other 
 
- 
1.22 
0.94 
1.20 
1.28 
 
- 
1.15 
0.88 
1.12 
1.15 
 
- 
1.30 
1.00 
1.29 
1.43 
 
- 
37.4521 (<.0001) 
4.1854 (0.0408) 
26.6587 (<.0001) 
21.1647 (<.0001) 
Median household 
income 
Poor* 
Lower average 
Higher average 
Rich 
 
 
- 
0.946  
0.962 
0.996  
 
 
 
- 
0.898 
0.912 
0.937  
 
 
- 
0.997 
1.015 
1.059    
 
 
- 
4.2286 (0.0397) 
2.0029 (0.1570) 
0.0135 (0.9076) 
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No. of chronic 
conditions 
0 
1 
2 
3 
4 
5* 
 
 
0.19 
0.25 
0.36 
0.51 
0.68 
- 
 
 
0.167 
0.22 
0.32 
0.46 
0.61 
- 
 
 
0.22 
0.29 
0.41 
0.57 
0.76 
- 
 
 
499.3691 (<.0001) 
389.0633 (<.0001) 
270.0749 (<.0001) 
138.9470 (<.0001) 
51.2393 (<.0001) 
- 
Drug abuse 
No 
  Yes* 
 
0.27 
- 
 
0.18 
- 
 
0.41 
- 
 
37.3729 (<.0001) 
- 
Depression 
No 
  Yes* 
 
0.44 
- 
 
0.42 
- 
 
0.47 
- 
 
989.6249 (<.0001) 
- 
Note: OR= odds ratio; CI= confidence interval 
 *Reference category 
 
Scenario analyses 
a. Including ED visits with prescription opioid poisoning listed as the first diagnosis (DX1): 
The adjusted analyses were conducted including only ED visits with prescription opioid 
poisoning listed as the first diagnosis using the variable DX1. All regression models had 
better fit compared to the baseline models as indicated by lower value of -2 Log L. This 
means that the ability to predict the observed outcome is better in these models compared 
to the base case models. Also, results of the scenario analyses for models that compared 
years 2013 and 2014 to 2011 indicated significant reduction in prescription opioid 
poisoning ED visits in Kentucky compared to North Carolina. However, results of the 
scenario analysis reported no significant difference in the likelihood of prescription 
opioid poisoning ED visits between years 2011 and 2012 for Kentucky and North 
Carolina.  
b. Considering only unintentional prescription opioid poisoning ED visits: 
The adjusted analyses were conducted considering only ED visits with unintentional 
prescription opioid poisoning. All models experienced good fit based on Pearson 
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Goodness-of-Fit Statistic. Also, the models had better fit compared to the baseline models 
as indicated by lower value of -2 Log L. Holding all other variables constant, the odds of 
having an opioid poisoning ED visit was not significantly different in Kentucky than 
North Carolina comparing the years 2011 and 2012. However, these odds were 
significantly lower comparing 2013 and 2014 to 2011. 
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Chapter 6 
 
 
 
Methods and results for specific aim 4: 
A. To estimate the direct medical costs associated with prescription opioid poisoning ED 
visits in Kentucky and North Carolina. 
B. To estimate the economic impact of prescriber use mandates in Kentucky. 
Section 6.1 Methods 
Conceptual framework 
Opioid poisoning is a life-threatening condition characterized mainly by respiratory depression; 
but, it is reversible. Patients who develop an opioid poisoning event need to be transferred to the 
ED for immediate medical intervention, although some patients may refuse medical help for fear 
of legal issues or the use of an opioid antagonist available to the community. Most patients 
transferred to the ED are treated and released. Others may be admitted to the hospital for further 
medical supervision. In some cases, patients die during the ED visit or the hospital stay.  
Figure 6.1 illustrates the conceptual model for patients who develop an opioid poisoning event. 
Costs are incurred in every step of the model. From a societal perspective, they include direct, 
indirect, and intangible costs. Direct costs are associated with delivery of care, including all cost 
that incur while treating patients in the ED or during hospital admission. 
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Direct non-medical costs include services that help in the provision of care such as transportation 
cost. Indirect costs are associated with loss of productivity due to illness (e.g. absenteeism). 
Intangible costs are hard to measure in monetary value, but include feeling, dissatisfaction, and 
confusion.  
The economic burden of prescription opioid poisoning was assessed from a societal perspective. 
When a societal perspective is used, three main types of costs are typically considered: direct 
costs, indirect costs, and intangible costs. However, the current study was interested in output 
costs resulting from resource utilization associated with prescription opioid poisoning ED visits.  
 
                                           
 
 
 
 
 
 
Study design 
Data from current literature was used to develop a cost of illness framework (Figure 6.1). In the 
model, direct medical costs of prescription opioid poisoning (associated with ED visits) were 
investigated. Costs associated with inpatients stays, indirect, and intangible costs were not 
Patient 
develops 
opioid 
poisoning 
Transferred to the ED by 
ambulance or other means 
Not transferred to the ED 
Treated and released  
Died 
Admitted to the 
hospital  
Treated by 
naloxone or other 
opioid antagonist 
available in the 
community 
Died  
Died 
Discharged 
alive 
Figure 6.1: Conceptual model for treating patients who develop opioid poisoning 
 
Figure 6. 1: Conceptual model for treating patients who develop opioid poisoning 
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considered. Direct medical costs associated with ED visits were estimated over one-year period 
using a bottom up approach. In this approach, the average unit cost (i.e. costs per ED visit) is 
multiplied by its prevalence (i.e. number of ED visits). Yearly healthcare inflation rates were 
used to convert all cost estimates to 2018 monetary values. 
Study setting 
Prescription opioid poisoning ED visits (including ED visits that resulted in hospital admission) 
in Kentucky and North Carolina for the years 2011 to 2014. 
Data source 
The SEDD (treat and release ED visits) and the SID (ED visits that resulted in hospital admission) 
for Kentucky and North Carolina. See section 4.1. 
Sample  
Inclusion and exclusion criteria can be found in section 4.1. The final sample size for Kentucky 
and North Carolina for the years 2011 – 2014 is reported in Table 6.1.  
Table 6. 1: Final sample size for specific aim 4  
State Sample size (n) 
2011             2012             2013             2014 
 
Total 
Kentucky 2189               2037            1553             1640 7,419 
North 
Carolina 
2949                  3101           3292             3256 12,598 
 
Direct medical costs  
Direct medical costs considered in this study were costs of utilizing the ED (including treat and 
release ED visits and ED visits that resulted in hospital stays), physician ED service costs, and 
ambulance service costs. The current study focuses on ED visits related to prescription opioid 
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poisoning and thus, estimated costs associated with ED visits. Costs of inpatient stays is another 
type of direct medical costs associated with prescription opioid poisoning; however, these costs 
were not considered in this study. Also, due to data limitation, costs associated with other direct 
medical costs such as physician office cost, were not considered.  
Costs of ED visit  
Treat and Release 
Total ED visits costs were estimated by multiplying average cost per ED visit by the number of 
ED visits in Kentucky and North Carolina over four years period. Prescription opioid poisoning 
ED visits were identified using ICD-9-CM codes listed in Table 4.1. Prescription opioid 
poisoning ED visits in any listed diagnosis were considered. Costs per ED visit included cost of 
utilizing the ED and physician fee. Cost of utilizing the ED was obtained using the variable 
(TOTCHG), which represents total charge per visit. Physician fee costs were estimated by 
linking CPT-4 procedure codes to the publicly available Medicare Physician Fee Schedule 
(MPFS). The latter was created by the Centers for Medicare and Medicaid Services (CMS) and 
contain payment information for services provided by enrolled healthcare professionals. There 
are up to 25 CPT-4 procedure code recorded for each ED visit in the SEDD. However, only 
CPT-4 codes that describe physician visit to the ED were considered for the estimation of ED 
physician costs; these are 99281, 99282, 99283, 99284, and 99285. The latter was used to 
describe an ED visit for the evaluation and management of a patient, which requires these three 
key components: a comprehensive history, a comprehensive examination, and Medical decision 
making of high complexity.101 These characteristics may describe physician visit to the ED for 
an opioid poisoning case and thus, the code 99285 was used for the cost analysis. This was 
applied for all prescription opioid poisoning ED visits and the total physician fee costs were 
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calculated. The physician fee cost and the average cost of utilizing the ED were used to estimate 
total treat and release ED visits related costs.   
Costs of ED visits that ended with hospital admissions 
This section explains the methods used to estimate costs of ED visits that resulted in hospital 
admissions; however, costs of hospital admissions were not calculated in this study. ED visits 
that ended in hospital stays were obtained from the SID databases. To recall, the SID provide 
information on ED visits that ended with inpatient stays. Information on these ED visits are not 
available in the SEDD. Inpatient stays with evidence of ED visits related to prescription opioid 
poisoning were identified using ICD-9-CM codes listed in Table 4.1. Prescription opioid 
poisoning ED visits in any listed diagnosis were considered. To identify the charge of each ED 
visit, revenue center codes from the detail charge files were utilized. There are up to ten revenue 
codes (450 – 459) that can be reported on a discharge record that indicate ED services. Each 
revenue code has a corresponding charge; multiple revenue codes may be recorded for the same 
visit. To estimate total charge per ED visit, all revenue codes with their corresponding charges 
for that ED visit were considered. Unlike the SEDD, the SID do not provide CPT-4 codes. To 
estimate ED physician fee costs, CPT-4 code (99285) was used. The physician fee cost and the 
average cost of utilizing the ED were used to estimate total costs of ED visits that resulted in 
hospital stays.  
Ambulance service costs 
Ambulance service costs represent direct medical costs that might be incurred in prescription 
opioid poisoning ED visits. The proportion of ED visits that require ambulance service was 
assumed to be 38.2% based on a national study of ambulance transport for mental health 
problems.102 This proportion was applied to all ED visits (i.e. treat and release ED visits and ED 
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visits that resulted in hospital stays) to estimate the number of ED visits that require ambulance 
assistance. Ambulance service costs were obtained from the Ambulance Fee Schedule (AFS), 
which was created by the CMS in 2002 and updated annually. AFS provides payment 
information on state level. HCPCS codes for ambulance services were used to identify payment 
amount listed in the AFS. HCPCS code considered in this study and its associated payment 
amount is listed in Table 6.2. Total ambulance service cost was obtained by aggregating cost of 
ground ambulance services for all ED visits requiring ambulance service. Total ambulance 
service costs were estimated for Kentucky and North Carolina over a four-year period. 
Table 6. 2: HCPCS code for ambulance services and its reimbursement (in 2018 USD)  
HCPCS 
code 
Description Payment amounta,b ($) 
 
  KY NC 
A0427 Ambulance service, advanced life support, 
emergency transport, level 1 (ALS 1 – emergency) 
 
375.77 397.54 
a. Obtained from the 2018 AFS for the corresponding state. 
b. Based on the equation: base rate* Geographic Practice Cost Index (GPCI)* Relative Value Units (RVU). 
For KY payment amount = 224.74* 0.88* 1.9 = $375.77; NC payment amount = 224.74 * 0.931*1.9 = 
$397.54  
 
Total direct medical costs of ED visits  
The total direct medical costs associated with ED visits were calculated by summing total direct 
medical costs of treat and release ED visits and ED visits that resulted in hospital admissions.  
Cost to Charge Ratio (CCR) 
The SEDD and the SID provide total charge of an ED visit or a hospital stay. Also, the SID 
provide total charge of ED visits that ended with hospital admissions. Charges represent what 
hospitals bill for services, and they are higher than the actual cost of services or the amount paid 
for hospitals. The HCUP developed cost to charge ratios (CCRs) for the SID to help converting 
charge data to cost estimates. The CCR calculation is based on all-payer, inpatient cost and 
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charge information from the detailed reports by hospitals to the CMS. Both hospital specific and 
state average all payer inpatient CCR are provided. Most payers require a bundled bill for 
patients admitted to the hospital through the emergency department. Thus, the CCRs for the SID 
were utilized to convert charge of ED visits that ended with hospital admissions to cost 
estimates. The CCR file for each year was linked to the hospital linkage file using the variable 
(DSHOSPID); the result was linked to the SID file using hospital identifier variable (HOSPID). 
Total charge per ED visit that resulted in hospital admission was multiplied by the corresponding 
CCR (specific to each state/year) to obtain the cost estimate. When available, hospital specific all 
payer inpatient CCR, APICC was used to estimate total cost per visit. Otherwise, group average 
all-payer inpatient CCR, GAPICC was used.   
The HCUP do not provide CCRs specific to each hospital in the SEDD. However, it conducted a 
study including eight states and estimated average CCR for treat and release ED visits in these 
states.103 The report grouped hospitals based on hospital characteristics such as hospital 
ownership and location and provided CCR for each group. Also, weighted average CCR for all 
hospitals was estimated. The latter was used in this study because hospital ownership and 
hospital region variables are not available in the SEDD.  
Method for estimating the economic impact of prescriber use mandates in Kentucky 
The economic impact of prescriber use mandates in Kentucky was evaluated in terms of direct 
medical costs associated with ED visits considered in specific aim 4A. This was accomplished 
by calculating the odds ratio (OR) of the interaction term (mandates*post). The latter is called 
difference in difference estimator (DID) and it represents the difference in the change of opioid 
poisoning ED visits between Kentucky and North Carolina following policy implementation. 
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The DID was used to quantify the difference in the number of opioid poisoning ED visits in KY 
in the pre- and post-mandates periods. This can be explained by the following equation: 
Logit (poisoning_indicator=1) = β0 + β1 mandates + β2 post+ β3 (mandates*post) + β(4 – n) X(4 –n) 
 - Mandates is a dummy variable for prescriber mandates (1= Kentucky, 0= North Carolina). 
 - Post is a dummy variable for post mandates period (1= post mandates (i.e. second half of 2012, 
2013 and, 2014), 0= pre-mandates (i.e. 2011 and first half of 2012)). 
 - (Mandates * post) is an interaction term between the variables mandates and post. 
- β3 is the DID estimator which represents the true effect of mandates: 
  β3= (KY post - KY pre) - (NC post - NC pre). 
NC pre = β0  
NC post = β0 + β2 
KY pre = β0 + β1 
KY post = β0 + β1 + β2 + β3 
(KY post - KY pre) = β3 + β0 + β2 - β0 = β2 + β3 (suppose that β2 = -0.0333, β3 = -0.3556, post-
mandates is 2013, and pre-mandates is 2011)  
Thus, (KY post - KY pre) = -0.3889, OR = e-0.3889 = 0.68 (i.e. there is a 32% reduction in 
likelihood of opioid poisoning ED visits going from 2011 to 2013, controlling for NC in the 
model). Thus, there are (0.32 * number of opioid poisoning ED visits in 2011) fewer ED visits in 
2013 as compared to 2011. The economic impact of prescriber use mandates in 2013 was 
quantified by multiplying the average cost per ED visit by the difference in the number of opioid 
poisoning ED visits between the years 2011 and 2013 (i.e. 0.32 * number of opioid poisoning 
ED visits in 2011). The same method was applied to estimate the economic impact of the policy 
in 2012 and 2014.  
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Sensitivity analyses  
Sensitivity analyses were performed for Kentucky. Scenario analysis was conducted to test the 
impact of including ED visits with prescription opioid poisoning listed as the first diagnosis on 
the estimated total direct medical costs. One way-sensitivity analyses were performed to test the 
robustness of the base case cost estimates. These analyses included varying values of average 
CCR used to estimate cost of treat and release ED visits, the proportion of ED visits requiring 
ambulance run, and cost of ground ambulance run. Also, the estimate of the interaction term for 
each model was included in the one-way sensitivity analyses. Table 6.3 provides summary of 
ranges considered for each value.  
 
Table 6. 3: Ranges of values used in one-way sensitivity analysis 
Parameter Value in base case analysis Values used in one-way 
sensitivity analysis 
CCR 0.514a ± 95% CIb 
Proportion of ED visits requiring 
ambulance services 
38.2% ± 25% 
Cost of ground ambulance run $375.77 $316.43c 
β3d of the interaction term 
(mandates*post) 
(KY, 2012) = -0.0892 
(KY, 2013) = -0.3556 
(KY,2014) = -0.3532 
±95% CI 
 
a. Weighted average CCR for all hospitals reported in the HCUP study was used because hospital ownership 
and hospital region variables were not available in the SEDD. 
b. Estimated from the mean and standard deviation (SD) using the equation: mean± 1.96*SD. 
c. = (224.74* 0.88*1.6) which represents payment amount (in 2018 USD) for HCPCS code: A0429 
(ambulance service, basic life support, emergency transport (BLS – emergency)). 
d. β3 for each regression model was used. 
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Section 6.2 Results 
Aim 4A: To estimate the direct medical costs associated with prescription opioid poisoning in 
Kentucky and North Carolina. 
Kentucky 
There were a total of 7,419 prescription opioid poisoning ED visits over the period 2011 – 2014. 
Treat and release ED visits constituted 46% of total ED visits; the remaining ED visits (54%) 
resulted in hospital stays. The total (four years) average cost for a treat and release ED visit was 
estimated at $2,711.61 (see Appendix B for calculations) and the total mean cost for an ED visit 
that resulted in hospital stay was evaluated at $869.18 (see Appendix B for calculations). The 
annual average costs of a treat and release ED visit, ED visit that resulted in hospital stay, and 
physician fee cost are summarized in Table 6.4. The total (four year) ED related costs were 
estimated at $12.71 million (Table 6.4). About 73.0% of these costs were attributed to treat and 
release ED visits and 27.0% were related to ED visits that resulted in hospital stays. The total 
(four year) ambulance service costs of all ED visits were estimated at approximately one million 
dollars (Table 6.5). The total direct medical costs of prescription opioid poisoning ED visits were 
evaluated at $13.77 million (Table 6.6).
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Table 6. 4: Prescription opioid poisoning related-ED costs in Kentucky (in 2018 USD)  
 Average cost of utilizing the ED per year (SE)a,b 
 
 
2011                       2012                    2013                       2014 
Number of ED visits 
per year (n) 
 
2011  2012   2013   2014 
Total average cost per 
yearc 
(in million) 
2011  2012   2013   2014 
Total (four 
years) 
average 
costse 
(in million) 
Treat and 
release 
ED visits 
2,469.08 (69.33)   2,445.31 (68.14) d   2,500.21 (76.32)   2,749.53 (105.29) 970    911     712     835 
 
 2.56   2.38   1.90    2.44  
ED visits 
that 
resulted 
in 
hospital 
admission 
628.50 (20.81)      682.31 (25.88)       699.49 (28.05)       784.09 (33.44) 1,219 1,126   841    805 0.97    0.96   0.73     0.77  
Total 
average 
costs of 
all ED 
visits per 
yearf 
  3.53    3.34   2.63    3.21 12.71 
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits. 
b. Exclude physician fee cost which = $170.58. 
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED 
visits in that year (n). 
d. The estimated average cost was missing for one observation. 
e. Total (four years) average costs = total average cost of all ED visits in 2011($3.53 million) + total average cost of all ED visits in 2012 ($3.34 million) + 
total average cost of all ED visits in 2013 ($2.63 million) + total average cost of all ED visits in 2014 ($3.21 million) = $12.71 million. 
f. Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital 
admission in that year.
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Ambulance service costs  
Over the four years period, 1,310 treat and release ED visits and 1,517 ED visits that ended with 
hospital admissions were assumed to have involved ground ambulance transportation. The total 
(four year) ambulance services costs of all ED visits were estimated at approximately one million 
dollars (Table 6.5). About 46.2% of these costs were attributed to treat and release ED visits and 
53.8% were related to ED visits that resulted in hospital stays. The annual and total costs of 
ambulance services are summarized in Table 6.5.  
Table 6. 5: Annual and total (four years) costs of ground ambulance services in Kentucky (in 
2018 USD) 
 
 Number of ED visits 
requiring ambulance 
service per year (n)a 
 
2011  2012   2013   2014 
Total costs per yearb,c  
(in million) 
 
 
2011   2012   2013   2014 
Total (four 
years) 
costsd 
(in million) 
 
Treat and 
release ED 
visits 
371   348      272     319 0.14    0.13    0.1    0.12  
ED visits 
that 
resulted in 
hospital 
admission 
466   430     322      308 0.17    0.16    0.12    0.12  
Total costs 
of 
ambulance 
services 
for all ED 
visits per 
year 
 0.31   0.29   0.22   0.24 1.06 
a. Number of ED visits requiring ambulance service per year = (38.2%) * No. of ED visits in that year. 
b. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED 
visits. 
c. Total average cost per year= cost per ambulance run ($375.77) * number of ED visits requiring ambulance 
services in a year. 
d. Total (four years) costs = total costs of ambulance services for all ED visits in 2011($0.31 million) + total 
costs of ambulance services for all ED visits in 2012 ($0.29 million) + total costs of ambulance services for 
all ED visits in 2013 ($0.22 million) + total costs of ambulance services for all ED visits in 2014 ($0.24 
million) = $1.06 million.  
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Total direct medical costs of ED visits 
Total (four year) direct medical costs associated with ED visits were estimated at $13.77 million. 
About 29.1% of these costs were attributed to ED visits that ended with hospital admissions and 
70.9% were related to treat and release ED visits. The annual and total direct medical costs for 
the period 2011 to 2014 are summarized in Table 6.6. 
Table 6. 6: The annual and total direct medical costs of prescription opioid poisoning ED visits 
in Kentucky (in 2018 USD) 
 
    2011        2012    2013    2014 Total (four year) direct medical 
costs (in millions)d 
Total average costs of all ED visits 
per yeara 
    3.53       3.34       2.63       3.21  
 
Total ambulance service costs for 
all ED visits per yearb 
    0.31       0.29      0.22        0.24 
 
 
 
Total direct medical costs per 
yearc  
    3.84        3.63       2.85       3.45 13.77 
 
a. Estimated in Table 6.4. 
b. Estimated in Table 6.5. 
c. Total direct medical costs per year = total average costs of all ED visits + total ambulance service costs in 
that year. 
d. Total (four year) direct medical costs = total direct medical costs in 2011 ($3.84 million) + total direct 
medical costs in 2012 ($3.63 million) + total direct medical costs in 2013 ($2.85 million) + total direct 
medical costs in 2014 ($3.45 million) = $13.77 million. 
 
North Carolina  
There were a total of 12,598 opioid poisoning related ED visits over the period 2011 – 2014. 
Treat and release ED visits constituted 44.8% of total ED visits; the remaining ED visits (55.2%) 
resulted in hospital stays. Over the four years period, the average cost for a treat and release ED 
visit was estimated at $ 2,766.67 (see Appendix B for calculations), and the mean cost for an ED 
visit that resulted in hospital stay was evaluated at $1,011.94 (see Appendix B for calculations). 
The annual average cost of a treat and release ED visit, ED visit that resulted in hospital stay, and 
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physician fee cost are summarized in Table 6.7. The total (four years) ED related costs were 
estimated at $22.46 million (Table 6.7). About 96.9% of these costs were attributed to treat and 
release ED visits and 30.1% were related to ED visits that resulted in hospital stays. The total 
(four year) ambulance service costs of all ED visits were estimated at $1.9 million (Table 6.8). 
The total direct medical costs of prescription opioid poisoning ED visits were evaluated at 
$24.37 million (Table 6.9).
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Table 6. 7: Prescription opioid poisoning related- ED costs in North Carolina (in 2018 USD)  
 
 Average cost of utilizing the ED per year (SE)a,b 
 
 
2011                       2012                    2013                       2014 
Number of ED visits per 
year (n) 
 
2011  2012   2013   2014 
Total average cost per 
yearc 
(in million) 
2011  2012  2013  2014 
Total (four 
years) 
average 
costsd 
(in million) 
Treat and 
release 
ED visits 
2,251.19e (53.90)   2,588.65f (84.61)   2,648.11f (62.04)   2,896.95g (124.87) 
 
1,306  1,361  1,414 1,565 3.16   3.76   3.99   4.80  
ED visits 
that 
resulted 
in 
hospital 
admission 
765.26 (5.76)    832.34 (11.18)   850.04 (9.85)   918.35(11.60) 1,643  1,740 1,878  1,691 1.54    1.74    1.92  1.55  
Total 
average 
costs of 
all ED 
visits per 
yearh 
  4.70    5.50    5.91   6.35 22.46 
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits. 
b. Exclude physician fee cost which = $170.44. 
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED visits in 
that year (n). 
d. Total (four years) average costs = total average cost of all ED visits in 2011($4.70 million) + total average cost of all ED visits in 2012 ($5.50 million) + total 
average cost of all ED visits in 2013 ($5.90 million) + total average cost of all ED visits in 2014 ($6.35 million) = $22.46 million. 
e. The estimated average cost was missing for three observations. f. The estimated average cost was missing for four observations. 
g. The estimated average cost was missing for six observations. 
h. Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital 
admission in that year.
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Ambulance service costs  
Over the four years period, 2,157 treat and release ED visits and 2,656 ED visits that ended with 
hospital admissions were assumed to have involved ground ambulance transportation. The total 
(four years) ambulance services costs of all ED visits were estimated at $1.92 million. About 
44.8% of these costs were attributed to treat and release ED visits and 55.2% were related to ED 
visits that resulted in hospital stays. The annual and total costs of ambulance services are 
summarized in Table 6.8.  
Table 6. 8: Annual and total (four years) costs of ground ambulance services in North Carolina 
(in 2018 USD)  
 
 Number of ED visits requiring 
ambulance service per year (n)a 
 
 
2011  2012   2013   2014 
Total costs per yearb,c 
(in million) 
 
 
2011   2012   2013   2014 
Total (four 
years)  costsd 
(in million) 
 
Treat and release 
ED visits 
          499    520      540   598 0.20    0.21    0.21    0.24  
ED visits that 
resulted in hospital 
admission 
          628    665      717   646 0.25  0.26    0.29    0.26  
Total costs of 
ambulance services 
for all ED visits per 
year 
 0.45   0.47   0.50    0.50 1.92 
a. Number of ED visits requiring ambulance service per year = (38.2%) * No. of ED visits in that year. 
b. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits. 
c. Total average cost per year= cost per ambulance run ($397.54) * number of ED visits requiring ambulance 
services in a year. 
d. Total (four years) costs = total costs of ambulance services for all ED visits in 2011($0.45 million) + total costs of 
ambulance services for all ED visits in 2012 ($0.47 million) + total costs of ambulance services for all ED visits in 
2013 ($0.50 million) + total costs of ambulance services for all ED visits in 2014 ($0.50 million) = $1.92 million. 
 
Total direct medical costs of ED visits 
Total (four years) direct medical costs associated with ED visits were estimated at $24.37 
million. About 32.0% of these costs were attributed to ED visits that ended with hospital 
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admissions and 68.0% were related to treat and release ED visits. The annual and total direct 
medical costs for the period 2011 to 2014 are summarized in Table 6.9. 
Table 6. 9: The annual and total direct medical costs of prescription opioid poisoning ED visits 
in North Carolina (in 2018 USD) 
 
 2011    2012    2013    2014 Total (four 
year) direct 
medical costs 
(in millions)d 
Total average costs 
of all ED visits per 
yeara 
4.70    5.50     5.90    6.35  
 
 
Total ambulance 
service costs for all 
ED visits per yearb 
0.45      0.47    0.50    0.50  
 
 
Total direct 
medical costs per 
yearc  
5.15    5.97    6.40    6.85 24.37 
a. Estimated in Table 6.7. 
b. Estimated in Table 6.8. 
c. Total direct medical costs per year = total average costs of all ED visits + total ambulance service costs in that 
year. 
d. Total (four year) direct medical costs = total direct medical costs in 2011 ($5.15 million) + total direct medical 
costs in 2012 ($5.97 million) + total direct medical costs in 2013 ($6.40 million) + total direct medical costs in 2014 
($6.85 million) = $24.37 million. 
 
Specific aim 4B: To estimate the economic impact of prescriber use mandates in Kentucky. 
From 2011 to 2014, there was a 22.14% reduction in direct medical costs associated with 
prescription opioid poisoning ED visits. Following prescriber use mandates implementation, the 
total reduction of direct medical costs associated with ED visits was estimated at about $2.31 
million. Table 6.10 summarizes the impact of the policy on the number of opioid poisoning ED 
visits and the associated direct costs by year. 
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Table 6. 10: The impact of prescriber use mandates policy on the number of opioid poisoning ED 
visits and the associated direct costs (in 2018 USD, millions) 
 Pre-mandates 
2011 
Post-mandates 
2012              2013            2014 
No. of opioid poisoning ED visitsa 2,189 1,948             1,488           1,423 
Total direct medical costs 3.84     3.48b             2.74             2.99 
Change in total direct medical 
costs from 2011 to post mandatesc 
-     0.36              1.1               0.85 
Percent change in total direct 
medical costs from 2011 to post 
mandates 
- - 9.38           - 28.65       - 22.14 
a. No. of opioid poisoning ED visits for the years 2012, 2013, and 2014 were estimated based on the DID 
estimator equation (see Section 5.1 under specific aim 3B) as follow:  
KYpost – KYpre = β2 + β3 (where β2 is the estimate for the variable post (i.e. post-mandates) and β3 is the 
DID estimator). For the year 2012: 
KY2012 – KY2011= - 0.0326 + (- 0.0892) 
= -0.1218, OR = e-0.1218 = 0.89, then, no. of opioid poisoning ED visits in 2012 = 0.89 * no. of opioid 
poisoning ED visits in 2011 (2,189)  
= 1,948 ED visits in 2012. The same calculations will be applied to estimate no. of opioid poisoning ED 
visits in 2013 and 2014. 
b. Total direct medical costs for 2012 were estimated as follow: no. of opioid poisoning ED visits = 1,948 
(treat and release ED visits constituted 44.7% of total ED visits and hospital ED visits that resulted in 
hospital admission constituted 55.3% of total ED visits (Table 6.4). Thus, there are 871 treat and release 
ED visits and 1077 ED visits that resulted in hospital admission. Total average costs of treat and release ED 
visits = (871 * $2,615.89) = $2.28 million, total average costs of ED visits that resulted in hospital 
admission= (1077 * $852.89) = $0.92 million, total costs of ambulance services for all ED visits = 1,948 * 
38.2% = 744; $375.77 * 744 = $0.28 million. Total direct medical costs in 2012= 2.28 + 0.92 + 0.28 = 
$3.48 million. The same calculations will be applied to estimate total direct medical costs for 2013 and 
2014. 
c. Change in direct medical costs from 2011 to post mandates = total direct medical costs in 2012 (2013, or 
2014) - total direct medical costs in 2011 ($3.84 million). 
 
 
Sensitivity analyses 
Scenario analysis and one-way sensitivity analyses were conducted to test the robustness of the 
base case cost estimates in KY.  
Scenario analysis (including only ED visits with first listed diagnosis of prescription opioid 
poisoning): 
There were 2,322 treat and release ED visits and 2,266 ED visits that resulted in hospital 
admission, with first listed diagnosis of prescription opioid. Considering these ED visits, the total 
(four years) direct medical cost of prescription opioid poisoning in KY was estimated at $8.45 
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million (compared to $13.77 million in the base case analysis). Results of the scenario analysis 
are summarized in Table 6.11  
One-way sensitivity analyses: 
One-way sensitivity analyses were conducted by varying the proportion of average CCR of treat 
and release ED visits, ED visits requiring ambulance run, cost per ground ambulance run, and the 
estimate of the interaction term for each regression model. Varying the proportion of CCR over 
95% CI range resulted in approximately ± $7.7 million effect on the total (four years) estimated 
costs. When the proportion of ED visits with ambulance service varied between (28.65% and 
47.75%), the total (four years) direct medical costs ranged from $13.5 million to $14 million. 
Reducing ambulance cost to $316.43 decreased the total direct costs by $70 thousands. When the 
estimate of the interaction term for all models varied over 95% CI, the total reduction in direct 
medical costs in post mandates period compared to 2011 ranged from $1.6 million to $3.14 
million. Results of the one-way sensitivity analyses are summarized in Table 6.12 and 6.13.
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Table 6. 11: Direct medical costs of ED visits associated with prescription opioid poisoning listed as first diagnosis in Kentucky (in 
2018 USD) 
 
 Average cost of utilizing the ED per year (SE)a,b 
 
 
2011                       2012                    2013                       2014 
Number of ED visits 
per year (n) 
 
2011  2012  2013  2014 
Total average cost per 
yearc 
(in million) 
2011  2012   2013  2014 
Total 
(four 
years) 
average 
costsd 
(in 
million) 
Treat and 
release ED 
visits 
2,283.06 (81.87)    2,236.33e (73.34)    2,298.63 (79.03)    2,505.04 (122.92) 633     602    502   584 1.55   1.45    1.24   1.56  
ED visits 
that 
resulted in 
hospital 
admission 
649.92f (15.88)    701.72 (15.31)    707.40 (17.66)    791.71e (20.12) |686    671    470    436 0.56   0.59    0.41   0.42  
Total 
ambulance 
service 
costs for 
all ED 
visits per 
yearg 
  0.19   0.18    0.14   0.15  
Total 
direct 
medical 
costs of all 
ED visits 
per yearh 
  2.30    2.22   1.79   2.13 8.44 
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits. 
b. Exclude physician fee cost which = $170.58. 
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED 
visits in that year (n). 
d. Total (four years) average costs = total average cost of all ED visits in 2011($2.30 million) + total average cost of all ED visits in 2012 ($2.22 million) + 
total average cost of all ED visits in 2013 ($1.79 million) + total average cost of all ED visits in 2014 ($2.13 million) = $8.44 million. 
e. The estimated average cost is missing for one observation. 
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f. The estimated average cost is missing for two observations. 
g. Total ambulance service costs for all ED visits per year = no. of ED visits requiring ambulance service in that year * cost per ambulance run ($375.77). 
h. Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital 
admission in that year. 
 
Table 6. 12: One-way sensitivity analyses on the total estimated direct medical costs in Kentucky (in 2018 USD) 
Parameter Base 
case 
value 
Base case 
estimated 
total 
direct 
medical 
costs (in 
million) 
Value or range tested Change in 
estimated 
total direct 
medical costs 
(in million) 
CCR 0.514 13.77 95% limit (0.06 - 0.97) (6.10 - 21.50) 
Proportion 
of ED visits 
requiring 
ambulance 
run 
38.2% 13.77 ± 25% (28.65%, 47.75%) (13.52, 14.05) 
Cost of 
ground 
ambulancea 
$375.77 13.77 $316.43b 13.71 
a. Estimated from the mean and SD using the equation: mean± 1.96*SD (0.232) 
b. Payment amount (in 2018 USD) for HCPCS code: A0429 (ambulance service, basic life support, emergency transport (BLS – emergency)). 
 
Table 6. 13: One-way sensitivity analysis on the impact of prescriber use mandates (in 2018 USD) 
Parameter Base 
case 
value 
Range tested Total direct medical costs in 
post mandates period (per 
year) 
Change in total direct 
medical costs from 
2011a  
β3 associated with 
the interaction term 
(mandates * post): 
    
(KY, 2012) -0.0892 95% limit (-0.009 - -0.169) (3.20 - 3.75) (0.09 - 0.64) 
(KY, 2013) -0.3556 95% limit (- 0.272 - -0.439) (2.50 - 2.98)  (0.86 - 1.34) 
(KY, 2014) -0.3532 95% limit (-0.270 - -0.436) (2.71 - 3.22) (0.62- 1.13) 
a. Change in total direct medical costs from 2011 = total direct medical costs in 2012 (2013, or 2014) - total direct medical costs in 2011 ($3.84 million).
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Chapter 7 
 
 
 
Section 7.1: Discussion 
This is the first study to examine the impact of a PDMP prescriber use mandate policy on 
prescription opioid poisoning ED visits in the United States. The existing literature assessed the 
effectiveness of PDMPs in terms of their impact on prescribing behavior, opioid consumption, 
doctor shopping, and opioid-related morbidity (see Chapter 2). The framework used for this 
research was the Donabedian model (Figure 1.2). In addition, this study estimates the direct 
medical costs associated with prescription opioid poisoning ED visits and the economic impact 
of prescriber use mandates.  
This research focused on the impact of comprehensive prescriber use mandates.90 Difference in 
difference (DID) framework was used to examine the impact of the policy on prescription opioid 
poisoning ED visits. The DID model is a well-known statistical methodology used for policy 
impact evaluation.77, 86, 99, 100 This study was further strengthened by conducting three 
comparison models for the years 2012, 2013, and 2014 as compared to 2011.  
Prevalence of prescription opioid poisoning ED visits and associated characteristics 
This study found that the prevalence rate of prescription opioid poisoning ED visits in 2014 was 
43.82 per 100,000 residents for Kentucky and 37.45 per 100,000 residents for North Carolina. In 
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the same year, the Agency for Healthcare Research and Quality (AHRQ) estimated the national 
rate of opioid related ED visits to be 177.7 per 100,000 residents.104 However, this national 
estimate included all heroin and non-heroin related ED visits for all age groups. National data 
from another study was utilized to calculate the rate of non-heroin related ED visits in 2014;105 
the estimated national rate is lower compared to Kentucky and North Carolina (= 25.60 per 
100,000 residents). 
From 2010 to 2014, the national age adjusted rate of non-heroin related ED visits decreased by 
4%.105 Also, a recent report by the CDC found that the rate of opioid overdose ED visits among 
those aged 11 years and older decreased by 15% in Kentucky, and increased by 30% in North 
Carolina from July 2016 to September 2017.106 Our study estimated 26.1% reduction in the rate 
of prescription opioid poisoning ED visits in Kentucky and 3.2% increase in North Carolina 
from 2011 to 2014.  
Sociodemographic characteristics of prescription opioid poisoning ED visits described in our 
study were similar to the existing literature; prescription opioid poisoning ED visits were more 
prevalent in people aged 35- 50 years old and >50 years compared to other age groups. 105, 107  In 
addition, our study reported a higher proportion of visits occurring in urban areas, higher rates of 
opioid related ED visits among females, and white, non-Hispanics had the highest visit rates.105, 
108-110 Medicare was the largest payer for unintentional opioid poisoning; the latter can be caused 
by poly-pharmacy, which is more common in elderly. This finding is supported by previous 
studies.108, 111 Lastly, consistent with Monnat et al.,112 our study found non-significant 
relationship between patient location and opioid related ED visits.  
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Impact of prescriber use mandates on prescription opioid poisoning ED visits 
This study found evidence to support prescriber use mandates and how this differed in Kentucky 
and North Carolina. Prescriber use mandates implemented in Kentucky in July 2012 were 
associated with a moderate, but significant reduction in prescription opioid poisoning ED visits 
in 2012 as compared to 2011, controlling for North Carolina in the model. An even greater 
reduction in opioid related ED visits was seen in 2013. The impact of the policy has leveled off 
in 2014, as no further reduction was seen in prescription opioid poisoning ED visits. However, 
this does not ensure the sustainability of the policy impact; more data points are required to 
examine a pattern in the observed data. 
Results of this study expands the growing body of evidence on PDMP effectiveness. It differs 
with Maughan et al. who did not find a statistically significant difference in prescription opioid 
misuse related ED visits between states with and without PDMPs.83 One explanation for the non-
significant results reported by the authors was the low and variable utilization of PDMPs by 
prescribers at the time of their study.46-50, 52-62 PDMP use was much greater in Kentucky during 
the period of our study.  
The few studies specific to prescriber use mandates are generally supportive of them. In New 
York, prescription opioid related ED visits leveled off following prescriber use mandate 
implementation.84 New York also saw a significant reduction in opioid prescribing after 
prescriber use mandates.85 A national study by Dowell reported significant reduction in 
prescription opioid related deaths following prescriber use mandates.86 Only one study found 
non-significant impact of prescriber use mandates on opioid prescribing.87  
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Economic impact of prescriber use mandates policy 
The current study is the first to estimate the economic impact of prescriber use mandates on non-
fatal prescription opioid poisoning ED visits. Existing studies evaluated costs of opioid related 
ED visits using national estimates and included fatal and non-fatal ED visits. To date, four 
studies have estimated costs of opioid related ED visits utilizing national ED visits data. 
Inocencio et al. assessed direct and indirect costs associated with opioid misuse, abuse, and/or 
poisoning in the United States. The average estimated cost of a prescription opioid related ED 
visit was $2,337 in 2017 U.S. dollars.25 Another study by Yokell et al. estimated average charges 
of prescription opioid overdose ED visit at $4,454 to $5,043, which would be comparable to 
Inocencio’s cost figures after applying a cost to charge adjustment.110 Tadros et al. costs were 
also comparable to Inocencio’s.108 A study using 2007 data found lower average charges for drug 
poisoning related ED visit of $2,700.113 To our knowledge, only one study reported state level 
costs of opioid related ED visits and hospital admissions; in Florida, the total estimated costs of 
ED visits and inpatient stays was $208 million over one-year period (2010 – 2011).114 
In the current study, the average cost treat- and release ED visits were estimated at $2,500 in 
Kentucky and $2,600 in North Carolina. These estimated costs are comparable to the average 
costs reported by Incencio et al.25 In addition, the average charges per visits estimated in our 
study were similar to those reported by prior studies.108, 110 The current study estimated total 
direct medical costs of prescription opioid poisoning ED visits to be $13.77 and $24.37 million 
in Kentucky and North Carolina, respectively, over the period 2011 - 2014. Treat and release ED 
visits contributed to most of costs in both states.  
Surprisingly, the average costs of treat- and release ED visits were more than triple compared to 
the average cost of ED visits that resulted in hospital stays ($2500 vs. $700 for Kentucky and 
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$2600 vs. $840 for North Carolina). These findings can be explained through the severity of 
opioid cases. Patients who were seen in the ED and admitted to the hospital would have more 
severe cases and thus, require more procedures to be done in the ED. Most payers require 
bundled payments for patients who were first seen in the ED and then admitted to the hospital. 
Based on this model, the current study used inpatient CCRs to estimate costs of ED visits that 
ended in hospital stays. This may explain the low cost of ED visits that resulted in hospital 
admissions as compared to treat and release ED visits. No other studies have evaluated costs of 
emergency department services for inpatient stays; therefore, the current findings cannot be 
supported by any existing evidence. Payments for physician fees used in the current study were 
the highest documented payment in the MFS for ED services — which may inflate the total 
estimated direct costs. However, the CPT-4 code selected for use in this study appropriately 
describes ED services for opioid overdose. Sensitivity analysis was performed to test the 
robustness of the total estimated costs in Kentucky. Varying the CCR for treat and release ED 
visits over its 95% CI range had the largest impact on the total cost estimate (± 7 million effect). 
This was expected due to the large variation in CCR values between hospitals and states 
estimated in the HCUP report.103  
The current study evaluated the economic impact of the PDMP policy considering only direct 
medical costs. Following prescriber use mandates implementation, the reduction of total direct 
medical costs from 2011 to 2014 was estimated at $2.31 million. The estimated reduction in 
costs was doubled from 2012 to 2013 and leveled off in 2014 (Figure 7.1). It could be that the 
policy impact reached its maximum level a year after its implementation (i.e. in 2013) and thus, 
no further reduction in costs was noted in 2014. This may indicate that the policy need to be 
updated to increase its effect, or other policies should be implemented to synergize its impact. It 
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is worth to note that the estimated reduction in costs following the policy implementation does 
not reflect savings in cost. Abusers of prescription opioids may shift to heroin and thus, costs 
associated with abusing heroin and other non-prescription opioids may increase on the other side. 
A study by Dart et al. on trends on opioid analgesic abuse found a reduction in prescription 
opioid abuse and a concurrent increase in heroin abuse in the United States from 2010 to 2013.115 
The relationship between prescription opioid abuse and heroin abuse was further supported by 
Cicero et al.116  
 
Figure 7. 1: Economic impact of prescriber use mandates on prescription opioid poisoning ED 
visits in Kentucky (in 2018 USD) 
 
Findings of this study provide information surrounding the effectiveness of comprehensive 
prescriber use mandates in reducing prescription opioid poisoning ED visits. However, the 
impact of the policy cannot be isolated from pain clinic regulations, which were part of the 
House Bill 1 (HB1) legislation implemented in Kentucky in 2012. Also, Kentucky and North 
Carolina differ in the adoption of other policies, which could impact the assessment of prescriber 
use mandates (Table 7.1).  
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In 2011, North Carolina implemented a state-wide program called Project Lazarus. The program 
aimed to combat the prescription opioid abuse epidemic and related health outcomes. When first 
initiated in Wilkes county in 2008, Project Lazarus reduced overdose deaths and opioid abuse 
related ED visits by 69% and 15%, respectively.117 Despite the initiative in North Carolina, our 
study found a significant reduction in prescription opioid poisoning ED visits in Kentucky 
compared to North Carolina. This finding further supports the effectiveness of prescriber use 
mandates.  
It is important to note that the prescriber use mandate policy does not necessarily ensure 
prescribers’ utilization of PDMPs. Many prescribers oppose the use of PDMPs and, it is not 
feasible to verify prescriber’s use of the system. In addition, as of 2016, only 30 states explicitly 
provide civil and/or criminal immunity to prescribers and dispensers for accessing, failing to 
access, or reporting data to PDMPs.118 As mentioned earlier, there are seven other PDMPs 
practices proposed to increase PDMPs utilization.31 Also, other practices that increase PDMPs 
effectiveness should be considered.32 These policies and practices should work hand in hand with 
prescriber use mandates to curb the prescription opioid abuse epidemic. 
Table 7. 1: PDMPs practices and other related policies in Kentucky and North Carolina 
 KY 
     2011   2012   2013   2014 
NC 
   2011   2012   2013   2014 
Proactive reports 
to prescribers 
                                                             
Delegate access                                                                                               
Naloxone 
distribution* 
                                                              
Schedules 
monitored 
II - V II- V 
Operational 
PDMP 
1999 2007 
Require prescriber 
to be trained 
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before using 
PDMP 
Pain clinic law Yes (part of HB1)  
Proactive reports 
on prescriber (to 
law enforcement 
agency) 
Yes  (part of HB1)  
 Note:  means the policy was not implemented;  means the policy was not implemented 
* Effective in 3/2015 in Kentucky; Effective in 6/2016 in North Carolina; HB1= house bill1 
 
Limitations 
This study is the first to examine the impact of prescriber use mandates policy on prescription 
opioid poisoning ED visits using a controlled pre-post study design. However, the study has 
several limitations. 
The intended population were abusers who obtain their prescription opioids from doctors. 
Unfortunately, the data did not provide information to verify this. Physicians are one leading 
source of prescription opioids, however, there are other sources from which patients can obtain 
prescription opioids. According to National Survey on Drug Use and Health (NSDUH), half of 
non-medical users (50.5%) obtained their opioid from a friend or relative for free, 22.1% got it 
from one doctor, and 11% bought it from a friend or relative.119 Improperly stored prescription 
opioid in households represents another source for abuse that was not captured in the current 
study. A study by Lewis et al. (2014) reported stockpiling of unused opioids by 65% of patients 
with only 6.3% dispose unused opioids.120 Stockpiling opioids was associated with recreational 
use of these medications in 34% of patients. A similar study by Bates et al. (2011) investigated 
unused narcotics among discharged patients who underwent surgery.121 In this study, 67% of 
patients stockpiled unused narcotics. Therefore, educating patients and providing them with 
proper drug disposal methods is necessary to reduce the risk of abuse. 
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Prescription opioid poisoning is not limited to prescription opioid abusers. Polypharmacy, 
defined as taking five or more medications, 122 can be a leading cause. Polypharmacy is common 
in elderly due to having multiple medical conditions. The current study found that more than one 
third of opioid-related ED visits were attributed to patients >50 years old, however, the 
possibility of polypharmacy as an underlying cause cannot be determined. Furthermore, this 
study could not control for patient’s living condition (i.e. homelessness), marital status, 
education, and employment which are potential confounders. Evidence from the existing 
literature supports the relationship between these variables and opioid abuse; 123, 124 however, no 
information on these variables were available in the SEDD and the SID for the period of the 
study. Other data limitations are related to the ICD-9-CM codes; there are no specific codes that 
identify prescription opioid poisoning and thus, the analyses of this study may overestimate the 
occurrences of prescription opioid poisoning ED visits. 
Other state level unobserved factors may affect the findings of this study. There may be local 
policies or interventions that were implemented at similar time to prescriber use mandates, which 
could impact the estimated effect of the policy. These may include other opioid-related 
prescriber mandates, regulations of naloxone access, and others.  
Lastly, findings of the current study may not be generalizable to all states. This is related to two 
factors, first, differences among the states in conditions under which a prescriber is required to 
check the state PDMP. This research focused on comprehensive prescriber use mandates 
adopted in Kentucky. To recall, comprehensive prescriber use mandates require all prescribers to 
consult the PDMP before initial opioid and benzodiazepine prescriptions and at least every three 
months thereafter.90 Therefore, it represents the highest level of prescriber use mandates 
compared to other states. Second, in addition to prescriber use mandates, Kentucky HB1 
 140 
 
legislation included regulations for pain clinics.125 As a result, the reduction in opioid-related ED 
visits found in this study may not be attributed to prescriber use mandates only. 
Study implications 
The current study supports the effectiveness of prescriber use mandates in reducing the number 
of prescription opioid-related ED visits, also, the economic impact of the policy is considerable. 
These findings can be of a great importance to policy makers. States without prescriber use 
mandates policy should consider its adoption. To maximize prescriber use of PDMPs, other 
policies or practices should also be considered. Prescribers and other intended users of PDMPs 
should be educated about the importance of using the system and how to use it appropriately. In 
addition, prescriber should be given the right to authorize other staff, such as nurses to use the 
PDMP. This will save time for prescribers, hence enhancing PDMPs utilization. Proactive 
reports is another important practice; sending unsolicited reports to prescribers will notify them 
about high risk patients, and encourage them to coordinate care with other healthcare providers. 
Other policies or practices that might synergize the impact of prescriber use mandates are 
mentioned the NAMSDL report.31 In addition to these practices, states must adopt laws that 
specifically provide immunity to prescribers and other intended users for accessing the system 
and impose sanctions on those who fails to use it.  
The current study should guide future research to examine the impact of other prescriber use 
mandate policies on other opioid related-health outcomes. Findings of the current study are 
promising; further research is required to support the effectiveness of the policy. Lastly, to curb 
the prescription opioid abuse epidemic, PDMPs should not be the only area of focus; other plans 
proposed by the federal government should be considered.30  
 141 
 
 
 
 
Section 7.2: Conclusion 
The prescriber use mandate policy is effective in reducing prescription opioid poisoning ED 
visits and their associated costs. However, the impact of the policy cannot be isolated from pain 
clinic regulations and other regulations included in Kentucky HB1 legislation. PDMP use 
mandates are one of several policies that can increase prescribers and pharmacists use of the 
system, thereby support PDMPs effectiveness. Decision makers should consider ways to 
maximize the implementation of prescriber use mandates, and adopt other policies or practices 
that enhance the effectiveness of PDMPs.    
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Appendix A 
 
 
 
Single level CCS Type of cancer 
11 Cancer of head and neck 
12 Cancer of esophagus 
13 Cancer of stomach 
14 Cancer of colon 
15 Cancer of rectum and anus 
16 Cancer of liver and intrahepatic bile duct 
17 Cancer of pancreas 
18 Cancer of other GI organs; peritoneum 
19 Cancer of bronchus; lung 
20 Cancer; other respiratory and intrathoracic 
21 Cancer of bone and connective tissue 
22 Melanomas of skin 
23 Other non-epithelial cancer of skin 
24 Cancer of breast 
25 Cancer of uterus 
26 Cancer of cervix 
27 Cancer of ovary 
28 Cancer of other female genital organs 
29 Cancer of prostate 
30 Cancer of testis 
31 Cancer of other male genital organs 
32 Cancer of bladder 
33 Cancer of kidney and renal pelvis 
34 Cancer of other urinary organs 
35 Cancer of brain and nervous system 
36 Cancer of thyroid 
37 Hodgkin`s disease 
38 Non-Hodgkin`s lymphoma 
39 Leukemias 
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40 Multiple myeloma 
41 Cancer; other and unspecified primary 
42 Secondary malignancies 
43 Malignant neoplasm without specification of site 
44 Neoplasms of unspecified nature or uncertain 
behavior 
45 Maintenance chemotherapy; radiotherapy 
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Appendix B 
 
 
Total (four years) average cost of prescription opioid poisoning ED visits (in 2018 USD) 
 
 
 
 
Kentucky: 
Treat and release ED visits 
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+ 
average cost in 2014) / 4 + physician fee cost. 
= ($2,469.08 + $2,445.31 + $2,500.21 + $2,749.53)/ 4 + $170.58 
= $2,711.6 
ED visits that resulted in hospital admissions 
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+ 
average cost in 2014) / 4 + physician fee cost. 
= ($628.50 + $682.31 + $699.49 + $784.09) / 4 + $170.58 
= $869.18  
North Carolina: 
Treat and release ED visits 
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+ 
average cost in 2014) / 4 + physician fee cost. 
= ($2,251.19 + $2,588.65 + 42,648.11 + $2,896.95)/ 4 + $ 170.44 
= $12,766.67 
ED visits that resulted in hospital admissions 
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+ 
average cost in 2014) / 4 + physician fee cost. 
= ($765.26 + $832.34 + $850.04 + $918.35)/4 + $170.44= $1,011.94. 
